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Abstract 
 
Mycobacterium tuberculosis (Mtb) is the causative agent of tuberculosis (TB) and 
remains as one of the leading causes of death worldwide. Mtb encodes a limited 
number of ATP-binding cassette (ABC) importers for the acquisition of carbohydrates, 
potentially reflecting the nutrient scarce environment encountered within the host. The 
focus of this PhD therefore, was to carry out a structural and functional analysis of Mtb 
UgpB (Rv2833c), the substrate-binding protein of the Mtb UgpABCE transporter. 
 
The Mtb UgpB substrate-binding protein was successfully expressed and purified to 
homogeneity. Following purification, the function of Mtb UgpB was investigated. A 
panel of potential substrates were investigated using a thermal shift assay, which found 
that glycerol-3-phosphocholine (GPC) produced the highest thermal shift. Microscale 
thermophoresis revealed a clear binding preference for GPC with a Kd of 3.6 µM for 
apo-Mtb UgpB. Further to these studies, alternative glycerophosphodiesters were also 
found to bind to Mtb UgpB, demonstrating that Mtb UgpB is promiscuous for a wide 
range of glycerophosphodiester substrates. Structural studies were undertaken in both 
solid and solution state and revealed, for the first time, the molecular basis of GPC and 
glycerophosphodiester recognition. Genetically engineered variants of Mtb UgpB were 
created to investigate the direct role of residues that interact with GPC and further 
define the molecular basis of substrate recognition and the specificity for 
glycerophosphodiesters. In addition, further studies were undertaken to produce 
additional components of the Mtb UgpABCE transporter and the nucleotide binding 
protein, Mtb UgpC (Rv2832c) was successfully expressed and its ATPase activity 
investigated. 
 
Combined, these results have provided critical insights into the structural and functional 
role of Mtb UgpB, revealing the specificity is not limited to GPC, and that Mtb UgpB 
may have adapted to scavenge alternative glycerophosphodiester metabolites via a 
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Chapter 1: Introduction 
 
1.1 Introduction 
1.1.1 Tuberculosis history 
Tuberculosis (TB) has a vast history of infecting humans spanning over thousands of 
years (Morse et al., 1964). Paleopathology and ancient DNA analyses have revealed 
that TB was widespread in ancient Egypt (Crubezy et al., 1998) as Pott’s lesions that 
are characteristic of spinal TB have been identified in Egyptian mummies dating back 
to 2400 BC (Zimmerman, 1979). There is also evidence of Mycobacterium tuberculosis 
(Mtb) complex DNA and cell-wall mycolic acids identified in the first Egyptian mummy 
to be scientifically studied, “Dr Granville’s” mummy, confirming the likely cause of death 
to be TB (Donoghue et al., 2010). Amazingly TB was also present in South America 
long before the first European’s had colonised as archaeological and DNA evidence 
have been identified in the remains of ancient Peruvian mummies (Salo et al., 1994), 
indicating that TB was globally spread in ancient times just as it remains today. 
 
At around the start of the industrial revolution in Europe by the late 18th and early 19th 
Centuries, TB was an epidemic and staggeringly the leading cause of death in many 
counties (Barberis et al., 2017). It was reported there were 800-1,000 deaths per 
100,000 of population per year (Krause, 1928). During this period of history the basis of 
infectious diseases were being studied extensively and the causative agent of 
tuberculosis, the bacillus Mtb was first isolated by Dr Robert Koch in 1882 (R. Koch, 
1882). However TB couldn’t be effectively treated and it wasn’t until the first half of the 
20th Century when the first antibiotics were discovered and developed to successfully 
treat tuberculosis (Schatz et al., 1944) (Lehmann, 1946) (Robitzek et al., 1952) . 
Streptomycin was the first anti-TB antibiotic to be developed. Initially it appeared to 
reduce TB mortality (Long et al., 1950) however drug resistance developed rapidly and 
it was later found to be ineffective if used in isolation (Fox et al., 1954). As new drugs 
were discovered and developed for TB, combination therapies were investigated due to 
the possibility of reducing relapse/drug resistance (BMJ, 1955). It was later found that 
combining streptomycin and the first synthetic anti-TB drug, para-aminosalicylic acid 
reduced the incidence of streptomycin resistance however it didn’t completely resolve 
the resistance problem (Fox et al., 1956). A new drug: isoniazid, was discovered in 
1952 and found to be extremely effective; however, when used alone, resistance also 
occurred in 70 % of cases after 3 months of treatment (Sita Lumsden et al., 1952). As 
almost all of the identified resistant strains were only resistant to one of the three 
available drugs this led to increased investigations into three drug regimens (Fox et al., 
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1955). The first curative regime is considered to be isoniazid combined with 
streptomycin and para-aminosalicylic acid and it had very low relapse rates of only 4 % 
for people treated for 1-2 years (MRC, 1962) (Fox et al., 1999). However more 
effective antibiotics to treat TB were later developed. Pyrazinamide was discovered 
and found to kill the Mtb bacilli that persisted after treatment with isoniazid and 
streptomycin (R. M. McCune, Jr. et al., 1956) and rifampicin was found to increase 
killing of the Mtb bacilli located in mouse organs (Grumbach, 1970). A compound far 
more potent than streptomycin was also discovered called ethambutol (Thomas et al., 
1961). The discovery of these more effective drugs led to a continued focus on the 
ease of administration and reducing the treatment duration and adverse side effects. 
These developments eventually led to the current recommended 6 month regimen 
(WHO, 2010) for treating drug susceptible TB: A 2-month intensive phase of isoniazid, 
rifampicin, pyrazinamide and ethambutol combined, followed by a continuation phase 
of isoniazid and rifampicin for 4 months. 
 
Since the implementation of drug treatments developed from 1940-1960 there had 
been a gradual decline in the number of new cases of TB and mortality rates in the 
developed world (Griffith et al., 1996). TB was beginning to be controlled and 
considered a disease of the past (Griffith et al., 1996). However the incidence of TB 
increased dramatically during the 1980’s to 1990’s, mainly fuelled by the HIV/AIDS 
epidemic (Havlir et al., 1999) and inadequate treatment practices leading to the 
development of multi-drug resistant TB (Frieden et al., 1993) (Seung et al., 2004). 
Now, in 2019 according to the latest report from the World Health Organisation (WHO, 
2018), TB is one of the top 10 leading causes of death worldwide and in 2017 an 
estimated 1.7 million people died and 10.0 million new people acquired the disease 
mostly in less developed countries (WHO, 2018). Disease incidence varies hugely 
between different counties (Figure 1.1) and TB is generally associated with poverty and 
overcrowding (Hill et al., 2006).  Developed countries have <10 new cases per 100,000 
people (WHO, 2018). In contrast, the 30 highest TB burden countries have 150-400 
new cases per 100,000 and the 3 countries with the highest burden of TB: 
Mozambique, Philippines and South Africa have >500 new cases per 100,000 (WHO, 
2018). Shockingly, over the past 200 years it’s estimated that globally 1 billion people 
have died as a result of TB, more than from malaria, influenza, smallpox, HIV/AIDS, 
cholera and the plague combined (Paulson, 2013). 
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Figure 1.1: Global incidence map of tuberculosis in 2017 (WHO, 2018). The highest 
incidences of TB appear to be in Sub-Saharan Africa and South East Asia. Shaded colours 
represent the estimated number of new TB cases per 100,000 population per year. 
 
1.1.2 Drug resistant TB 
Currently drug resistant TB is a looming public health crisis and it’s estimated that in 
2017, 558,000 people developed rifampicin resistant TB (RR-TB) (WHO, 2018). 
Rifampicin is one of the most effective frontline anti-TB drugs (Goldstein, 2014).  Of the 
558,000 RR-TB individuals, 82 % had developed multidrug resistant TB (MDR-TB), 
defined as resistance to both rifampicin and isoniazid. This trend appears to be being 
driven by poor treatment practices and lack of drug availability (WHO, 2018). 
Astonishingly almost half of the cases of MDR-TB were attributed to only 3 countries 
combined: India, China and Russia. MDR-TB is much more difficult to treat and as a 
consequence resistance appears to be getting worse as 8.5 % of drug resistant TB is 
now extensively drug resistant (XDR-TB) - defined as being resistant to rifampicin, 
isoniazid and the second-line anti-TB drugs including fluoroquinolones and one of the 
injectable drugs (Table 1.1). Furthermore there are reports of a small number of cases 
of totally drug resistant (TDR-TB) for which there is no cure (Udwadia et al., 2012).  
One of the main problems is that there are not enough new drugs being developed to 
meet the drug resistance crisis (Laughon et al., 2017) as pharmaceutical companies do 
not have profit incentives to invest. There is however some positive news as recently 
the FDA approved a new more effective and shorter, 6-month treatment for MDR-TB 
and XDR-TB using pretomanid combined with bedaquiline and linezolid (FDA, 2019). 
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Table 1.1: Current first line anti-TB drugs and second line anti-TB drugs used to treat 
rifampicin resistant (RR-TB) and multi drug resistant tuberculosis (MDR-TB). Table 
adapted from (WHO treatment guidelines for drug-resistant tuberculosis, 2016). 
Grouping of drugs Drug  
First line anti-TB drugs Isoniazid, rifampicin, ethambutol, 
pyrazinamide 
Second line anti-TB drugs Recommended 
for the treatment of rifampicin-resistant and 
multidrug-resistant tuberculosis. 
During the 8 month intensive phase: 
Pyrazinamide + 4 second line drugs: 1 (group 
A), 1 (group B), at least 2 (group C), a drug 
from group D2 and D3 if the combination 
cannot be composed from the above. 
Group A Fluoroquinolones: (levofloxacin, moxifloxacin, 
gatifloxacin) 
 
Group B Injectables: (amikacin, capreomycin, 
kanamycin, streptomycin) 
 
Group C Other agents: (ethionamide, cycloserine, 
linezolid, clofazimine 
 
Group D Add-on agents: (D1: pyrazinamide, 
ethambutol, high-dose isoniazid, D2: 
bedaquiline, delamanid, D3: p-aminosalicylic 
acid, imipenem, meropenem, amoxicillin, 
thioacetazone) 
 
1.1.3 WHO End TB Strategy 
The WHO has bold aims to tackle TB and in 2014 and 2015 all member states of the 
WHO and the United Nations (UN) made a commitment to end the TB epidemic by 
endorsing the End TB strategy (WHO, 2014). The End TB Strategy has set out key 
milestones in 2020 and 2025 to reduce the number of TB cases and deaths in order to 
end the TB epidemic by 2035 (WHO, 2014). The specific target for the End TB 
Strategy is for a 90 % reduction in the number of TB deaths and 80 % reduction in TB 
incidence compared with levels in 2015. However, currently the worldwide TB disease 
burden is not falling fast enough to meet the first 2020 milestone of a 35 % reduction in 
the number of TB deaths and 20 % reduction in incidence (WHO, 2018). Better 
treatments and diagnostics are needed however this requires a more extensive 
fundamental understanding of the pathophysiology of TB. 
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1.1.4 Anti-TB drugs in the clinical pipeline 
Due to the emergence of drug resistant TB, treatment regimens have had to be altered 
to accommodate different drugs and treatment durations have had to be increased. 
Many of the current anti-TB drugs have adverse side effects therefore there is an 
urgent need to develop new drugs that are safer and more effective and require shorter 
treatment durations. There are several new drugs currently in clinical development 
(Table 1.2).  
 
Table 1.2: Anti-TB drugs currently in clinical development. Adapted from (Tornheim et al., 
2019) (Libardo et al., 2018) and TB Alliance. 









































































































































































 Chapter 1: Introduction 	  
 
 7 
Bedaquiline is a new diarylquinoline anti-TB drug and is the first in its class, currently 
FDA approved for the treatment of MDR-TB (Andries et al., 2005). Bedaquiline is the 
first anti-TB drug that binds to Mtb ATP synthase and inhibits cellular respiration 
(Preiss et al., 2015). Delamanid is a bicyclic nitroimidazole and is currently FDA 
approved for the treatment of MDR-TB. Delamanid inhibits synthesis of mycolic acids, 
which is expected to enhance Mtb drug susceptibility although the exact target is not 
currently known (Manjunatha et al., 2009). Pretomanid is also a nitroimidazole and was 
recently approved for the treatment of MDR-TB and XDR-TB in combination with 
bedaquiline and linezolid (FDA, 2019). TBA-7371 is a potent anti-TB compound that 
targets Mycobacteria decaprenylphosphoryl-D-ribose-2-epimerase (DprE1) by non-
covalent inhibition (Gawad et al., 2018). DprE1 is an epimerase involved in a crucial 
step of Mycobacterial cell wall lipoarabinomannan and arabinogalactan biosynthesis 
where decaprenylphosphoryl-D-ribose is converted to decaprenylphosphoryl-D-
arabinose (Gawad et al., 2018). TBA-7371 is currently in phase II clinical trials and has 
demonstrated in vivo efficacy and safety (TB Alliance). Sutezolid is a oxaziolidinone 
analogue of the currently approved anti-TB drug, linezolid (Maartens et al., 2015). 
Sutezolid targets binding of N-formylmethionyl tRNA to the ribosome and inhibits 
bacterial protein synthesis (Wallis et al., 2014). Sutezolid is currently in phase I clinical 
trials and research has found that it may be clinically more effective compared to 
linezolid (TB Alliance). SQ109 is an ethylenediamine, related to ethambutol and is 
currently in phase II clinical trials. SQ109 was found to disrupt mycolic acid cell wall 
assembly by potentially targeting MmpL3, the transporter of trehalose monomycolate 
(TMM) (Tahlan et al., 2012). Nitazoxanide is an approved anti parasitic drug however it 
was found to have bactericidal activity against Mtb and is currently being tested in 
phase II clinical trials (Shigyo et al., 2013). Q203 is an imidazopyridine that targets 
respiration by inhibiting the QcrB subunit of the cytochrome. Q203 has been shown to 
inhibit MDR and XDR-TB growth (Pethe et al., 2013). Spectinamide is in phase I 
clinical trials and is being developed to treat drug resistant TB. Spectinamide inhibits 
the ribosome (Liu et al., 2017) and can overcome efflux by the Mtb Rv1258c efflux 
pump. Many of these compounds have novel activities; however considering the 
possibility of failure there is still an urgent need to develop new drugs. 
 
1.1.5 Causative agent of tuberculosis 
Dr Robert Koch first isolated Mtb the causative agent of TB in 1882. Mtb is part of the 
Mycobacteria genus made up of approximately 170 species many of which are non-
pathogenic, environmental saprophytes commonly found in the soil and water (Fedrizzi 
et al., 2017). Mycobacteria species have a characteristic morphology being rod-
shaped, acid-fast bacilli and have a unique thick and waxy cell wall (Petit et al., 1969) 
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(Lederer et al., 1975) (Minnikin et al., 1984) (Besra & Brennan, 1997) (Alderwick et al., 
2015). Historically the different Mycobacteria species have been classified as being 
fast growers or slow growers however they can be classified based on differences in 
16S rRNA sequence (Figure 1.2). Interestingly all of the human pathogens are found in 




Figure 1.2: Phylogenetic tree of selected Mycobacteria species based on partial 16S 
rRNA sequence (Rue-Albrecht et al., 2014). Red refers to species of the Mycobacterium 
tuberculosis complex MTBC and green refers to species of the Mycobacterium avium complex. 
	  
 
1.1.6 The Mycobacterium tuberculosis complex (MTBC) 
The Mycobacterium tuberculosis complex (MTBC) consists of species that can cause 
tuberculosis. Members of the MTBC include: Mycobacterium tuberculosis, 
Mycobacterium africanum, Mycobacterium bovis, Mycobacterium microti, 
Mycobacterium canettii, Mycobacterium pinnipedii, Mycobacterium caprae, 
Mycobacterium orygis, Mycobacterium suricattae and Mycobacterium mungi 
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(Gagneux, 2018). Species of the MTBC are very closely related at the nucleotide level 
sharing >99 % sequence similarity (Brosch et al., 2002) apart from Mycobacterium 
canettii that is only 97.3 % similar (Supply et al., 2013). They are most effectively 
distinguished by genetic markers including single nucleotide polymorphisms (SNP’s) in 
the 16S rRNA gene, DNA gyrase subunit B gyrB gene and large sequence 
polymorphisms called regions of difference (RD) (Huard et al., 2006). Other ways of 
distinguishing the different species are by their characteristic phenotypes, different host 
niches and pathogenicity.  
 
It was first believed that transmission of Mycobacterium bovis from domesticated 
animals during the Neolithic age led to the evolution of Mtb and human’s acquiring 
tuberculosis however more recent evidence suggests this is not the case (Manchester, 
1984). For example the order of gene loss identified from the Mycobacterium bovis 
genome (Garnier et al., 2003) suggested that humans may have actually transmitted 
tuberculosis to animals (Brosch et al., 2002) (Mostowy et al., 2002).  It is currently 
believed that the MTBC complex evolved from environmental Mycobacteria that 
adapted and gained the ability to survive intracellularly. One theory is that amoeba, a 
type of free-living animal more accurately a protozoon, that normally consumes 
bacteria could have provided the intracellular niche for the MTBC progenitor to first 
evolve (Jang et al., 2008). The first MTBC progenitor is likely to have acquired genes 
potentially by horizontal gene transfer and also gene loss that enabled it to survive 
inside anaerobic conditions however no single genetic feature appears to be 
responsible for MTBC virulence (Veyrier et al., 2011).  
 
More recently evidence seems to point to the origin of the human adapted MTBC being 
from Africa, and Africa incidentally also has all 7 human adapted MTBC lineages 
(Figure 1.3) and the largest lineage diversity (Gutierrez et al., 2005). It is thought that 
the first MTBC progenitor evolved from an organism most similar to Mycobacterium 
canetti (Supply et al., 2013), a smooth tubercle bacilli that are the closest relatives of 
the MTBC only found in the Horn of Africa and sharing 97.3 % nucleotide similarity to 
Mtb. However the exact age of the MTBC progenitor is not known, one study estimated 
it to have existed 70,000 years ago based on the co-divergence of humans and MTBC 
and the first migrations out of Africa (Comas et al., 2013). 
 
Of the MTBC species, only two are primarily associated with causing tuberculosis in 
humans and include Mtb and Mycobacterium africanum (Brites et al., 2015). Mtb and 
Mycobacterium africanum are further divided into 7 phylogenetic lineages and have 
enabled ecological mapping: L1, L2, L3, L4 and L7 are the Mtb lineages and L5 and L6 
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are the Mycobacterium africanum West Africa 1 and 2 lineages. Mtb L2 and L4 
lineages are the most wide spread lineages throughout the world (Figure 1.3) and 
cases of TB have been reported on every continent. 
 
 
Figure 1.3: Genetic phylogeny and global distribution of the MTBC lineages (Gagneux, 
2018). Coloured symbols refer to the seven human-adapted MTBC lineages. Grey symbols 
refer to the primarily animal adapted MTBC lineages. RD refers to genome region of deletion 
found in the lineages. Mycobacterium tuberculosis lineages L2 and L4 are the most wide spread 
globally.  
 
The other MTBC species are mainly adapted to cause tuberculosis in animals; more 
specifically mammals however there have also been reports of transmission events to 
humans. For example Mycobacterium bovis is the primary cause of tuberculosis in 
cattle and believed to be transmitted from wildlife animals where it causes significant 
economic damage to the agriculture industry (Pollock et al., 2002).  In the United 
Kingdom, the role that badgers have in maintaining bovine tuberculosis in cattle is very 
controversial. The results of the randomised badger culling trial found that badger 
culling reduced the incidence of TB in cattle herds (Donnelly et al., 2007). However if 
less than 70 % of badgers are culled in the area defined by the study there is evidence 
that bovine TB could increase due to the perturbation effect (Donnelly et al., 2006). In 
the long-term badger culling is not considered to be sustainable and it is also strongly 
opposed by the public for being inhumane. Furthermore the validity of DEFRA 
published data (DEFRA, 2014) has been strongly criticised for being misleading and 
puts into question the efficacy of these culls. Interestingly there have been cases of 
humans acquiring Mycobacterium bovis and developing tuberculosis (Grange, 2001) 
and the consumption of unpasteurised milk or products made from infected animals is 
 Chapter 1: Introduction 	  
 
 11 
thought to be how it is transmitted (Hancox, 2002). More recently transmission of 
Mycobacterium pinnipedii from sea lions to humans in a zoo was reported to have 
caused tuberculosis in humans therefore there appears to be the propensity for other 
members of the MTBC to cross the species barrier and infect humans (Kiers et al., 
2008). In contrast other non-tuberculosis Mycobacteria species exist that infect 
humans however do not cause tuberculosis including Mycobacterium abscessus, 
Mycobacterium avium, Mycobacterium marinum Mycobacterium xenopi, 
Mycobacterium gordonae and Mycobacterium kanasii (Gagneux, 2018). Genetically 
these species have diverged from the MTBC (Porvaznik et al., 2017) for example 
Mycobacterium avium is associated with causing disease mostly in 
immunocompromised individuals (Kiehn et al., 1985) and Mycobacterium marinum is 
able to cause skin infections and tuberculosis-like disease in immunocompromised 
individuals (Aubry et al., 2002) (Parent et al., 1995). 
 
1.1.7 Comparative genomics of the M. tuberculosis complex (MTBC) 
The complete genome sequence of the first characterised strain of Mtb, H37Rv was 
deciphered in 1998 (Cole et al., 1998) however many other strains of Mtb have since 
been fully sequenced (Zhang et al., 2011) (Manson et al., 2017). The complete 
genome sequence revealed that the Mtb genome is approximately 4.4 Mbp and has a 
very high guanine + cytosine content.  Currently the Mtb genome is annotated to 
encode 4173 genes (Mycobrowser, 2019). Several other species of Mycobacteria 
complete genomes have since been sequenced and are available (Sanger, 2019) 
These datasets are invaluable tools to investigating the fundamental biology of 
Mycobacteria because comparative genomics can be used to explore differences at 
the genetic and biochemical level that may influence pathogenicity and survival. One of 
the key insights came from comparing the genomes of Mycobacterium tuberculosis, to 
Mycobacterium bovis and Mycobacterium bovis BCG (Mahairas et al., 1996), the live-
attenuated vaccine strain that is unable to infect humans. Comparative genomics 
revealed 16 distinct genomic regions of deletion that were deleted in Mycobacterium 
bovis and Mycobacterium bovis BCG (Behr et al., 1999) that may have a role in its loss 
of pathogenicity. Of particular note was a spontaneous deletion in the type VII 
secretion system ESX-1 a key virulence factor involved in host cell lysis that led toward 
the attenuation of Mycobacterium bovis BCG (Groschel et al., 2016). 
 
Another important genomic insight came from sequencing the complete genome of 
Mycobacterium leprae (Vissa et al., 2001). Mycobacterium leprae is the causative 
agent of leprosy (R. Koch, 1882). This study revealed that Mycobacterium leprae had 
undergone massive genome decay and pseudogenes now occupy half of its genome 
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(Vissa et al., 2001). The Mycobacterium leprae genome is only 3.2 Mbp and 
approximately one third of its genome had been lost. Because Mycobacterium leprae is 
pathogenic, its 2963 genes (Mycobrowser, 2019) are considered to be the minimal set 
of genes required for the survival and pathogenesis of Mycobacteria (Monot et al., 
2009). Therefore any genes conserved between Mycobacterium tuberculosis and 
Mycobacterium leprae are likely to be essential for its survival (Vissa et al., 2001).  
 
1.1.8 Finding essential genes  
Complete genome sequencing of Mycobacteria species has led to advancements in 
identifying the genes that are essential for Mtb growth, that are therefore most likely to 
be suitable drug targets. Early technologies used transposon site hybridisation (TraSH) 
knockout libraries and microarrays (Sassetti et al., 2001) to identify essential genes 
however deep sequencing of transposon (Tn) insertion (TnSeq) libraries has been a 
more powerful tool to identify essential genes required for Mtb growth in vitro and in 
host macrophages in vivo. The most recent study identified 625 open reading frames 
(ORF’s) that are essential for optimal Mtb growth in vitro (DeJesus et al., 2017). A 
drawback of these studies is that they do not fully reflect the nutrient scarce 
environment encountered inside host macrophages. 
 
1.1.9 Lifecycle and pathogenesis of M. tuberculosis infection 
Mtb is well adapted to infect humans. However, unlike many other pathogens, due to 
its infection life cycle it has to cause disease in order to transmit between individuals 
(Brites et al., 2012). TB primarily affects the lungs where it is called pulmonary TB 
however the bacteria have the potential to enter the lymphatic system and 
bloodstream, disseminate to distant tissue and cause disease in TB susceptible 
regions including the lymph nodes, kidneys, brain, bones and spine (Yates et al., 1993) 
(Garg et al., 2011) (Eastwood et al., 2001) (Garg, 1999). Once disseminated the 
disease is now classified as extra-pulmonary TB, and is more difficult to treat (J. Lee, 
2015). For the majority of individuals that are initially infected with Mtb, the immune 
response is sufficient to effectively control the infection however individuals with 
weakened immune systems are inherently more susceptible to developing active TB 
(Cadena et al., 2017). Individuals with active TB are clinically symptomatic and able to 
readily transmit the disease. However for the other infected individuals classified as 
latent TB infected, containment of the disease is a lifelong standoff where bacterial 
replication is controlled by the immune system yet there is the potential for it to 
reactivate and become active TB (Getahun et al., 2015). Approximately one-quarter of 
the global population are latent infected (WHO, 2018). This represents a huge potential 
infection reservoir of clinically asymptomatic, non-infectious individuals and 
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approximately 5-10 % of latent infected TB individuals will develop active TB at some 




Figure 1.4: Stages of Mtb infection. Mtb transmission results in either active infection or latent 
infection. Latent infection can commonly develop into active infection if immunosuppressed. * 
refers to drug-susceptible TB, ** refers to if not treated (Koul et al., 2011). 
 
A schematic of the life cycle of Mtb infection is described (Figure 1.5). Actively infected 
TB individuals transmit TB by the air-borne route. The bacteria, contained inside small-
aerosolised droplets only 0.65-7 µm in diameter (Fennelly et al., 2004) are released by 
coughing or sneezing and inhaled by nearby individuals (Loudon et al., 1969). 
Aerosolised droplets accommodating one-three individual bacteria remain suspended 
in the atmosphere for several hours (Fennelly et al., 2004). Prolonged close contact 
with active TB infected individuals therefore is necessary to transmit the infection. 
Once inhaled, aerosolised droplets enter the respiratory tract, reaching the bronchi and 
distal alveoli where the infection establishes. Resident alveolar macrophages and other 
phagocytes are recruited to the site of infection and interact with the bacteria using C-
type lectin receptors (Goyal et al., 2016), scavenger receptors (Zimmerli et al., 1996) 
and complement receptors (Hirsch et al., 1994) resulting in phagocytosis of the 
bacteria (Jo, 2008) (Russell, 2011). Most of the bacteria are destroyed by this innate 
immune response however a small number are able to survive as the bacteria prevent 
key defence pathways including phagosome maturation and reside inside a 
compartment that resembles the early endosome where they are able to replicate 
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intracelluarly (Ehrt et al., 2009). The macrophage also facilitates transport of the 
bacteria across the lung epithelium to deeper tissue (Cambier, Takaki, et al., 2014). 
Additional immune cells and macrophages are recruited to the infection site and form a 
granuloma that serves as a barrier to confine the infection from spreading however 
importantly this does not eradicate the infection (Chao et al., 2010). The bacteria are 
instead able to survive and persist in the granuloma for decades where it is called 
latent TB.  Latent TB has a high risk of reactivation if the individual is 
immunocompromised e.g. receiving an organ-transplant (Aguado et al., 1997), chronic 
renal failure (Hussein et al., 2002) or receiving anti-TNF therapy (Solovic et al., 2010). 
Other lower risk factors include diabetes mellitus (Harries et al., 2011), smoking (Slama 
et al., 2007), steroid treatment (Jick et al., 2006) and malnutrition (Comstock, 2008). 
However by far the greatest risk of latent TB developing into active TB is if infected with 
HIV as the risk increases dramatically by 10-110 times (Ai et al., 2016). Eventually 
death of the granuloma infected cells causes a necrotic zone enabling bacteria to be 
released into the lung and further transmitted (Sharma et al., 2005). 
 
Figure 1.5: Infection life-cycle of Mycobacterium tuberculosis (Cambier, Falkow, et al., 
2014). 
 
1.1.10 Modelling tuberculosis 
As latent tuberculosis represents such an enormous disease reservoir there has been 
intensive research focus towards combatting the latent phase of the disease and 
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several models are now available to study latent TB. In vitro models are the most 
practical and widely amenable to research methods however animal infection models 
are better because they more accurately recapitulate the similarities in human TB. 
Nutrient depravation in culture is a useful way of simulating the environment Mtb 
encounters in necrotic granulomas. For example in the Hobby and Lenert model, the 
carbon source from logarithmic bacterial cultures was removed by washing the cells 
and resuspending them into PBS. The result was bacterial growth arrest, reduced 
metabolism and the bacteria were refractory to isoniazid and p-aminosalicylic acid and 
showed similar antibiotic susceptibility profiles to latent TB (Hobby et al., 1957). 
However the best characterised model of dormancy is the Wayne and Hayes 
progressive hypoxia model (Wayne et al., 1996). In this model, bacteria are exposed to 
progressive hypoxia that mimics the low O2 environment in necrotic granulomas. At <1 
% dissolved O2 the outer cell wall thickens and DNA replication and transcription stops. 
If the dissolved O2 is reduced further to <0.06 % the bacteria are more refractory to 
isoniazid and rifampicin. Diluting the bacteria into O2 rich media reversed these effects 
and triggered reactivation (Wayne et al., 1996). Nutrient starvation models are 
particularly useful to understand what nutrients Mtb utilises by culturing in minimal 
media and observing the effect of adding single substrates. As a drug discovery tool, 
the streptomycin dependent Mtb strain 18b is also a useful model because it mimics 
latent non-replicating bacteria in the absence of streptomycin (Benjak et al., 2016). 
 
Animal infections models have been used to establish drug and vaccine efficacy, 
understand the immunological response to Mtb infection, the pathophysiology of 
disease and to model latent disease and reactivation. Mice are the most widely used 
models of pulmonary TB because they are practically easy to manage and have similar 
immunological responses to humans (A. M. Cooper, 2014). However one limitation is 
that they demonstrate different pathologies possibly because Mtb is not a natural 
pathogen of mice. For example one of the hallmarks of human TB are progressive 
caseating granulomas and lung cavitations that are not observed in mice infected with 
Mtb (Apt et al., 2009). Instead in mice most of the Mtb bacteria are found intracellularly 
in the lungs (Hoff et al., 2011). The murine, persistence model is the best characterised 
in vivo model of persistence and was developed by McCune and McDermott (R. M. 
McCune et al., 1966). In this model, mice were first infected with a high dose of Mtb 
and then treated with isoniazid and pyrazinamide until the recovered bacteria were no 
longer able to be cultured. When the antibiotics were stopped or high dose 
corticosteroids were added the persistent bacteria reactivated.  
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Guinea pigs have a very high susceptibility to Mtb infection and similar to in humans 
the disease is progressive as necrotic primary granulomas form. As Guinea pigs have 
a high susceptibility to disease they are used extensively for vaccine testing (U. D. 
Gupta et al., 2009). In contrast Rabbits are resistant to H37Rv Mtb however they are 
susceptible to M. bovis infection and demonstrate similar disease pathologies as 
humans (Manabe et al., 2003). Non-human primates are the best model of HIV/TB co-
infection since they have been used for modelling simian immunodeficiency virus (SIV) 
infection (Lin et al., 2006). Non-human primates are evolutionary more similar to 
humans and therefore are used for TB drug and vaccine efficacy. However they are 
incredibly difficult and costly to house and there use raises significant ethical issues. 
Zebrafish are used extensively as an experimental animal model using the natural 
pathogen M. marinum. M. marinum is approximately 85 % similar to Mtb at the genome 
level (Stinear et al., 2008). M. marinum infection of zebrafish causes systemic disease 
and granuloma formation similar to in humans  (Swaim et al., 2006). Zebrafish can be 
genetically manipulated, are easily infected and the optical properties of embryos 
enable fluorescent imaging therefore they are frequently used to model latent disease 
(Benard et al., 2012).  
 
1.1.11 Mtb Survival tactics and the Mtb cell wall 
Sputum acid-fast staining is the gold standard diagnostic for tuberculosis infection 
particularly in developing countries (M. Koch et al., 1965). The method is effective 
because of the unique and complex structure of the Mtb cell envelope, made up of 
approximately 40 % lipids by dry cell mass (Goren et al., 1974) (Minnikin et al., 1984). 
The high amounts of lipids make the Mtb cell envelope highly hydrophobic and confer 
an excellent barrier to impermeable antibiotics and contribute to TB being so difficult to 
treat (Jarlier et al., 1994). Several drugs including isoniazid (Banerjee et al., 1994), 
ethambutol (Telenti et al., 1997) and ethionamide (Banerjee et al., 1994) target the 
synthesis of the cell envelope and are used to effectively treat TB therefore the 
synthesis of the cell envelope has been the subject of intensive research effort 
(Belanger et al., 1996) (Belisle et al., 1997) (Marrakchi et al., 2000) (DeBarber et al., 
2000) (Alderwick et al., 2006) (Alderwick et al., 2007). 
 
Although the Mtb cell envelope is classified as Gram-positive it does not stain Gram-
positive with crystal violet and its architecture more accurately resembles the Gram-
negative cell envelope (Brennan et al., 1995). The current model of the Mtb cell 
envelope postulates it is made up of an inner plasma membrane surrounded by an 
outer membrane composed of a large mycolyl-arabinogalactan-peptidoglycan (mAGP) 
complex (Minnikin et al., 1984) (Figure 1.6) (Alderwick et al., 2015). The peptidoglycan 
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layer serves as the anchor that is bridged by arabinogalactan covalently attached to 
the mycolic acid layer. Mycolic acids are long chained C60-C90 fatty acids that confer 
the high hydrophobicity of the cell envelope (Daffe et al., 1998). However, additional to 
the mAGP, several other lipids intercalate with the mycolic acid layer and plasma 
membrane. These include: phosphatidylinositol mannosides (PIM) (Lee et al., 1964), 
pthiocerol dimycocerosates (PDIM) (Daffe et al., 1998) phenolic glycolipids (PGL) (van 
Soolingen et al., 1997), acetyltrehalose (Takayama et al., 1977) and mannose-capped 
lipoarabinomannan (LAM) (Besra, Morehouse, et al., 1997). A capsule makes up the 
outermost layer of the cell envelope and is made up of polysaccharides, proteins and a 
small amount of lipids (Daffe et al., 1999). Because the cell envelope is at the interface 
of the bacteria and host many of its components are involved in host-pathogen 
interactions by mediating interactions with specialist phagocyte receptors (Stanley et 
al., 2013), involved in impairment of phagosome maturation in the macrophage 
(Russell, 2011). Inside the macrophage Mtb modulates the function of host cells by 
inhibiting maturation of phagolysosomes (Deretic et al., 2006), inhibiting acidification of 
phagolysosomes (Vandal et al., 2009), inhibiting apoptosis and autophagy (Briken et 











Figure 1.6: Schematic of the cell envelope of M. tuberculosis. Peptidoglycan (PG), 
arabinogalactan (AG), mycolic acids, lipoglycans: phosphatidylinositol mannosides (PIM), 
lipomannan (LM), lipoarabinomannan (LAM). Trehalose dimycolate (TDM), trehalose 
monomycolate (TMM), sulpholipids (SL), phthiocerol dimycocerosate (PDIM), di-acyl trehalose 
(DAT) (Alderwick, 2019). 
 
1.1.12 Lipids found in the inner cell membrane of Mycobacteria 
In all living organisms phospholipids are key structural components of cell membranes 
and make up the inner phospholipid bilayer (Figure 1.7) (Bansal-Mutalik et al., 2014). 
The most comprehensive quantitative analysis of the inner membrane lipids of 
Mycobacteria is from a study that successfully separated the ‘outer’ mycomembrane 
from the inner membrane of M. smegmatis by reverse micelle extraction (Figure 1.7) 
(Bansal-Mutalik et al., 2014).  
 
Phospholipids were found to be exclusively present in the inner membrane of M. 
smegmatis and included: phosphatidylglycerol (∼1.16 %), phosphatidylinositol (∼0.37 
%) and phosphatidylethanolamine (∼0.52 %) by dry cell mass (Bansal-Mutalik et al., 
2014). However by far the most abundant lipid found in the inner membrane was diacyl 
phosphatidylinositol dimannoside (Ac2PIM2) accounting for ∼42 % by weight of all lipids 
found in the inner membrane (Bansal-Mutalik et al., 2014). Other phosphatidylinositol 
mannosides (PIMs) identified were either mono or diacylated and contained variable 
degrees of mannosylation including: AcPIM2, AcPIM4/Ac2PIM4, and AcPIM6/Ac2PIM6 
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accounting for ∼3% dry cell mass (Bansal-Mutalik et al., 2014). Trehalose 
monomycolate (TMM) and apolar lipids were also found in the inner membrane 
(Bansal-Mutalik et al., 2014). TMM is thought to be produced in the cytosol and 











Figure 1.7: Model of the Mycobacterial inner membrane (Bansal-Mutalik et al., 2014). IM 
refers to inner membrane. PL refers to the phospholipids: phosphatidylglycerol, 
phosphatidylinositol and phosphatidylethanolamine. AcPIM6, Ac2PIM6 and Ac2PIM2 refer to 
phosphatidylinositol mannosides (PIM’s), Ac refers to the degree of acylation and TMM refers to 
trehalose monomycolate. 
 
Interestingly, phosphatidylinositol is rarely found in the membranes of prokaryotes 
however it is found in some actinomycetes including Mtb where it is a major 
phospholipid (Jackson et al., 2000) that serves as a lipid anchor for the cell envelope  
hyper-mannosylated PIM’s: linear lipomannan (LM) and branched lipoarabinomannan 
(LAM) (Briken et al., 2004). LM and LAM are involved in virulence and have immuno-
modulatory activities (Pitarque et al., 2008). Phosphatidylinositol is considered to be 
essential for membrane stability and cell survival and its importance is highlighted by 
Mycobacteria also encoding an inositol metabolic pathway and an essential 
phosphatidylinositol synthase pgsA gene (Jackson et al., 2000). Inositol is either 
scavenged or synthesised from glucose-6-phosphate and then made into 
phosphatidylinositol or intracellular mycothiol. Phosphatidylinositol either forms the cell 
membrane or is modified to form mono and diacylated PIM and the hyper-
mannosylated LM and LAM (Jackson et al., 2000).  
 
1.1.13 Lipids found in the cell membrane of macrophages 
Mtb is able to survive in macrophages for decades (Pieters, 2008) however we don’t 
fully understand exactly what nutrients it utilises. Macrophage membranes are made of 
several important components that Mtb may be able to scavenge and utilise. 
Macrophage membranes are made of >80 % phospholipids, the other major lipids are 
cholesterol, triacylglycerol (TAG) and cardiolipin (Figure 1.8) (Sahu et al., 1977). Of the 
different phospholipid types the major phospholipid found in the plasma membrane is 
phosphatidylcholine and it is mainly localised to the outer layer of the plasma 
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membrane (Leventis et al., 2010). Whereas the amino-group containing phospholipids: 
phosphatidylserine and phosphatidylethanolamine are mainly located in the inner layer 
of the plasma membrane (Leventis et al., 2010). Other important phospholipids of 
macrophages are phosphatidylglycerol, lyso-(bis)phosphatidic acid, sphingomyelin and 
phosphoinositides (Sahu et al., 1977). Phosphoinositides are made of 
phosphatidylinositol that is phosphorylated at different positions of the inositol ring. 
Phosphoinositides are important eukaryote intracellular signalling mediators and have 
critical roles during intracellular infection (Defacque et al., 2002) (De Matteis et al., 
2004).  
 





Figure 1.8: Structures of the major lipids found in macrophage membranes. R refers to the 
fatty acid tail. The displayed phosphatidyl-inositol-4-phosphate is a phosphoinositide however 
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One of the strategies used by Mtb to escape macrophage phagocytosis is by blocking 
phagosomal maturation through interfering with macrophage phosphatidylinositol-3-
kinase signalling (Figure 1.9A) (Deretic et al., 2006). LAM in the Mtb cell envelope acts 
as a phosphatidylinositol-3-phosphate analogue and inhibits macrophage cytosolic 
Ca2+ release leading to blockade of the phosphatidylinositol-3-kinase cascade. As a 
result phagosomes do not mature because phosphatidylinositol-3-phosphate is not 
produced on liposome and phagosome membranes (Vergne et al., 2003). However the 
macrophage is also able to utilise its membrane phospholipids for innate defences 
(Callahan et al., 2000). Redistribution of macrophage phosphatidylserine triggers 
efferocytosis, an apoptotic cell engulfment process where un-infected macrophages 
phagocytose the apoptotic Mtb infected macrophage to kill and restrict Mtb growth 
(Figure 1.9B) (Callahan et al., 2000). 
 
 
Figure 1.9: Manipulation of host phospholipids by Mtb and macrophage phospholipid 
defence strategy (Teng et al., 2017). A) Mtb escapes macrophage phagocytosis by blocking 
phagosomal maturation using LAM to interfere with macrophage phosphatidylinositol-3-kinase 
signalling. B) Redistribution of macrophage phosphatidylserine leads to efferocytosis, 
phagocytosis of apoptotic Mtb infected macrophages. 
 
 
1.1.14 Mycobacterium tuberculosis nutrient acquisition  
Mtb resides in a nutrient limited environment and the complete nutritional requirements 
required for its survival are not well characterised. By identifying the specific nutrients it 
utilises, targeted methods could be developed to restrict nutrient uptake and effectively 
starve the bacteria. However to date, the complete nutritional profile utilised by Mtb 
during infection in the host is not known (Titgemeyer et al., 2007). Studies in the early 
20th Century (Edson, 1951) investigated the growth of Mtb in minimal media and 
different carbon sources and found that Mtb most effectively grows on glycerol or 
sodium salts of fatty acids. In 1925 Novy and Soule (Novy, 1925) developed respiratory 
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exchange to determine the oxygen consumption and carbon dioxide production of Mtb 
grown on nutrient agar containing either glycerol or glucose. Later Loebel, Shorr and 
Richardson (Loebel, 1930) studied Mtb respiration in suspended cultures containing 
phosphate buffer and single substrates and found that either glycerol or sodium salts of 
fatty acids were the most effective stimulants of respiration. Whereas glucose 
produced only a weak stimulation and arabinose, fructose, mannose and inositol 
produced no significant effects (Loebel, 1930). A more extensive study by Nakamura 
(Nakamura, 1938) measured oxygen consumption of Mtb in the presence of 25 
different substrates and found that glycerol was the only substrate that produced an 
increase with a small stimulatory effect for glutamate. However it wasn’t until the 
1950’s when 7H9 broth and 7H10 agar media were developed and found to be 
instrumental to routinely culture Mtb (Middlebrook et al., 1954) (Middlebrook et al., 
1958). These media effectively support the growth of Mtb if supplemented with 
nutrients such as glycerol, oleic acid, albumin and dextrose provided by Middlebrook 
OADC/ADC enrichment. The primary carbon sources in these media are glycerol, 
dextrose and the fatty acid, oleic acid. It was later found that Mtb is also able to utilise 
tween 80 as a carbon source that is frequently added to cultures to prevent cell 
clumping (Lyon et al., 1963). It is presumed that due to the slow growth rate of Mtb, 
doubling every 24 hours, glycerol is able to freely diffuse across the membrane at a 
sufficient rate to support cell growth (Paula et al., 1996). However it is argued that all 
molecules are imported by specific transporter proteins (Kell, 2015). Intracellular 
glycerol kinases may convert glycerol to glycerol-3-phosphate where it enters central 
carbon metabolism pathways to generate ATP (Niederweis, 2008). However the 
conditions that Mtb encounters during infection are far more complex compared to in 
culture.  
 
Studies have found that Mtb utilises carbohydrates during the early stages of infection 
(Sassetti et al., 2003). However it is thought that the host immune response triggers a 
switch to fatty acids becoming the primary nutrient source (Kalscheuer et al., 2010). 
Evidence for fatty acid utilisation is supported by the glyoxylate cycle being essential 
for Mtb survival in mice as isocitrate lyases, malate synthases and β-oxidation 
enzymes that convert fatty acids to acetate that flow into the citric acid cycle are 
required to sustain growth and persistence in macrophages (McKinney et al., 2000) 
(Schnappinger et al., 2003) (Dubnau et al., 2005) (Timm et al., 2003). However the 
types of fatty acids that may be utilised, where they are sourced and how they are 
imported are not fully understood. 
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Cholesterol is an important molecule found in eukaryote cell membranes including 
macrophages and studies have demonstrated that Mtb utilises cholesterol and that it is 
required for growth and persistence in animal infection models (J. C. Chang et al., 
2009) (Van der Geize et al., 2007). Mtb encodes >80 genes (Van der Geize et al., 
2007) dedicated to cholesterol import and metabolism as it provides the precursors, 
propionyl-CoA and methyl malonyl-CoA of important cell wall lipids including PDIM and 
SL as well as pyruvate that enters the citric acid cycle (Wilburn et al., 2018). 
Cholesterol has also been found to accumulate in the granuloma in animal infection 
models (Kim et al., 2010). 
 
One of the major challenges that Mtb faces is how to import these different nutrients 
across the outer and inner impermeable cell membranes, similar to how it is so difficult 
for antibiotics to penetrate the cell envelope. To date we don’t fully understand what 
transporters Mtb utilises to facilitate nutrient import. Recently, sophisticated NMR 
(Somashekar et al., 2011) and mass spectrometry, metabolomics methods 
(Nandakumar et al., 2015) have investigated the metabolites that fluctuate during Mtb 
infection of macrophages and in animal models. High-resolution magic angle spinning 
NMR spectroscopy revealed that in Mtb infected guinea pig granuloma, the rate of 
metabolic flux for carbohydrates, amino acids, phospholipid components and other 
metabolites increases (Somashekar et al., 2011). This suggested that Mtb potentially 
utilises alternative energy sources through the glycolytic, pentose phosphate and citric 
acid cycle pathways in developing granuloma (Somashekar et al., 2011). 13C 
metabolomics studies have also revealed metabolic pathway remodelling. For 
example, during hypoxia the Mtb citric acid cycle slows and increases production of 
succinate in order to flexibly sustain membrane potential, ATP synthesis and 
anaplerosis (Eoh et al., 2013).  However further investigations are required because 
Mtb has probably evolved multiple complex strategies to utilise nutrients in the varied 
and scarce environments it encounters in the macrophage, the granuloma, the 
extracellular environment and specific Mtb susceptible tissues. 
	  
1.1.15 Carbohydrate transporters of Mycobacterium tuberculosis 
Bioinformatics analysis of the Mtb H37Rv and M. smegmatis genomes revealed that 
Mtb only encodes 5 putative carbohydrate transporters whereas M. smegmatis the 
non-pathogenic environmental saprophyte encodes an enormous 28 putative 
carbohydrate transporters (Figure 1.10), suggesting it is well adapted to import 
environmental carbohydrates (Titgemeyer et al., 2007). Therefore the limited number of 
putative carbohydrate transporters encoded by Mtb may reflect the nutrient scarce host 
cell macrophage environment (Titgemeyer et al., 2007).  







Figure 1.10: Comparison of the putative carbohydrate transporters of Mycobacterium 
smegmatis and Mycobacterium tuberculosis (Niederweis, 2008). MFS refers to major 
facilitator superfamily, PTS refers to phosphotransferase system, MIP refers to major intrinsic 
protein family, SSS refers to sodium solute superfamily and ABC refers to ATP-binding cassette 
transporter. 
 
Of the 5 putative transporters encoded by Mtb, 4 belong to the ATP-binding cassette 
(ABC) transporter class and only 1 is a permease that belongs to the major facilitator 
superfamily (Braibant et al., 2000). ABC transporters facilitate nutrient import in an ATP 
hydrolysis dependent alternating access mechanism (Locher, 2016). They are typically 
composed of 4 subunits (Figure 1.11), the substrate binding protein (SBP) specifically 
binds to cognate ligand in the periplasm, the membrane spanning domains  (MSD’s) 
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2016). In contrast, permeases of the major facilitator superfamily are single integral 
membrane proteins made up of 12-14 transmembrane α-helices and also facilitate 
nutrient import by alternating access (Pao et al., 1998). The predicted Mtb 
carbohydrate permease of the major facilitator superfamily is SugI and the 4 ABC 
carbohydrate transporters include: LpqY-SugABC, UspABC, Rv2041c-2040c-2039c-
2038c and UgpABCE (Figure 1.10) (Niederweis, 2008). Little knowledge about the 
substrate preference can be predicted because the sequence similarities of these 
transporters are very low outside of the Mycobacteria genus (Titgemeyer et al., 2007). 
Many of these transporters are encoded by other Mycobacteria pathogens as well as 
non-pathogenic species. Overall SugI, UspABC, Rv2041c-2040c-2039c-2038c and 
UgpABCE are poorly characterised. LpqY-SugABC was predicted to bind to maltose 
however it was found to actually bind to trehalose (Kalscheuer et al., 2010).  Further 
studies of these transporters could reveal important nutrient uptake pathways utilised 
by Mtb during infection and identify new targets for drug development. 
 
 
Figure 1.11: Architecture of an ATP-binding cassette (ABC) importer. SBP refers to the 
substrate binding protein, MSD refers to the membrane spanning domains, and NBP refers to 
the nucleotide binding proteins. The location of the subunits relative to the cytoplasm and 
periplasm are indicated. 
 
1.1.15.1 Mtb SugI 
SugI is a predicted integral membrane protein and member of the major facilitator 
superfamily. SugI is predicted to be composed of 12 transmembrane α-helices 
(ExPASy TMPred) (K. Hofmann, 1993). By amino acid sequence homology SugI is 
most similar to the glucose permease GlcP (28 %) of S. coelicolor and to the galactose 
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transporters import monosaccharides SugI may also be involved in the transport of 
monosaccharides (Niederweis, 2008). Recently a study identified a mutation in SugI 
that generated a premature stop codon and caused N-terminal truncation of SugI. This 
mutation in SugI was associated with resistance to the anti-TB antibiotic, D-cycloserine 
(Chen et al., 2017). Interestingly D-cycloserine has a similar overall structure to the 
furanose pentose monosaccharides therefore SugI may be involved in the import of 
arabinose and assembly of the arabinogalactan layer of the cell envelope (Figure 
1.12). However to date SugI has not been biochemically characterised. As it is a single 




Figure 1.12: Comparison of the structures of the furanose pentose monosaccharide, 
arabinose, D-Cycloserine and Mtb arabinogalactan. 
 
1.1.15.2 Mtb LpqY-SugABC 
LpqY-SugABC is especially interesting because it was the first of the 5 predicted 
carbohydrate importers of Mtb to be identified as critical for virulence (Kalscheuer et 
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disaccharide trehalose. Trehalose is a sugar not present in mammals as only a small 
amount of dietary trehalose is ingested and enzymatically digested by trehalase 
enzymes to be utilised as glucose (Gudmand-Hoyer et al., 1996). However, in Mtb 
trehalose is released as a by-product of mycolic acid synthesis by the activity of the 
Ag85 complex that synthesises the lipid trehalose dimycolate (TDM) (Takayama et al., 
2005) (Ronning et al., 2000). The released free trehalose is recycled and transported 
by LpqY-SugABC where it is used to synthesise trehalose monomycolate (TMM). 
MmpL3 exports TMM across the inner membrane where it is processed by Ag85 to 
TDM and forms the mycomembrane (Figure 1.13) (Wolber et al., 2017). Interestingly a 
mutant Mtb LpqY-SugABC strain showed strong attenuation in an 
immunocompromised mice model and a severe growth defect in the mice lungs during 
the acute phase of infection however it could persist during the chronic infection and 
demonstrates a role for this transporter in the early stages of infection (Kalscheuer et 
al., 2010). In a separate study trehalose was chemically modified to have azido, deoxy 
and fluoro-sterochemical modifications at positions 2-, 5- and 6- and when added to M. 
smegmatis cells inhibited growth and the ability for biofilm formation (Wolber et al., 
2017). Although studies of LpqY-SugABC in whole Mtb cells have been carried out it 
















































Figure 1.13: Potential trehalose recycling pathway. LpqY-SugABC imports free trehalose 
that is either converted to α-Glucans, glucose or trehalose monomycolate (TMM). TMM is 
exported by MmpL3 and converted to TDM by Ag85. TDM is converted to mycolic acids and 
free trehalose is released and recycled (Wolber et al., 2017). 
 
1.1.15.3 Mtb UspABC 
UspABC is interesting because it may be involved in the uptake of cell wall 
peptidoglycan fragments (Fullam et al., 2016). UspABC is also an ABC transporter and 
similar to LpqY-SugABC it is also found in Mycobacterium leprae indicating that it may 
be critical for the core life cycle of Mycobacteria (Vissa et al., 2001). Recently the 
structure of the substrate binding protein, UspC was determined by X-ray 
crystallography in the open ligand unbound conformation (Figure 1.14A) and revealed 
it had the general architecture of substrate binding proteins. UspC was also found to 
bind to amino-sugars specifically with an amino group at position C2 or C3. Binding 
was detected to D-glucosamine-6-phosphate and chitobiose, carbohydrates that 
structurally resemble peptidoglycan fragments (Figure 1.14B). This implicates a 
potential role for UspABC in peptidoglycan recycling (Fullam et al., 2016). Also as 
UspC is present near the inner membrane it is located in the perisplamic space 
proximal to the cell wall peptidoglycan of which fragments could be released by the 
activity of resuscitation promoting factors that have muramidase and amidase activities 
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(Kana et al., 2008). Further studies are underway to characterise the precise substrate 




Figure 1.14: Overall structure of Mtb UspC and ligands identified to bind (Fullam et al., 
2016). A) Overall structure of Mtb UspC. B) Structures of glucosamine-6-phosphate, chitobiose 
and the peptidoglycan backbone. 
 
1.1.15.4 Mtb Rv2041c-2040c-2039c-2038c 
Rv2041c-2040c-2039c-2038c is a predicted ABC transporter and may be important for 
when Mtb adapts to stressful conditions (Shin et al., 2009). Interestingly, Rv2041c was 
found to be highly expressed in Mtb at low pH 6.0 and hypoxia (13 % O2 in Mtb 
infected macrophages) (Shin et al., 2009). These conditions are similar to the 
intracellular phagosome environment. Rv2041c is predicted to be a substrate binding 
protein however its substrate is currently not known. A previous study expressed 
Rv2041c however Rv2041c was insoluble in inclusion bodies and was solubilised with 
guanidine hydrochloride. Immunoblotting of TB patient and mice infected with Mtb sera 
identified the presence of antibodies against Rv2041c therefore It could be used to 
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1.1.15.5 Mtb UgpABCE 
UgpABCE is the final predicted Mtb carbohydrate ABC transporter and is the focus of 
this PhD project. The UgpABCE transporter is predicted to have the typical architecture 
of Mtb ATP-binding cassette importers (Locher, 2009) (Figure 1.15). The structure of 
the ligand unbound substrate-binding protein UgpB was previously determined by X-
ray crystallography (PDB ID 4MFI) (Figure 1.15) (Jiang et al., 2014). In these previous 
studies, UgpB was identified to bind to glycerol-3-phosphocholine (GPC) the head-
group of phosphatidylcholine, which is one of the most abundant lipids found in 
eukaryote cell membranes (Yang et al., 2018). However phosphatidylcholine is not an 
abundant phospholipid in the Mycobacteria membranes (Bansal-Mutalik et al., 2014). 
The identification of binding of UgpB to GPC by ITC suggests that UgpABCE may be 
involved in the uptake of host derived catabolised lipids where GPC is imported and 
further metabolised to be used as a phosphate or carbon nutrient supply or enter 
phospholipid biosynthesis. Importantly we do not know the structural basis of how GPC 
binds to UgpB or indeed if it is the physiological ligand and other alternative higher 
affinity ligands may still exist. The ugpB gene is not essential from in vitro transposon 
hybridisation studies (DeJesus et al., 2017) however UgpB is up regulated in vivo 
during Mtb infection of guinea pigs (Kruh et al., 2010). Intriguingly, the vaccine strain 
Mycobacterium bovis BCG also encodes a UgpABCE transporter however it has a 
frame shift mutation in UgpB making it non-functional (Brosch et al., 2007). Serial 
passage of M. bovis onto potato slices containing glycerol is thought to have led to the 
loss of virulence of the resulting M. bovis BCG strain (Calmette, 1922) and may have 
also selected for this UgpB mutation because in contrast the pathogenic species, 
Mycobacterium bovis has an intact UgpB gene (Brosch et al., 2007).  
 
 





Figure 1.15: Overall structure of Mtb UgpB and ligands (Jiang et al., 2014). A) Overall 
structure of Mtb UgpB (PDB ID 4MFI). B) Structure of phosphatidylcholine the phospholipid 
derivative of glycerol-3-phosphocholine. C) Structure of glycerol-3-phosphate that did not show 
binding to Mtb UgpB. C) Structure of glycerol-3-phosphocholine that showed binding to Mtb 
UgpB. 
 
1.1.16 Glycerol-3-phosphate/Glycerophosphodiester uptake in other bacteria 
Mtb may encounter phosphate depletion inside the phagosome (Rengarajan et al., 
2005) therefore it has likely evolved several different strategies to acquire this essential 
nutrient. Mtb encodes two putative inorganic phosphate uptake systems (Pst) however 
it is not fully known how these systems are regulated (Tischler et al., 2016). In contrast 
the Mtb UgpABCE transporter is potentially adapted to specifically uptake organic 
phosphate. Many different species of bacteria also encode UgpABCE transporters for 
the uptake of glycerol-3-phosphate (G3P) in phosphate-limited conditions (Luo et al., 
2009) (Wuttge et al., 2012) (Chandravanshi et al., 2016). 
  
E. coli encodes a UgpABCE ABC-transporter however compared to Mtb UgpB the 
substrate binding protein E. coli UgpB binds to both G3P and GPC (Wuttge et al., 
2012). The structure of G3P bound E. coli UgpB was solved by X-ray crystallography 
(PDB ID 4AQ4) (Wuttge et al., 2012). However at the amino acid level Mtb UgpB and 
E. coli UgpB are only 26.4 % similar over 83 % read (BLAST) and suggests they may 
be functionally different. In addition to UgpABCE, E. coli also encodes a GlpT proton 
symporter that actively transport G3P into the cell indicating that there are multiple 
systems available for G3P import (Lemieux et al., 2004). Interestingly, from 
comparative genomics Mtb does not encode a GlpT proton symporter and therefore 
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A wide variety of marine environmental bacteria are also predicted to encode a 
UgpABCE transporters which they may use to import dissolved organic phosphorous 
as dissolved organic phosphorous is an essential marine nutrient (Luo et al., 2009). 
The largest phyla predicted to encode UgpABCE transporters are the α-proteobacteria. 
However the study found that the mean number of UgpABCE transporter genes was 
greater in samples collected from the open ocean compared to coastal waters 
suggesting that the UgpABCE transporter is important for uptake of glycerol-3-
phosphate from the oceans (Luo et al., 2009).  
 
Extremophile bacteria are also predicted to encode UgpABCE transporters. The Gram-
negative thermophile Thermus thermophillus encodes a predicted UgpABCE 
transporter that based on computational analysis also binds to GPC and has a similar 
ligand-binding pocket to E. coli UgpB (Chandravanshi et al., 2016).  
 
Interestingly other human pathogens encode a predicted UgpABCE transporter 
including Mycoplasma pneumonia the causative agent of atypical pneumonia (Schmidl 
et al., 2011). However M. pneumoniae only encodes the following genes: ugpC, ugpA 
and ugpE (MPN134, MPN135, MPN136) and does not encode a predicted ugpB gene 
for the substrate binding protein. Interestingly M. pneumonia thrives on lung epithelia 
as a source of phospholipids for nutrients (E. J. Veldhuizen et al., 2000). The UgpACE 
transporter of M. pneumoniae may actually have a different substrate specificity 
because M. pneumonia is not able to grow on the single carbon source glycerol-3-
phosphate (Schmidl et al., 2011). In addition to a UgpACE transporter, M. pneumonia 
also encodes GlpU a permease of the major facilitator superfamily that is responsible 
for import of glycerol-3-phosphocholine (GPC) (Grosshennig et al., 2013). Interestingly 
as Mtb does not encode a GlpU permease instead it may have adapted its UgpABCE 
transporter to specifically import GPC. Eukaryotes also possess transporters for 
glycerophosphodiesters for example, the yeast Saccharomyces cerevisiae encodes 
GIT1 a permease used to import glycerophosphoinositol during inositol restricted 
conditions in order to synthesise the essential phosphatidylinositol membrane lipids 
(Patton-Vogt et al., 1998). 
 
Collectively, species comparisons do not provide much additional information about the 
function and substrate specificity of the Mtb UgpABCE transporter therefore a more 
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1.1.17 Are glycerophosphodiesters the physiological substrate of Mtb UgpABCE 
Phospholipid recycling by Mycobacteria is an emerging area of research accelerated 
by the search to understand what nutrients Mtb utilises during infection. During 
infection Mtb occupies many different host niches however it resides primarily inside 
macrophages (Pieters, 2008). Macrophage membranes are made of the major 
phospholipids of which many glycerophosphodiesters are derived including: 
phosphatidylcholine, phosphatidylserine, phosphatidylethanolamine, 
phosphatidylglycerol and phosphoinositides as described previously (1.1.13) (Figure 
1.8). Phosphatidylcholine, specifically the diacyl dipalmitoylphosphatidylcholine is also 
an abundant extracellular component of lung surfactant (Veldhuizen et al., 2000).   In 
Mtb infected guinea pig granuloma, GPC is increased with a concomitant decrease in 
the level of phosphatidylcholine suggesting that phospholipids may be catabolised by 
the Mtb bacilli (Somashekar et al., 2011). Previous studies of Mtb UgpB described 
earlier (1.1.20) indicated that Mtb UgpB binds to the glycerophosphodiester, glycerol-3-
phosphocholine (GPC) derived from the phospholipid phosphatidylcholine. However to 
date it hasn’t been investigated if the Mtb UgpABCE transporter is able to bind and 
import other lipids with alternative phospholipid head-groups that are potentially 
derived from host macrophage membranes (Figure 1.16).  
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1.1.18 Phospholipase enzymes 
Phospholipase enzymes are required to convert phospholipids to 
glycerophosphodiesters (Dennis, 2015). It is not yet established if Mtb is able to utilise 
glycerophosphodiesters derived from macrophage membranes or lung surfactant 
however both the host and Mtb do encode genes that have phospholipase activity. 
Additionally, host phospholipases are well established to have critical roles in 
eukaryote phospholipid biosynthesis and cellular signalling and may be involved in 
generating substrates (Burke et al., 2009). 
 
Phospholipase enzymes are classified as having activities that catalyse the hydrolysis 
of phospholipids (Figure 1.17). These activities result in either the release of 
hydrophobic fatty acid tails or soluble components of the glycerophosphate head-group 
(Figure 1.17) (Dennis, 2015). Phospholipase A1 hydrolyses at position sn-1 to release a 
fatty acid tail and phospholipase A2 hydrolyses at position sn-2 to release the other 
fatty acid tail. Phospholipase C hydrolyses the glycerophosphate bond to release a 
phosphor head-group. Phospholipase D hydrolyses the phosphodiester bond to 
release phosphatidic acid and a free head-group. Phospholipase C enzymes are 
encoded by Mtb and found to be up regulated in phosphate starvation conditions (Le 
Chevalier et al., 2015). Recently a phospholipase C Mtb deletion mutant was identified 
to not be able to grow if phosphatidylcholine was the only phosphate source indicating 
that the ability to degrade phospholipids is important for Mtb bacilli growth (Le 
Chevalier et al., 2015). Further investigations are being carried out to establish the 
importance of Mtb phospholipase C’s. However it is the activities of phospholipase A1 
and A2 that are required to produce glycerophosphodiesters, which have also been 
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1.1.19 Phospholipase A1 and A2 activities produce glycerophosphodiesters 
In order to produce glycerophosphodiesters, phospholipase A1 and A2 enzymatic 
activity is required. Phospholipase A activities have been identified in Mtb. For example 
two secreted cutinases Rv1984 and Rv3452 were found to hydrolyse medium chain 
carboxylic esters and monoacylglycerols (Brust et al., 2011) Rv3542 also has 
phospholipase A2 activity (Schue et al., 2010). Another enzyme annotated as Rv3802 
was found to hydrolyse the following host derived and Mycobacteria derived 
phospholipids: phosphatidylcholine, phosphatidylethanolamine and phosphatidylserine 
(Goins et al., 2018). However, secreted host macrophage phospholipases A1 and A2 
enzymes may also be involved in producing glycerophosphodiesters (B. E. Schneider 
et al., 2014). For example lysosomal phospholipase A2 is implicated in the ability to 
control intracellular Mycobacteria growth however the exact lipid mediator is not known 
(Teng et al., 2017). Establishing if Mtb UgpABCE binds to a range of 
glycerophosphodiesters would provide a firm basis to rigorously investigate the source 
of the substrates. 
 
1.1.20 Cleavage of glycerophosphodiesters either extracellular or intracellular 
Instead of directly importing glycerophosphodiesters some organisms secrete enzymes 
that degrade glycerophosphodiesters to glycerol-3-phosphate. For example E. coli 
secretes a Ca2+-dependent GlpQ enzyme into the periplasm that has been identified to 
hydrolyse the following glycerophosphodiesters (Tommassen et al., 1991): 
glycerophosphoethanolamine (GPE), glycerophosphocholine (GPC), 
glycerophosphoglycerol (GPG) and bis(glycerophospho)glycerol to glycerol-3-
phosphate. Glycerol-3-phosphate can then be imported by the proton symporter GlpT 
(Figure 1.18) (Larson et al., 1983) (Huang et al., 2003).  
 
In addition to the periplasmic GlpQ, E. coli also encodes a cytosolic 
glycerophosphodiesterase UgpQ adjacent to the UgpABCE transporter in its genome 
(Ohshima et al., 2008). UgpQ converts imported glycerophosphodiesters to glycerol-3-
phosphate (Figure 1.18). Mtb also encodes two genes annotated to have 
glycerophosphodiesterase activity: glpQ1 and glpQ2 that may be involved in converting 
imported glycerophosphodiesters to glycerol-3-phosphate that enter 
glycerophospholipid metabolism or glycolysis. However these Mtb GlpQ enzymes in 
contrast to E. coli GlpQ are found in the cytosol and therefore likely to be active 
intracellularly (Larrouy-Maumus et al., 2013). Mycoplasma pneumonia also encodes a 
GlpQ enzyme immediately downstream of the permease GlpU (Grosshennig et al., 
2013) that specifically cleaves GPC to G3P, and is potentially used as an energy 
source as M. pneumonia thrives in lung epithelia (Veldhuizen et al., 1998). 




Figure 1.18: GlpT permease and UgpABCE transporter of E. coli (Chandravanshi et al., 
2016). E. coli secretes GlpQ that converts glycerophosphodiesters to glycerol-3-phosphate. 
Glycerol-3-phosphate is transported by GlpT. UgpABCE is also able to bind to 
glycerophosphodiesters and glycerol-3-phosphate (Wuttge et al., 2012). 
 
Possibly because of the different host environment encountered by Mtb compared to E. 
coli, the Mtb UgpABCE transporter may have evolved to specifically recognise GPC 
directly instead of relying on a secreted glycerophosphodiesterase enzyme to convert 
extracellular GPC to G3P. This is supported by a previous study that indicated Mtb 
UgpB only binds to GPC and not to G3P (Jiang et al., 2014). However GPC may not be 
the only glycerophosphodiester recognised by the Mtb UgpABCE transporter and we 
wanted to investigate if UgpB was promiscuous for any alternative lipid head-groups 
that it may scavenge throughout its infection life cycle. 
 
1.1.21 A potential Mtb glycerophospholipid recycling pathway  
Interestingly a putative phospholipid-recycling pathway was recently identified in Mtb 
(Larrouy-Maumus et al., 2013). Rv1692 encodes a glycerol-3-phosphate phosphatase 
that was proposed to be the final enzyme in a glycerophospholipid-recycling pathway 
that converts glycerol-3-phosphate to free phosphate and glycerol (Figure 1.19). 
Glycerol may then be utilised directly by the bacteria as a nutrient source. Rv1692 was 
not essential for the in vitro survival of Mtb however deletion of Rv1692 led to 
increases in the amount of glycerol phosphate, phosphatidylglycerol and 
glycerophosphoinositol suggesting it is part of a phospholipid recycling pathway 
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(Larrouy-Maumus et al., 2013). A large increase in radiolabelled 14C 
glycerophosphoethanolamine and glycerophosphoinositol was also observed in the 
Rv1692 deletion mutant suggesting that degradation of these polar lipid head groups 
was decreased in the absence of Rv1692.  
 
 
Figure 1.19: Proposed glycerophosphodiester catabolism pathway in Mycobacterium 
tuberculosis (Larrouy-Maumus et al., 2013). Glycerophospholipids are degraded to lipid polar 
heads by cutinases/lipases. Lipid polar heads are degraded to glycerol-3-phosphate by 
glycerophosphoryl diester phosphodiesterases. Glycerol-3-phosphate is converted to glycerol 
by glycerol phosphate phosphatase and glycerol enters metabolic pathways. Alternatively 
glycerol-3-phosphate is converted to glycerophospholipids.  
 
 
Many of the genes in this putative glycerophospholipid-recycling pathway need to be 
fully characterised. For example two genes previously described called Rv1984 and 
Rv3452 have been shown to have lipase and esterase activity (Brust et al., 2011) and 
may be important for producing glycerophosphodiesters however host phospholipases 
and previously uncharacterised enzymes may also be involved. 
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1.1.22 Summary  
To conclude, the Mtb UgpABCE ABC-transporter may have adapted to bind to 
glycerophosphodiesters. It is not yet known if binding is limited to glycerol-3-
phosphocholine, or if glycerophosphodiesters containing alternative head-groups could 
also bind. Due to the recent identification of putative phospholipid recycling pathways, 
the Mtb UgpABCE transporter may have an important role in host phospholipid 
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1.2 Hypotheses and Aims 
The overall hypothesis of this study was that Mtb uses the UgpABCE transporter to 
transport a wide range of glycerophosphodiester ligands. The promiscuity of this 
transporter may provide carbon and phosphate nutrient sources that are further 
metabolised by the bacteria. This may aid the ability for Mtb to survive in nutrient 
scarce environments such as that found inside macrophages. The details of how I 
tested these hypotheses are outlined in the hypotheses and aims sections of chapters 
3-6. 
 
1.3 Specific aims 
The specific aims of the work presented in this study are: 
• Chapter 3: Express and purify Mtb UgpB and genetic variants. 
• Chapter 4: Biochemical characterisation of Mtb UgpB. 
• Chapter 5: Structural analysis of Mtb UgpB ligand interactions. 
• Chapter 6: Express and purify Mtb UgpC and determine if it is a functional 
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All chemicals and reagents used for biochemical studies were purchased from 
Carbosynth, Fisher Scientific, New England Biolabs, Sigma Aldrich, Tebu Bio or 
Thermo Scientific unless otherwise stated. All kits were used according to the 
manufacturers instructions unless otherwise stated. The University of Warwick Life 
Sciences media preparation service provided routine microbiological media and 
antibiotics.  
 
Table 2.1: Buffers  
Buffer Components 
Tris acetic acid 
EDTA buffer (TAE) 
10 mM tris-HCl  





137 mM NaCl 
2.7 mM KCl 





137 mM NaCl 
10 mM NaH2PO4  
2.5 mM KCl 
2.5 mM KH2PO4 
0.05 % (v/v) tween-20  
pH 7.4 
Tris buffered saline  20 mM tris-HCl 
0.9% (w/v) NaCl  
pH 7.4 
Tris buffered saline 
tween-20  
(TBST) 
20 mM tris-HCl 
0.9% (w/v) NaCl  
0.1 % (v/v) tween-20  
pH 7.4 
UgpB lysis buffer 20 mM NaH2PO4 
500 mM NaCl 
0.1 % (v/v) triton X-100  
pH 7.4 
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UgpB buffer 1 20 mM NaH2PO4 
500 mM NaCl  
pH 7.4 
UgpB wash buffer 20 mM NaH2PO4 
1 M NaCl  
pH 7.4 
UgpB dialysis buffer 
1 
25 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid  (HEPES) 
150 mM NaCl  
pH 7.0 
UgpB dialysis buffer 
2 
25 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid  (HEPES) 
150 mM NaCl  
10 % (v/v) glycerol  
pH 7.0 
UgpC buffer 20 mM tris-HCl  
300 mM NaCl  




20 mM tris-HCl  
300 mM NaCl  
10 % glycerol  
pH 7.5 
10X SDS-PAGE gel 
running buffer  
24.8 mM tris-HCl 
0.192 M glycine 
0.1 % (w/v) sodium dodecyl sulphate 
(SDS) 
2X SDS loading dye 100 mM tris-HCl  
4 % (w/v) sodium dodecyl sulphate 
(SDS) 
0.2 % (w/v) bromophenol blue 
20 % (v/v) glycerol 
200 mM dithiothreiotol (DTT)  
pH 6.8 
Gel wash buffer 50 mM ammonium bicarbonate  
50 % (v/v) ethanol 
Reducing buffer 10 mM dithiothreitol (DTT) 
50 mM ammonium bicarbonate 
Alkylation buffer  55 mM iodoacetamide 
50 mM ammonium bicarbonate 
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Trypsin buffer 2.5 ng/µL trypsin solution 
50 mM ammonium bicarbonate 
Low salt phosphate 
buffer 
25 mM NaH2PO4  
100 mM NaCl  





20 mM tris-HCl  
300 mM NaCl  
4 % glycerol 1 mM MgCl2  
pH 7.5 
Western blot transfer 
buffer 
25 mM tris-HCl 
192 mM glycine 
10 % MetOH 
Bio-Layer buffer A 25 mM NaOAc 
 150 mM NaCl  
10% glycerol  
pH 5.5 
Bio-Layer buffer B 25 mM NaH2PO4 
150 mM NaCl  
10 % glycerol  
pH 7.0 
Bio-Layer buffer C 25 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid  (HEPES) 
 150 mM NaCl  
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Table 2.2: Cloning primers 
Name Use Sequence (5’-3’) 
UgpB_T_pYUB_F Constructed by Dr James 
Harrison and used to 
clone truncated Mtb UgpB 
(amino acid residues 1-
34) pYUB1062, NdeI 
restriction site 
aaaaaacatatgggttccggcccaatcgacttctgg 
UgpB_T_pYUB_R Constructed by Dr James 
Harrison and used to 






Clone Mtb UgpC pET 







Clone Mtb UgpC pET 





Clone Mtb UgpC pYUB 




Clone Mtb UgpC pYUB 





Clone Mtb UgpC 
pYUB1062 GFP, HindIII 
restriction site 
aaaaaagctttgcgaagccgggt 
UgpAE pWaldo_F Clone Mtb UgpAE 
pWaldo, NdeI restriction 
site 
aaaaaacatatggcggcgccgca 
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Table 2.3: Sequencing primers 
T7_F Sequence pYUB1062 and 
pWaldo constructs 
taatacgactcactataggg 
T7_R Sequence pYUB1062 and 
pWaldo constructs 
ccctatagtgagtcgtatta 









Table 2.4: Mtb UgpB site directed mutagenesis primers 
Tyr78Ala_F Mutate Mtb UgpB residue 
Tyr78Ala 
ggcaaggacgccgacgaggtg 
Tyr78Ala_R Mutate Mtb UgpB residue 
Tyr78Ala 
cacctcgtcggcgtccttgcc 
Asp102Ala_F Mutate Mtb UgpB residue 
Asp102Ala 
cgttttgctcgacgcccgatggtggttcc 
Asp102Ala_R Mutate Mtb UgpB residue 
Asp102Ala 
ggaaccaccatcgggcgtcgagcaaaacg 
Ser153Ala_F Mutate Mtb UgpB residue 
Ser153Ala 
ccgtatgctcgcgcgacgccgctgttc 
Ser153Ala_R Mutate Mtb UgpB residue 
Ser153Ala 
gaacagcggcgtcgcgcgagcatacgg 
Leu205Ala_F Mutate Mtb UgpB residue 
Leu205Ala 
gctaacgccgacgccatctcgtggacg 
Leu205Ala_R Mutate Mtb UgpB residue 
Leu205Ala 
cgtccacgagatggcgtcggcgttagc 
Trp208Ala_F Mutate Mtb UgpB residue 
Trp208Ala 
ccgacctcatctcggcgacgtttcagggacc 
Trp208Ala_R Mutate Mtb UgpB residue 
Trp208Ala 
ggtccctgaaacgtcgccgagatgaggtcgg 
Ser272Ala_F Mutate Mtb UgpB residue 
Ser272Ala 
gccgtggcagccaccggctcg 
Ser272Ala_R Mutate Mtb UgpB residue 
Gly306Ala 
cgagccggtggctgccacggc 
Gly306Ala_F Mutate Mtb UgpB residue 
Ser272Ala 
ccgacgggcgctgcggggctg 
Gly306Ala_R Mutate Mtb UgpB residue cagccccgcagcgcccgtcgg 
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Gly306Ala  
Tyr345Ala_F  Mutate Mtb UgpB residue 
Tyr345Ala 
cagcaaaccggcgctctgccggtgcgcaag 
Tyr345Ala_R Mutate Mtb UgpB residue 
Tyr345Ala 
cttgcgcaccggcagagcgccggtttgctg 
Arg385Ala_F Mutate Mtb UgpB residue 
Arg385Ala 
cacaagactacgcagcggttttcctgcc 
Arg385Ala_R Mutate Mtb UgpB residue 
Arg385Ala 
ggcaggaaaaccgctgcgtagtcttgtg 
Sequences in bold are the locations of the site-directed mutations. 
 
 
Table 2.5: Empty vectors 
Vector Antibiotic resistance Sequencing primer 
pYUB1062 Hygromycin T7_F and T7_R 
pET160-DEST Ampicillin T7_F and T7_R 
pET SUMO Kanamycin SUMO_F and T7_R 
pYUB1062-GFP Hygromycin T7_F and pWaldo-R 
pWaldo Kanamycin T7_F and pWaldo-R 
 
 
Table 2.6: Constructs 
Vector Use Reference 
pYUB1062-UgpB Expression of truncated UgpB (amino acid 
residues 1-34) in M. smegmatis 
Constructed by Dr 
James Harrison, 
University of Warwick 
pET160-DEST-
UgpC 
Expression of UgpC in E. coli Glycerol stock 
pET SUMO-UgpC Expression of UgpC in E. coli This study 
pYUB1062-UgpC Expression of UgpC in M. smegmatis This study 
pYUB1062-UgpC-
GFP 
Expression of UgpC GFP in M. 
smegmatis 
This study 
pWaldo-UgpC Expression of UgpC GFP in E. coli Glycerol stock 
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Table 2.7: Bacterial strains 
Strain Genotype Use 
E. coli Top 10 F– mcrA Δ(mrr-hsdRMS-mcrBC) φ80lacZΔM15 
ΔlacX74 recA1 araD139 Δ(ara-leu)7697 galU galK 






E. coli DH5a F– φ80lacZΔM15 Δ(lacZYA-
argF)U169 recA1 endA1 hsdR17(rK–, 





E. coli BL21 
(DE3) 
F– ompT hsdSB (rB–, mB–) gal dcm (DE3) 
 
Protein expression 
E. coli BL21 
(DE3) pLysS 





Shuffle® T7  
 
F´ lac, pro, lacIq / Δ(ara-leu)7697 araD139 fhuA2 
lacZ::T7 gene1 Δ(phoA)PvuII phoR ahpC* galE (or 
U) galK λatt::pNEB3-r1-cDsbC(SpecR, lacIq) ΔtrxB 
rpsL150(StrR) Δgor Δ(malF)3 
 
Protein expression 
E. coli Lemo21 
(DE3) 
fhuA2 [lon] ompT gal (λ DE3) [dcm] ∆hsdS/ 
pLemo(CamR) 
 λ DE3 = λ sBamHIo ∆EcoRI-
B int::(lacI::PlacUV5::T7 gene1) i21 ∆nin5 




mc2155 F- pYUB1232 acetamidase promoter T7 
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1 % (w/v) Tryptone (Sigma Aldrich) 0.5 
% (w/v) yeast extract (Sigma Aldrich) 
 10 mM NaCl pH 7 in dH2O 
Luria-Bertani agar 
(LBA) 
15 g/L Bacteriological agar (Sigma 
Aldrich) in LB media 
Tryptic soy broth 
tween-80 (TSBT) 
Tryptic soy broth powder 
 0.2 % (v/v) glycerol 
 0.05 % (v/v) tween-80 in dH2O 
Luria-Bertani glycerol 
tween-20 (LBGT) 
LB broth powder 
 0.2 % (v/v) glycerol 
 0.05 % (v/v) tween-20 in dH2O 
Terrific broth (TB) TB broth powder 
 1.0 % (v/v) glycerol 
PASM-5052 media 2 mM MgSO4 0.2X trace metals  
1X 5052 1X NPS  
0.1 µM vitamin B12 100 µL 17aa  
0.5 mg/mL methionine 
 
 
Table 2.9: Antibiotics 
 Bacterial species  
Antibiotic E. coli M. smegmatis 
Ampicillin 100 µg/mL 100 µg/mL 
Chloramphenicol 30 µg/mL - 
Kanamycin 50 µg/mL 25 µg/mL 
Hygromycin  150 µg/mL 100 µg/mL 
All antibiotics were dissolved in dH2O apart from chloramphenicol that was dissolved in EtOH 
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Table 2.10: Thin layer chromatography (TLC) stains 
Stain Components Detects 
Sulphuric acid 10.5 mL sulphuric acid 95 %   
89.5 mL ethanol 100 % 
Carbohydrates 
Ninhydrin  1.5 g ninhydrin (Sigma Aldrich) 
100 mL n-butan-1-ol 




1.5 g KMnO4 
10 g K2CO3  
1.25 mL 10 % (w/v) NaOH 




Table 2.11: Commercially available crystallisation sparse matrix screens 
Screen name Supplier Number of conditions 
JCSG-plusTM Molecular Dimensions 96 
Morpheus® 
HT-96 




Molecular Dimensions 96 
MIDASTM Molecular Dimensions 96 
Additive 
Screen HT 
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2.2 Vector maps 
2.2.1 pYUB1062 vector 
pYUB1062 (Wang et al., 2010) (Figure 2.1) is an E. coli-mycobacteria shuttle vector 
which is 4802 bp nucleotides long and contains a hygromycin resistance gene for 
selection purposes. The vector contains an ori for replication in E. coli and an f1 ori for 
replication in Mycobacteria. Expression of the insert is induced by the addition of 
acetamide in Mycobacterium smegmatis mc24517, a strain containing a copy of the T7 
RNA polymerase integrated into its chromosome under the control of the acetamidase 
promoter. Acetamide induces T7 RNA polymerase production and expresses the insert 
under the control of the T7 promoter. The vector also has a hexa-histidine fusion tag 
region and in this study the gene cloned in this vector has a C-terminal tag for 




Figure 2.1: pYUB1062 vector map. Abbreviations: HygR hygromycin resistance gene, f1 ori 
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2.2.2 pET160-DEST vector 
pET160-DEST (Figure 2.2) is an E. coli gateway destination, expression vector which 
is 7437 bp nucleotides long and contains an ampicillin resistance gene for selection 
purposes. It has two recombination sites attR1 and attR2 downstream of the T7lac 
IPTG inducible promoter for recombination cloning. It has an N-terminal or C-terminal 




Figure 2.2: pET160-DEST vector map. Abbreviations: AmpR ampicillin resistance gene, ori 
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2.2.3 pYUB1062-GFP vector 
pYUB1062-GFP (Fullam et.al, 2018) (Figure 2.3) is a modified E. coli-mycobacterial 
shuttle vector based on pYUB1062 (Wang et al., 2010) which is 5542 bp nucleotides 
long. The modified vector has a C-terminal tobaccoetch virus (TEV) protease cleavage 









Figure 2.3: pYUB1062-GFP vector map (Fullam et.al, 2018). Abbreviations: HygR hygromycin 
resistance gene, ori and f1 ori origins of replication in E. coli and Mycobacteria, GFP superfolder 
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2.2.4 pET SUMO vector 
pET SUMO (Invitrogen) (Figure 2.4) is an E. coli expression vector which is 5642 bp 
nucleotides long and contains a kanamycin resistance gene for selection purposes. 
The vector utilises the T7 promoter to control expression of the insert. Expression of 
the insert is induced by the addition of isopropyl β-D-1-thiogalactopyranoside (IPTG) in 
BL21 (DE3) lysogen expression E. coli host strain. The vector has an N-terminal 
terminal hexa-histidine fusion tag (His.Tag®) and SUMO (Saccharomyces cerevisiae 
Smt3 protein) fusion solubility tag for purification purposes using immobilised metal 
affinity chromatography (IMAC). 
 
Figure 2.4: pET SUMO vector map (Invitrogen). Abbreviations: KanR kanamycin resistance 
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2.2.5 pWaldo vector 
pWaldo (Drew et.al, 2001) (Figure 2.5) is an E. coli expression vector which is 6381 bp 
nucleotides long and contains a kanamycin resistance gene for selection purposes. 
Expression of the insert is induced by the addition of isopropyl β-D-1-
thiogalactopyranoside (IPTG) in BL21 (DE3) lysogen expression E. coli host strain. The 
vector is modified from pET28(a+) to contain a C-terminal tobaccoetch virus (TEV) 
protease cleavage site and GFP fluorescent tag. The GFP variant is selected to fold 
well in E. coli and has the red-shifted mutation S65T and the folding mutation F64L and 
a hexa-histidine fusion tag (His.Tag®) for purification purposes using immobilised 








Figure 2.5: pWaldo vector map (Drew et.al, 2001). Abbreviations: KanR kanamycin 
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2.3 Molecular biology 
2.3.1 Agarose gel electrophoresis 
Agarose gels were prepared using agarose 1 % (w/v) in TAE buffer (Table 2.1). 0.5 µM 
ethidium bromide was added to the dissolved agarose solution prior to casting of the 
gel. DNA loading dye (Thermo Scientific) was added to DNA samples and a 1 kbp DNA 
ladder (Thermo Scientific) was loaded onto the gel. The gels were electrophoresed at 
120 V in TAE buffer and visualised using a UV transilluminator. 
 
2.3.2 Determination of DNA concentration 
DNA concentration was determined spectrophotometrically using a NanoDrop 2000 
(Thermo Scientific) at 260 nm. The 260/280 nm ratio was also checked to assess DNA 
quality. 
 
2.3.3 PCR amplification and cloning 
 
2.3.3.1 PCR amplification and cloning of ugpB pYUB1062 from M. tuberculosis 
Dr James Harrison carried out the following PCR and cloning. The UgpB gene was 
amplified from M. tuberculosis HR37 genomic DNA by PCR using primers 
UgpB_T_pYUB_F and UgpB_T_pYUB_R specific for ugpB (Table 2.2). The PCR 
reaction mixture contained Q5 DNA polymerase (NEB), Q5 DNA polymerase buffer, 
0.2 mM dNTP’s, 6 % (v/v) DMSO and 1 µM forward and reverse primers. The PCR 
cycle consisted of: denaturation (98 °C, 30 s) followed by 30 cycles of annealing (70 
°C, 30 s), extension (72 °C, 90 s), followed by a final extension step (72 °C, 5 min).  
 
The purified ugpB PCR product and pYUB1062 vector were digested with restriction 
endonucleases NdeI and HindIII (1 µL, 37 °C, 3 hours). The digested product was then 
ligated using T4 DNA ligase and ligase buffer (NEB) with a 3:1 ratio of vector: insert 
DNA (1 µL, 22 °C, 1 hour). The ligation product was transformed into E. coli Top10 and 
plated onto LB hygromycin (150 µg/mL) plates and left at 37 °C overnight until colonies 
appeared. Colonies were cultivated and the plasmid was isolated and sequenced with 
primers T7_F and T7_R (Table 2.3). 
 
2.3.3.2 PCR amplification and cloning of ugpC pYUB1062 and ugpC pYUB1062-
GFP from M. tuberculosis  
The ugpC gene was amplified from M. tuberculosis HR37 genomic DNA by PCR using 
the following primers specific for UgpC: (UgpC pYUB1062_F and UgpC pYUB1062_R) 
or (UgpC pYUB1062_F and UgpC pYUB1062 GFP_R)  (Table 2.2). The PCR reaction 
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mixture contained Q5 DNA polymerase (NEB), Q5 DNA polymerase buffer, 0.2 mM 
dNTP’s, 6 % (v/v) DMSO and 0.5 µM forward and reverse primers. The PCR cycle 
consisted of: denaturation (98 °C, 30 s) followed by 30 cycles of annealing gradient 
(64-80 °C, 30 s), extension (72 °C, 90 s), followed by a final extension step (72 °C, 5 
min).  
 
The purified ugpC PCR product, pYUB1062 and pYUB1062-GFP vectors were 
digested with restriction endonucleases NdeI and HindIII (1 µL, 37 °C, 3 hours). The 
digested product was then ligated using T4 DNA ligase and ligase buffer (NEB) with a 
3:1 ratio of vector: insert DNA (1 µL, 22 °C, 1 hour). The ligation product was 
transformed into E. coli Top10 and plated onto LB hygromycin plates and left at 37 °C 
overnight until colonies appeared. The presence of the insert was determined by 
colony PCR using primers (UgpC pYUB1062_F and UgpC pYUB1062_R) or (UgpC 
pYUB1062_F and UgpC pYUB1062 GFP_R). The plasmid was isolated from colonies 
containing the insert and sequenced with the primers T7_F and T7-R for UgpC 
pYUB1062 and T7_F and pWaldo-R for UgpC pYUB1062-GFP (Table 2.3). 
 
2.3.3.3 PCR amplification and cloning of ugpC pETSUMO from M. tuberculosis  
The ugpC gene was amplified from M. tuberculosis HR37 genomic DNA by PCR using 
the following primers specific for UgpC: UgpC pET SUMO_F and UgpC pET SUMO_R 
(Table 2.2). The PCR reaction mixture contained Q5 DNA polymerase (NEB), Q5 DNA 
polymerase buffer, 0.2 mM dNTP’s, 6 % (v/v) DMSO and 0.5 µM forward and reverse 
primers. The PCR cycle consisted of: denaturation (98 °C, 30 s) followed by 30 cycles 
of annealing gradient (68-80 °C, 30 s), extension (72 °C, 90 s), followed by a final 
extension step (72 °C, 5 min). 
 
The purified ugpC PCR product and pETSUMO vectors were digested with restriction 
endonucleases BamHI and HindIII (1 µL, 37 °C, 3 hours). The digested product was 
then ligated using T4 DNA ligase and ligase buffer (NEB) with a 3:1 ratio of vector: 
insert DNA (1 µL, 22 °C, 1 hour). The ligation product was transformed into E. coli 
Top10 and plated onto LB kanamycin plates and left at 37 °C overnight until colonies 
appeared. The presence of the insert was determined by colony PCR using primers 
UgpC pET SUMO_F and UgpC pET SUMO_R (Table 2.2) The plasmid was isolated 
from colonies containing the insert and sequenced with the primers SUMO_F and 
T7_R (Table 2.3). 
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2.3.3.4 PCR amplification and cloning of ugpAE from M. tuberculosis  
The UgpAE gene was amplified from M. tuberculosis HR37 genomic DNA by PCR 
using primers specific for UgpAE: UgpAE pWaldo_F and UgpAE pWaldo_R (Table 
2.2). The PCR reaction mixture contained Q5 DNA polymerase (NEB), Q5 DNA 
polymerase buffer, 0.2 mM dNTP’s, 6 % (v/v) DMSO and 0.5 µM forward and reverse 
primers. The PCR cycle consisted of: denaturation (98 °C, 30 s) followed by 30 cycles 
of annealing gradient (72-82 °C, 30 s), extension (72 °C, 90 s), followed by a final 
extension step (72 °C, 5 min).  
 
The purified ugpAE PCR product, and pWaldo vector were digested with restriction 
endonucleases NdeI and BamHI (1 µL, 37 °C, 3 hours). The digested product was then 
ligated using T4 DNA ligase and ligase buffer (NEB) with a 3:1 ratio of vector: insert 
DNA (1 µL, 22 °C, 1 hour). The ligation product was transformed into E. coli Top10 and 
plated onto LB kanamycin plates and left at 37 °C overnight until colonies appeared. 
The presence of the insert was determined by colony PCR using primers UgpAE 
pWaldo_F and UgpAE pWaldo_R (Table 2.2). The plasmid was isolated from colonies 
containing the insert and sequenced with primers T7_F and pWaldo-R (Table 2.3). 
 
2.3.4 DNA purification 
Plasmid DNA samples were purified from overnight bacterial cultures of E. coli using a 
QIAprep spin mini prep kit (Qiagen). PCR products and enzymes reactions were 
purified using a QIAquick PCR purification kit (Qiagen). DNA purified from agarose gels 
was purified using a QIAquick gel extraction kit (Qiagen). All kits were used according 
to the manufacturers instructions. 
 
2.3.5 Restriction endonucleases 
Purified DNA samples were digested with restriction endonucleases (NEB) typically 
using 10U per µg of DNA at 37 °C. Endonuclease reactions were purified using a 
QIAquick PCR purification kit (Qiagen). The digested vectors were dephosphorylated 
with calf-intestinal alkaline phosphatase (NEB) using 1U per pmol of DNA at 37 °C for 
30 min to dephosphorylate the 3’ ends. 
 
2.3.6 Site-directed mutagenesis of Mtb ugpB-pYUB1062 
The pYUB1062 plasmid containing the ugpB insert was isolated and purified from E. 
coli Top 10 cells. Targeted single-site substitutions were introduced into the ugpB gene 
using forward and reverse primers specific for the substitutions (Table 2.4). Site-
directed mutagenesis was carried out by PCR using Phusion high fidelity DNA 
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polymerase (NEB). The PCR cycle consisted of: denaturation (98 °C, 30 s) followed by 
20 cycles of annealing at a temperature 5 °C below the primer melting temperature (30 
s), extension (72 °C, 90 s), followed by a final extension step (72 °C, 5 min). 1 µL of the 
restriction endonuclease DpnI (NEB) was added and the PCR reaction was incubated 
at 37 °C for 3 h and transformed into E. coli.  
 
2.3.7 Transformation of E. coli via heat shock 
The ligation mixtures or DpnI digested mutated plasmid (1-2 µL) was added to 50 µL of 
thawed E. coli Top 10 cells at 4 °C in pre-chilled sterile 14 mL ventilated culture tubes, 
gently mixed and incubated on ice for 30 min. The transformation mix was heated to 42 
°C for 45 s and then incubated on ice for 5 min. LB media (200 µL) was added and the 
bacterial culture grown at 37 °C for 1 h with shaking at 180 rpm and then spread onto 
LB agar plates supplemented with the appropriate antibiotics. The plates were 
incubated at 37 °C for 16 h. The colonies were screened for the presence of the correct 
plasmid containing insert by PCR and the plasmid containing the insert was extracted 
and confirmed by sequencing.  
 
2.3.8 Sequencing plasmids 
Individual colonies containing plasmid were picked, and incubated in 4 mL of LB in 
ventilated culture tubes supplemented with the appropriate antibiotics at 37 °C 
overnight with shaking at 180 rpm overnight. The plasmid was extracted using a mini-
prep kit (Qiagen). The DNA was sent for sequencing (GATC Biotech) using the specific 
sequencing primers (Table 2.3). 
 
2.3.9 Storage of transformed E. coli cells 
E. coli cells containing the confirmed constructs were stored at -80 °C as glycerol 
stocks. A single colony containing the correct sequenced insert was picked from an LB 
agar plate and used to inoculate 4 mL of LB media containing the appropriate 
antibiotics. The cultures were grown at 37 °C with shaking at 180 rpm until the culture 
reached mid-log phase (OD600nm = 0.6 – 0.8). Sterile glycerol was added to the culture 
to give a final concentration of 10 % (v/v), divided into 1 mL aliquots in 2 mL cryovials 
(Nalgene) and stored at -80 °C. 
 
2.3.10 Preparation of competent M. smegmatis mc24517 
A glycerol stock of M. smegmatis mc24517 was streaked into LB plates and incubated 
at 37 °C for 2 -3 days until colonies appeared. A single colony was picked and used to 
inoculate 4 mL of TSBT media in 14 mL ventilated culture tubes and incubated at 37 °C 
for 2-3 days with shaking at 180 rpm. This culture was used to inoculate 50 mL of 
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TSBT in a 1:100 dilution until OD600nm = 0.8-1.0 was reached. The cells were incubated 
at 4 °C for 30 min and centrifuged at 3,000 g for 15 min. The cells were resuspended in 
10 mL of ice-cold 10 % glycerol at 4 °C and centrifuged at 3,000 g for 15 min. The 
supernatant was discarded and cells were resuspended in 5 mL 10 % glycerol at 4 °C, 
aliquoted into 0.2 mL and stored at -80 °C. 
 
2.3.11 Electroporation of M. smegmatis mc24517 
0.5-5 µg of DNA was added to 0.2 mL electrocompetent M. smegmatis MC24517 cell 
aliquots and transferred to 0.2 mL electroporation cuvettes (Biorad). After incubation on 
ice for 10 min the cuvette was placed in the electroporator and pulsed at 2.5 kV. The 
cells were diluted with 2 mL LBGT media and incubated at 37 °C for 3 h without 
antibiotics. Cells were then plated onto LB supplemented with the appropriate 
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2.4 Protein expression and purification 
2.4.1 Expression of M. tuberculosis UgpB-pYUB1062 in M. smegmatis and 
genetic variants 
A single colony of M. smegmatis mc24517 UgpB-pYUB1062 was used to inoculate 100 
mL of LBGT media containing the appropriate antibiotics (25 μg/mL of kanamycin and 
100 μg/mL hygromycin). The starter culture was incubated for 72 h at 37 °C with 
shaking at 180 rpm. 14 mL of starter culture was used to inoculate 6 L of LBGT media 
to give a starting optical density (OD600nm) of 0.1. The culture was incubated at 37 °C 
with shaking at 180 rpm until the OD600nm reached 0.4. Gene expression was induced 
by the addition of 0.2 % (w/v) acetamide and the culture was incubated at 37 °C for 20 
h. Cells were centrifuged at (10,000 g, 40 min, 4 °C) and washed by re-suspending in 
phosphate buffered saline (PBS) and pelleted again (3,000 g, 40 min, 4 °C) prior to 
freezing at -80 °C. 
 
2.4.2 Expression of M. tuberculosis UgpC-pET SUMO in E. coli 
A single colony of UgpC-pET SUMO E. coli BL21 (DE3) was picked and inoculated in a 
50 mL starter culture of LB kanamycin (50 µg/mL) at 37 °C with shaking overnight. The 
starter culture was used to inoculate a 1:100 dilution of 1 L terrific broth containing 
kanamycin (50 µg/mL) and incubated at 27 °C with shaking at 180 rpm until OD600nm of 
0.6 was reached. 1 mM of IPTG was added and the temperature was shifted to 16 °C 
overnight. Cells were centrifuged at (10,000 g, 40 min, 4 °C) and washed by re-
suspending in phosphate buffered saline (PBS) and pelleted again (3,000 g, 40 min, 4 
°C) prior to freezing at -80 °C. 
 
2.4.3 Expression of M. tuberculosis UgpC-pYUB1062/pYUB1062-GFP in M. 
smegmatis 
A single colony of M. smegmatis mc24517 containing either UgpC-pYUB1062 or UgpC-
pYUB1062-GFP was used to inoculate 100 mL of LBGT media containing the 
appropriate antibiotics (25 μg/mL of kanamycin and 100 μg/mL hygromycin). The 
starter culture was incubated for 72 h at 37 °C with shaking at 180 rpm. 14 mL of 
starter culture was used to inoculate 1 L of LBGT media to give a starting optical 
density (OD600nm) of 0.1. The culture was incubated at 37 °C with shaking at 180 rpm 
until the OD600nm reached 0.4. Gene expression was induced by the addition of 0.2 % 
(w/v) acetamide and the culture was incubated at 37 °C for 20 h. After this time, 1 mL 
of the UgpC-pYUB1062-GFP cells was centrifuged (10,000 g, 10 min) and 
resuspended in 100 µL PBS and GFP fluorescence was measured at λex 485 nm λem 
535 nm in a plate reader (Tecan Infinite F200, gain 35). The remaining 1 L culture was 
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centrifuged at (10,000 g, 40 min, 4 °C) and washed by re-suspending in phosphate 
buffered saline (PBS) and pelleted again (3,000 g, 40 min, 4 °C) prior to freezing at -80 
°C. 
 
2.4.4 Expression of M. tuberculosis UgpC and UgpAE-pWaldo in E. coli 
A single colony of E. coli Lemo21 (DE3) containing either UgpC-pWaldo or UgpAE-
pWaldo was used to inoculate 5 mL of PASM-5052 media (Table 2.1) containing the 
appropriate antibiotics (30 μg/mL of chloramphenicol and 50 μg/mL kanamycin). The 
starter culture was incubated overnight at 37 °C with shaking at 200 rpm. 50 µL of the 
starter culture (1: 100 ratio dilution) was used to inoculate 5 mL of PASM-5052 media 
and the culture was incubated at 37 °C with shaking at 200 rpm until the OD600nm 
reached 0.6. Gene expression was induced by the addition of 0.4 mM IPTG and 6 
concentrations of a L-rhamnose gradient (0 – 1 mM final concentration) and the 
cultures were incubated at 25 °C with shaking at 200 rpm for 15 h. After induction the 
OD600nm was measured and 1 mL of the cells were centrifuged (10,000 g, 10 min) and 
resuspended in 100 µL PBS and GFP fluorescence was measured at λex 485 nm λem 
535 nm in a plate reader (Tecan Infinite F200, gain 35). Cells were centrifuged at 
(3,000 g, 40 min, 4 °C) and washed by re-suspending in phosphate buffered saline 
(PBS) and pelleted again (3,000 g, 40 min, 4 °C) prior to freezing at -80 °C. 
 
2.4.5 Cell lysis 
Cell pellets were thawed at 4 °C and re-suspended in 20 mL of the appropriate lysis 
buffer (Table 2.1) supplemented with one EDTA-free protease inhibitor cocktail tablet 
(Pierce) and 1 µg/mL DNAse (Roche). The cell suspensions were ultrasonicated at 4 
°C (Misonix) at 70 % power for 20 cycles of 30 s ON and 30 s OFF and centrifuged 
(12,000 g, 1h, 4 °C) to remove insoluble cell debris. The supernatant was filtered 
through a 0.45 μm filter (EMD Millipore) prior to immobilised metal affinity 
chromatography (IMAC). 
 
2.4.6 Purification of M. tuberculosis UgpB-pYUB1062 
Purification of recombinant 6x his tagged proteins was carried out using cobalt 
immobilised metal affinity chromatography. A gravity flow column (PD20 BioRad) was 
prepared by the addition of a 2 mL bed volume of HisPur™ cobalt chromatography 
resin (Thermo Scientific). The resin was washed twice with 10 mL of dH2O and 
equilibrated in 20 mL of UgpB buffer 1 (Table 2.1). The filtered cell lysate was added to 
the column and the flow through was collected and passed over the column again. The 
bound lysate was washed with UgpB wash buffer (Table 2.1) followed by UgpB buffer 1 
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containing increasing concentration of imidazole from 5 mM, 10 mM, 20 mM, 50 mM, 
100 mM, 250 mM, 500 mM and 1 M to elute the bound proteins. Samples of collected 
fractions were subjected to SDS-PAGE and samples that contained UgpB or the 
genetic mutants of UgpB were combined and dialysed (12-14 kDa MWCO Medicell 
Membranes) overnight at 4 °C in UgpB dialysis buffer 1 (Table 2.1) which was replaced 
the following day twice over 4 h. 
 
After dialysis the protein was filtered (0.22 μm EMD Millipore). A 5 mL HiTrap QHP ion 
exchange chromatography column (GE Healthcare) was equilibrated in UgpB dialysis 
buffer 1 (Table 2.1). The protein was passed over the column at approximately 1 
mL/min and the flow-through was collected and re-passed over the column. A step-
wise salt gradient was performed from 150 mM – 1 M NaCl in UgpB dialysis buffer 1, 5 
mL (Table 2.1) to elute the bound proteins. Fractions were collected and subjected to 
SDS-PAGE. 
 
Fractions containing the UgpB protein at the expected size were combined and 
concentrated by ultrafiltration (Vivaspin 10 kDa MWCO) to 2 mL prior to loading onto 
the AKTA pure system connected to a HiLoad 16/600 Superdex 75 pg gel filtration 
chromatography column (GE Healthcare). The HiLoad 16/600 Superdex 75 pg gel 
filtration chromatography column was first equilibrated in UgpB dialysis buffer 2 (Table 
1) and the proteins were separated at 0.5 mL/min and the absorbance was monitored 
at 280 nm. The chromatogram sample peak fractions were subjected to SDS-PAGE 
and fractions containing pure UgpB protein at the expected size were combined, and 
concentrated to ~ 2-10 mg/mL by ultrafiltration (Vivaspin 10 kDa MWCO) prior to flash 
freezing and storage at -80 °C. 
 
2.4.7 Purification of M. tuberculosis UgpC-pET SUMO  
The cell pellet was thawed and re-suspended in 20 mL of UgpC lysis buffer (Table 2.1) 
supplemented with 0.1 % Triton-X 100 and one EDTA-free protease inhibitor cocktail 
tablet (Pierce). The cell suspension was ultrasonicated (Misonix) at 70 % power for 10 
cycles of 30 s ON and 30 s OFF and centrifuged (12,000 g, 1h, 4 °C) to remove 
insoluble cell debris. The supernatant was filtered through a 0.45 μm filter (EMD 
Millipore) prior to nickel immobilised metal affinity chromatography (IMAC). UgpC was 
eluted from the Ni2+ column in UgpC lysis buffer (Table 2.1) with a step-wise imidazole 
gradient. Fractions containing the protein were dialysed to remove imidazole and 150 
µL SUMO protease (0.3 mg/mL) was added and incubated at 30 °C for 30 min. The 
digested protein was loaded onto another Ni2+ column and eluted from the column in 
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UgpC lysis buffer with a step-wise imidazole gradient. The flow through and wash were 
combined, concentrated to 2 mL (Vivaspin 10 kDa MWCO) prior to loading onto the 
AKTA pure system connected to a HiLoad 16/600 Superdex 200 pg gel filtration 
chromatography column (GE Healthcare). The HiLoad 16/600 Superdex 200 pg gel 
filtration chromatography column column was first equilibrated in UgpC lysis buffer 
(Table 2.1) and the proteins were separated at 0.5 mL/min and the absorbance was 
monitored at 280 nm. The chromatogram sample peak fractions were subjected to 
SDS-PAGE and fractions containing pure UgpB protein at the expected size were 
combined, and concentrated to ~ 2-10 mg/mL by ultrafiltration (Vivaspin 10 kDa 
MWCO) prior to flash freezing and storage at -80 °C. 
 
2.4.8 Attempts to purify M. tuberculosis UgpC-pYUB1062/pYUB1062-GFP 
Purification of recombinant 6x his tagged proteins was carried out using nickel 
immobilised metal affinity chromatography. A gravity flow column (PD20 BioRad) was 
prepared by the addition of a 2 mL bed volume of HisPur™ nickel-NTA 
chromatography resin (Thermo Scientific). The resin was washed twice with 10 mL of 
dH2O and equilibrated in 20 mL of UgpC buffer  (Table 2.1). The filtered cell lysate was 
added to the column and the flow through was collected and passed over the column 
again. The bound lysate was washed with UgpC buffer (Table 2.1) followed by UgpC 
buffer containing increasing concentration of imidazole from 5 mM, 10 mM, 20 mM, 50 
mM, 100 mM, 250 mM, 500 mM and 1 M to elute the bound proteins. Samples of 
collected fractions were subjected to SDS-PAGE and in-gel GFP fluorescence was 
measured. 
 
2.4.9 Attempts to purify M. tuberculosis UgpC/UgpAE-pWaldo 
Purification of recombinant 6x his tagged proteins was carried out using nickel 
immobilised metal affinity chromatography. A gravity flow column (PD20 BioRad) was 
prepared by the addition of a 2 mL bed volume of HisPur™ nickel-NTA 
chromatography resin (Thermo Scientific). The resin was washed twice with 10 mL of 
dH2O and equilibrated in 20 mL of pWaldo purification buffer  (Table 2.1). The filtered 
cell lysate was added to the column and the flow through was collected and passed 
over the column again. The bound lysate was washed with pWaldo purification buffer 
(Table 2.1) followed by UgpC buffer containing increasing concentration of imidazole 
from 5 mM, 10 mM, 20 mM, 50 mM, 100 mM, 250 mM, 500 mM and 1 M to elute the 
bound proteins. Samples of collected fractions were subjected to SDS-PAGE and in-
gel GFP fluorescence was measured. 
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2.4.10 Concentration of protein samples 
Proteins were concentrated by ultrafiltration (Vivaspin 10 kDa MWCO) prior to flash 
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2.5 Protein characterisation 
2.5.1 SDS-PAGE  
Samples were prepared by adding 2X SDS-loading dye to protein samples (Table 2.1) 
and heating to 95 °C for 5 min. Electrophoresis was performed at 50 mA for 33 min in 
1X gel running buffer (Table 2.1) using precast polyacrylamide gels (BioRad AnykD). 
PageRuler prestained protein ladder (NEB) was used as a molecular weight reference. 
Gels were stained in InstantBlueTM (Expedeon) and de-stained overnight in dH2O. 
 
2.5.2 Determination of protein concentration 
Protein concentration was determined spectrophotometrically using a NanoDrop 2000 
(Thermo Scientific) at 280 nm. 
 
2.5.3 GFP fluorescence 
Prior to harvesting the cells, 1 mL of the culture was removed, centrifuged (2,600 g, 10 min, 
4 °C), the pellet resuspended in 100 µL PBS and the fluorescence monitored at λex 485 
nm λem 535 nm (Tecan Infinite F200, gain 35).  
 
2.5.4 In-gel GFP fluorescence 
Samples for SDS-PAGE were mixed in a 1:1 ratio with SDS-loading buffer and 15 µL 
samples were loaded directly onto the gel without heating. Following SDS-PAGE (2.5.1) 
however without staining with InstantBlueTM the in-gel fluorescence was imaged 
immediately using λex 473 nm [LBP], 450 V PMT, 50-µm-pixel size (TyphoonTM FLA 
9500). The gels were then stained with InstantBlueTM. 
 
2.5.5 In-gel proteomic analysis 
Gel slices containing the protein of interest were cut out using a clean scalpel, diced 
into 2-4 mm cubes and transferred to a 1.5 mL tube. The gel dices were de-stained by 
addition of 500 µL of gel wash buffer (Table 2.1) and heated at 55 °C for 20 min with 
shaking 650 rpm. The wash step was repeated 3 times. The gel dices were dehydrated 
by addition of 150 µL of 100 % ethanol and incubated at room temperature for 5 min 
with shaking 650 rpm. 150 µL of reducing buffer (Table 2.1) was then added to reduce 
the disulphide bonds and the gel dices were heated at 55 °C for 30 min with shaking 
650 rpm. The liquid was removed and 150 µL of alkylation buffer (Table 2.1) was 
added, the tube was covered with foil and left at room temperature for 20 min to 
alkylate the free cysteine residues. The gel dices were washed 2 times with 500 µL gel 
wash buffer (Table 2.1) and incubated at room temperature for 20 min with shaking 
650 rpm. The gel dices were dehydrated by the addition of 150 µL of 100 % ethanol 
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and incubated at room temperature for 5 min with shaking 650 rpm, rehydrated by the 
addition of 60 µL of trypsin buffer (Table 2.1), covered with aluminium foil and digested 
overnight at 37 °C. Peptides were extracted 2 times by the addition of 120 µL of 25 % 
(v/v) acetonitrile and 5 % (v/v) formic acid and sonicated for 10 min. The peptide 
extract was centrifugal filtered (Costar 0.22 µm), transferred to a clean tube and 
concentrated (SpeedVac) to a volume of 20 µL. Peptides were re-suspended to 50 µL 
in 2.5 % (v/v) acetonitrile and 0.05 % (v/v) trifluoroacetic acid.  
 
A 20 µL aliquot was analysed by nanoLC-ESI-MS/MS using the Ultimate 3000/Orbitrap 
Fusion instrument (Thermo Scientific) specifying a 60-min LC separation on a 50 cm 
column. Data were used to interrogate the Mycobacterium tuberculosis, 
Mycobacterium smegmatis and E.coli proteome databases (UniProt) and the common 
contaminant database (MaxQuant) to identify and quantify any proteins present. The 
results were presented and analysed (Scaffold). 
 
2.5.6 Circular dichroism analysis 
Purified Mtb UgpB proteins were dialysed (12-14 kDa MWCO Medicell Membranes) 
into low salt phosphate buffer (Table 2.1), diluted to 0.25 mg/mL and transferred to a 1 
mm path length quartz cuvette. The cuvette was cleaned between analyses with 2 M 
HNO3, dH2O, 1 % (v/v) Helmanex III (Sigma Aldrich) and dH2O followed by drying with 
N2. Circular dichroism spectra were acquired on a Jasco J-810 DC spectrometer from 
198-260 nm in triplicate and averaged after subtraction of the buffer background. 
 
2.5.7 Western blot 
SDS-PAGE gels were run (2.5.1) and then transferred to a nitrocellulose membrane 
(Amersham Hybond ECL) (1 h, 20 V, 300 mA) in transfer buffer (Table 2.1). The 
membrane was blocked in 5 % milk (w/v) TBS-tween for 60 min at room temperature 
with shaking. Penta-His antibody, BSA-free (Sigma) was prepared (1 in 1000 dilution) 
in 25 mL TBS-tween containing 0.1 % milk (w/v). The 5 % milk TBS-tween was 
replaced with Penta-His antibody solution and incubated for 30 min at room 
temperature with shaking. The membrane was washed with 50 mL TBS-tween for 5 
min three times. 1 µL of Anti-mouse IgG-Alkaline Phosphatase secondary antibody 
(Sigma) was added to 25 mL TBS-tween containing 0.1 % milk (w/v) and incubated 
with the membrane for 30 min at room temperature with shaking. The membrane was 
washed with 50 mL TBS-tween for 5 min three times and a final 50 mL of TBS. One 
SigmaFast BCIP/NBT tablet was dissolved in 10 mL of dH2O and added to the 
membrane and allowed to stain for 5 min until bands appeared. 
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2.5.8 Thermal shift assay 
The transition unfolding temperature Tm of the UgpB protein (22 µM) was measured in 
the presence or the absence of ligands. The screen used a single ligand concentration 
of 100 mM. Measurements were performed in a total volume of 20 µL using a Rotor-
Gene Q Detection System (Qiagen), setting the excitation wavelength to 470 nm and 
detecting emission at 557 nm of the SYPRO Orange protein gel stain, 15 X final 
concentration (Invitrogen). The following cycle was used: melt ramp from 30 °C to 95 
°C, increasing temperature in 1 °C steps and time intervals of 5 s. Fluorescence 
intensity was plotted as a function of the temperature and the Tm was determined using 
the Rotor-Gene Q software and Analysis Melt functionality. All experiments were 
performed in triplicate. 
 
2.5.9 Phospho and sphingo lipid strips 
Phosphoinositide strip, phosphoinostide array and sphingo strip membranes (Echelon 
Biosciences) were probed according to the manufacturers guidance. The membranes 
were transferred to 50 mL falcon tubes and blocked at 4 °C overnight with rolling in 5 
mL of TBST (Table 2.1) supplemented with 3 % fatty acid free bovine serum albumin 
(Sigma Aldrich). The TBST blocking buffer was replaced and Mtb UgpB (5 µg/mL) was 
added and incubated for 2 h at room temperature with rolling. The membranes were 
washed 6 times with 5 mL of TBST every 5 min for 30 min after all incubation steps. 
Before and during the antibody detection steps the membranes were blocked in TBST 
(Table 2.1) supplemented with 1 % (w/v) fatty acid free bovine serum albumin (Sigma 
Aldrich). Bound UgpB was detected by incubating with Penta-His primary antibody 
(Qiagen) diluted 1:1000 for 1 h at room temperature followed by washes and 
incubating with anti-mouse IgG-HRP secondary antibody (Santa Cruz Biotech) diluted 
1:2000 for 1 h at room temperature. Chemiluminescence using enhanced 
chemiluminescence reagent (ECL Pierce™) was used to detect the bound antibody by 
covering the membrane with 1 mL of ECL and incubating 5 min and imaged using an 
ImageQuant LAS 500 imager set to record images incrementally every 30 s. 
 
The membranes were quantified by calculating the integrated density of spots in 
ImageJ (Fiji). The 8-min incremental exposure time images were used in all 
quantifications. A 52 by 52-pixel circle was specified to measure the integrated density 
of the lipid spots. The solvent blank was subtracted from all density values and the 
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2.5.10 Microarray array 
All analyses were performed at ambient temperature and microarray slides were 
initially blocked with 10 mM HEPES pH 7.4, 150 mM NaCl, 5 mM CaCl2 containing 1 % 
BSA and 0.02 % casein for 1 hour. For the non-precomplexed experiment, Mtb UgpB 
protein was diluted in the blocking solution to (100 µg/mL) and overlaid for 1.5 hours, 
followed by detection with primary monoclonal anti-polyHistidine antibody and 
secondary biotinylated anti-mouse IgG at (10 µg/mL) each incubated for 1 hour. For 
the pre-complex experiment, protein-antibodies complexes were prepared by pre-
incubating primary antibody and secondary antibody for 15 minutes, followed by 
addition of Mtb UgpB protein and incubation for a further 15 minutes, the ratio of His-
tagged protein: primary antibody: secondary antibody was 1:2:2 (w/w/w). After diluting 
in the blocking solution, the complexes were overlaid at 25 µg/mL (concentration of Mtb 
UgpB) for 1.5 hour. For both the non-precomplexed and precomplexed protein, binding 
was detected after 30 minutes overlay with streptavidin-Alexa Fluor 647 (1 µg/mL). 
 
2.5.11 Bio-Layer interferometry 
Biolayer interferometry was carried out on a ForteBio Octet Red 96 instrument (Forte 
Bio). Assays were performed in black 96 well half-area plates (Greiner bio-one). 
Assays were carried out at room temperature using Bio-Layer buffers (Table 2.1) 
keeping the same particular buffer throughout for individual experiments. UgpB protein 
was first dialysed into the appropriate Bio-Layer buffer and diluted 5-20 µg/mL. EDC-
NHS biosensor tips (Forte Bio) were hydrated in dH2O for at least 10 min prior to use 
and the biosensor tip agitation speed was set to 1,000 rpm. The tips were 
functionalised by loading UgpB (5-20 µg/mL) and the experimental setup was the 
following: 1. dH2O (equilibration 0-60 s), 2. EDC (20 mM) NHS (10 mM) (activation 60-
360 s), 3. UgpB (loading 360-960 s), 4. Ethanolamine (1M) (quenching 960-1260 s), 5. 
buffer (buffer baseline 1260-1380 s), 6. glycerol-3-phoshocholine (association 1380-
1675 s) and 7. buffer (dissociation 1675-1980 s). 
 
2.5.12 Microscale thermophoresis (MST)  
Mtb UgpB protein was labelled using Monolith His-tag labelling kit RED-Tris-NTA 
(NanoTemper Technologies) according to the manufactures guidance. PBST (Table 
2.1) and a constant concentration of UgpB (50 nM) were used throughout. The ligands 
to test were prepared in PBST in the concentration range 0-0.5 M. Samples were 
loaded into the MonoLith NT.115 standard treated capillaries and incubated for 10 min 
before analysis using the Monolith NT.115 instrument (NanoTemper Technologies) at 
21 °C using medium laser power and 40 % LED power. The binding affinities were 
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calculated by fitting a Kd model using the in-built MST analysis software and curves 
were plotted in GraphPad (Prism Version 7.0). All experiments were carried out in 
triplicate. 
 
2.5.13 Malachite green phosphate assay 
A malachite green phosphate assay kit (Sigma Aldrich) was used according to the 
manufacturers instructions. UgpC protein was washed extensively with assay buffer 
(Table 2.1) using a Vivaspin 10 kDa MWCO centrifugal concentrator and a final 
concentration of 0.6 mg/mL of UgpC protein was used in the assay. ATP (0.1 mM) and 
MgCl2 (1 mM) were added in each 80 µL assay. Reactions were incubated at 37 °C, 
300 rpm and quenched at different time points by the addition of 20 µL of freshly 
prepared working reagent (Sigma Aldrich), incubated at room temperature for 30 min 
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2.6 Protein structure determination 
2.6.1 Methylation of Mtb UgpB 
Purified Mtb UgpB was diluted to 1 mg/mL in UgpB dialysis buffer 2 (Table 2.1) and 
reductively methylated following a previous study (Walter et al., 2006). Briefly, 1 M 
dimethylamine borane complex (DMAB) and 1 M formaldehyde were dissolved in 
UgpB dialysis buffer 2. DMAB and formaldehyde were added to 280 µL of Mtb UgpB (1 
mg/mL) to a final concentration of 20 mM DMAB and 40 mM formaldehyde. The 
mixture was incubated (100 rpm, 4 oC, 2 h) and after 2 h incubation, 6 µL of DMAB (1 
M) and 12 µL of formaldehyde (1 M) was added and incubated (100 rpm, 4 oC for 2 h). 
This step was repeated twice. Tris-HCl pH 7.0 was added to a final concentration of 
100 mM to remove any excess unreacted DMAB. The methylated protein was dialysed 
in 2 L of UgpB dialysis buffer 2 (4o C, 16 h) and dialysis was repeated the following day 
(4 oC, 4 h). Methylated Mtb UgpB was then concentrated by ultrafiltration (Vivaspin 10 
kDa MWCO) to 7 mg/mL. 
 
2.6.2 Crystallisation and structure determination GPC bound Mtb UgpB 
For co-crystallisation experiments methylated Mtb UgpB was incubated with 10 mM 
glycerophosphocholine (GPC) (Carbosynth) and incubated at 4 °C for 30 min before 
crystallisation. Crystals of UgpB in complex with GPC were grown by sitting-drop 
vapour diffusion in 96-well plates (Swiss-Ci) using a Mosquito liquid handling system 
(TTP LabTech) by mixing 1:1, 2:1 and 1:2 volumes (150 nL) of concentrated 
methylated UgpB (7 mg/mL) with reservoir solution. UgpB crystals typically grew within 
three days at 22 °C in 0.2 M MgCl2, 0.1 M tris pH 8.5, 20 % w/v PEG 8,000. The UgpB 
crystals were cryoprotected with 20 % glycerol and flash frozen in liquid N2 prior to data 
collection. 
 
The X-ray diffraction data for the ligand bound UgpB crystals were collected at the I04-
1 beamline of Diamond Light Source. The diffraction data were indexed, integrated and 
scaled with XDS (Kabsch et al,. 2010) through the XIA2 pipeline and CCP4 suite of 
programmes (Collaborative computational project. 2019). Initial phases were 
determined by molecular replacement using PHASER (McCoy et al,. 2007) and the 
separate domains (Domain I residues 34-153 and 305-378/Domain II residues 154-304 
and 379-424) of the apo-UgpB structure as two ensembles as a search model (PDB 
4MFI) specifying to search for 4 copies in the asymmetric unit. Autobuild (Terwilliger et 
al,. 2008) was initially used for model building followed by iterative cycles of alternating 
manual rebuilding in COOT (Emsley et al,. 2004) and reciprocal space crystallographic 
refinement with PHENIX-REFINE (Afonine et al,. 2012) assigning each domain as a 
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separate TLS group. The coordinates for the GPC ligand were downloaded from the 
PDB ligand expo (PDB CH5) and fitted into unoccupied electron densities in all four 
chains of the asymmetric unit. The restraints for use in refinement were calculated 
using REEL (Moriarty et al,. 2017). Magnesium ions and glycerol molecules were also 
fitted into the unoccupied densities as well as waters. Methylated lysine (MLZ) was 
fitted at position 161 in all chains. 
 
The model of the ligand-bound structure comprises residues 36-428 in all chains (A-D), 
with an additional 1 residue in chains B and D and 2 residues in chain C. There is a 
disordered region between residues 355-366 in chains C and D and these residues 
were not modelled. No Ramachandran outliers were identified and structure validations 
were done by MolProbity (Chen et al,. 2010). Figures were prepared using Pymol (The 
PyMOL Molecular Graphics System, Version 2.0 Schrodinger, LLC), except for those 
showing electron density, which were prepared using CCP4mg (McNicholas et al,. 
2011). 
 
2.6.3 Crystallisation and structure determination GPS bound Mtb UgpB 
For co-crystallisation experiments methylated Mtb UgpB was incubated with 20 mM 
glycerophosphserine (GPS) and incubated at 4 °C for 30 min before crystallisation. 
Crystals of UgpB in complex with GPS were grown by sitting-drop vapour diffusion in 
96-well plates (Swiss-Ci) using a Mosquito liquid handling system (TTP LabTech) by 
mixing 1:1, 1:2 and 2:1 ratiometric volumes of protein with reservoir solution to produce 
drop sizes of 0.3-0.45 µL. The crystallisation conditions that were initially screened 
included JCSG-plus, Morpheus, Midas and Structure Screen I and II (Molecular 
Dimensions). We got crystals in condition D4 from JCSG-plus (0.1 M sodium acetate, 
0.2 M lithium sulphate, pH 4.5, 30 % w/v PEG8000) and therefore we optimised using 
this condition. The Hampton additive screen (Hampton Research) was used at 
manufacturers guidance to give a final 10 % additive concentration In the additive 
screen several crystals were identified after 2 weeks in the additives: ethylene glycol 
(3.0 %), acetone (4.0 %), ethyl acetate (0.5 %) and trimethylamine hydrochloride (0.01 
M). The crystals were flash frozen in liquid nitrogen prior to diffraction data collection at 
the I-24 beamline (Diamond Light Source). No cryo-protection was added due to the 
high concentration of PEG8000 (30 % w/v) in the crystallisation condition. The crystal 
that produced high-resolution diffraction data (1.76 Å) grew in the additive ethylene 
glycol (3.0 %).  
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To solve the phases molecular replacement (PHASER) (McCoy et al., 2007) was used 
specifying the most well refined chain A of GPC bound Mtb UgpB as the single search 
model. The calculated phases were well defined and the model was visualised (COOT) 
(Emsley et al., 2004)  and appeared to be identical to GPC bound Mtb UgpB. However 
the specific regions of amino acids, 90-93 did not fit well to the density and had to be 
manually adjusted. No methylated lysines were identified in the structure despite 
reductively methylating the protein prior to crystal trials. At the centre of the structure 
between the two-α/β domains an electron dense region was identified as the putatively 
bound GPS ligand. The glycerol and phosphate electron densities were clearly defined 
and GPS (PDB ID GSE) was manually fitted and the molecular restraints were 
calculated (eLBOW) (Adams et al., 2010). To finally build the model, H2O molecules 
were fitted into the appropriate densities. 
 
All STD-NMR experiments were performed by: Dr Ridvan Nepravishta and Dr Jesus 
Angulo, School of Pharmacy, University of East Anglia.  
 
2.6.4 1H STD-NMR experiments 
Mtb UgpB was expressed and purified as described (2.4.1 and 2.4.6). The protein was 
buffer exchanged into deuterated PBS pH 7.5 by ultrafiltration (Vivaspin 10 kDa 
MWCO) by 5x 10 mL additions of deuterated PBS and concentrating, bringing the 
volume from 10 mL to 0.5 mL after each exchange. After buffer exchange, Mtb UgpB 
was concentrated to 3.1 mg/mL. For all STD-NMR experiments the ligands were 
dissolved in deuterated PBS. For the complex of Mtb UgpB/GPC the protein 
concentration was 68 µM and the ligand concentration was 5 mM. STD-NMR spectra 
were acquired on a Bruker Avance 500.13 MHz at 298 K. The on- and off-resonance 
spectra were acquired using a train of 50 ms Gaussian selective saturation pulses 
using a variable saturation time from 0.5 s to 4 s, and a relaxation delay (D1) of 4 s. 
The water signal was suppressed using the watergate technique while the residual 
protein resonances were filtered using a T1ρ-filter of 50 ms. All the spectra were 
acquired with a spectral width of 5 kHz and 32K data points using 128 scans. The on-
resonance spectra were acquired by saturating at 0.77 or 6.78 ppm while the off-
resonance spectra were acquired by saturating at 40 ppm. Instead, for the Mtb 
UgpB/GPIP4 complex, the protein concentration was 35 µM while the ligand 
concentration was 2.5 mM. STD-NMR spectra were acquired on a Bruker Avance 
800.23 MHz at 278 K. The on- and off-resonance spectra were acquired using a train 
of 50 ms Gaussian selective saturation pulses using a variable saturation time from 0.5 
s to 4 s and a relaxation delay (D1) of 5 s. The water signal was suppressed by using 
the excitation sculpting technique while the residual protein resonances were filtered 
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using a T1ρ -filter of 24 ms. All the spectra were acquired with a spectral width of 12.82 
kHz and 32K data points using 64 scans. The on-resonance spectra were acquired by 
saturating at 0.7 or 6.67 ppm while the off-resonance spectra were acquired by 
saturating at 40 ppm. To get accurate structural information from the STD-NMR data 
and in order to minimize the T1 relaxation bias, the STD build up curves were fitted to 
the equation STD(tsat) = STDmax*(1-exp(-ksat*tsat) calculating the initial growth rate STD0 
factor as STDmax*ksat = STD0 and then normalizing all of them to the highest value. 
 
All CORCEMA-ST calculations were performed by: Dr Ridvan Nepravishta and Dr 
Jesus Angulo, School of Pharmacy, University of East Anglia.  
 
2.6.5 CORCEMA-ST calculations 
The CORCEMA-ST software was used to calculate the theoretical STD intensities from 
the crystallographic structure of the Mtb UgpB/GPC complex. The parameters used for 
the calculations were: saturation frequency range 0-1.1 ppm; protein correlation time 
45 ns; Kd 0.005 mM; order parameter 0.85; ligand correlation time 0.3 ns; ρ-leak 0.35 s; 
τm 10 ps; cutoff 8 Å; [L]0 5 mM; [E]0 68 µM; field 500 MHz. While for the Mtb 
UgpB/GPIP4 complex model obtained from docking calculations, the theoretical STD 
intensities were calculated using the following parameters: saturation frequency range 
0-0.9 ppm; protein correlation time 45 ns; Kd 1 mM; order parameter 0.85; ligand 
correlation time 0.3 ns; ρ-leak 0.1 s; τm 10 ps; cutoff 8 Å; [L]0 5 mM; [E]0 68 µM; field 
800 MHz. The calculations were repeated in order to have the best fitting possible 
between the calculated and the experimental 1H STD-NMR intensities. For CH2 protons 
showing the same chemical shift an averaged calculated 1H STD-NMR intensity was 
assumed. NOE factor was used to evaluate the best fit to the experimental data. 
 
All AutoDock Vina docking calculations were performed by: Dr Ridvan Nepravishta and 
Dr Jesus Angulo, School of Pharmacy, University of East Anglia.  
 
2.6.6 AutoDock Vina docking calculations 
Autodock tools were used to prepare for docking both the ligand GPIP4 and the Mtb 
UgpB protein. The calculations were performed by positioning a grid of 20 x 24 x 22 Å 
in the center of the binding site of Mtb UgpB, which was maintained rigid while the 
ligand was considered flexible. The calculations were performed using Autodock Vina. 
 
All DEEP STD-NMR experiments were performed by: Ridvan Nepravishta and Jesus 
Angulo, School of Pharmacy, University of East Anglia.  
 Chapter 2: Materials and methods 	  
 
	   74 
2.6.7 DEEP STD-NMR 
DEEP-STD factors were obtained. Briefly, frequencies derived from shiftx2 for aliphatic 
and aromatic residues present in the binding site of Mtb UgpB were used for the 
position of the saturating selective pulse. The STD obtained using a saturation of 0.5 s 
on aliphatic or aromatic regions (0.7 or 6.67 ppm, respectively) were then used to 
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2.7 Chemistry 
2.7.1 General methods 
Unless otherwise stated, chemicals and solvents used in the synthesis were purchased 
from Sigma Aldrich and used as supplied without further purification. Methanol 
(MeOH), dichloromethane (DCM), chloroform, pyridine, triethylamine, ammonium 
hydroxide and magnesium sulphate (MgSO4) were purchased from Fisher Scientific at 
laboratory reagent grade. Anhydrous tetrahydrofuran (THF) 99.9 %, anhydrous 
dichloromethane (DCM) 99.8 %, deuterium oxide (D2O) 99.9 % was purchased from 
Sigma Aldrich. Deuterochloroform (CDCl3) 99.8 % was purchased from Apollo 
Scientific.  All reactions were performed using oven-dried glassware and heat transfer 
was achieved using an oil bath. 
 
Thin layer chromatography (TLC) was carried out using aluminium-backed sheets 
coated with 60 F254 silica gel (Merck). Visualization was carried out using the stains 
(Table 2.10). Flash column chromatography was carried out using silica gel 60, 35-75 
µm (Merck) as the stationary phase.  
 
Chemistry procedures and analyses were carried out with the assistance of Dr Collette 
Guy (Professor Matthew Gibson’s Laboratory, Chemistry Department, University of 
Warwick). 
 
2.7.2 Nuclear magnetic resonance spectroscopy 
Proton (1H), carbon (13C) and phosphorous (31P) NMR spectra were obtained at 298 K. 
All NMR spectra were recorded on either the Bruker DPX-300 or DPX-400 instruments 
and spectra were fully assigned using COSY, HSQC and HMBC. Chemical shifts were 
stated in parts per million (ppm) using the residual solvent as internal standard. 
Coupling constants (J) are reported in hertz (Hz) using the abbreviations: s singlet, d 
doublet, t triplet, q quartet, quin quintet, m multiplet, br broad.  
 
2.7.3 Mass spectrometry 
Low resolution mass spectra were recorded on a Bruker Esquire 2000 instrument using 
electrospray ionisation (ESI), negative/positive mode where indicated. High-resolution 
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2.7.4 Chemoenzymatic production of glycerophosphoethanolamine (GPE), 
glycerophosphoserine (GPS) and glycerol-3-phosphocholine enantiomer (GPC): 
Phospholipase A1 from Aspergillus oryzae (Sigma Aldrich) was dialysed into PBS 
(Table 2.1) overnight at 4°C prior to use to remove sorbitol. The enzymatic reaction 
contained either 50 mg of 1,2-Dipalmitoyl-sn-glycero-3-phosphoethanolamine (Sigma 
Aldrich), 25 mg of 1,2-Diacyl-sn-glycero-3-phospho-L-serine (Sigma Aldrich) or 12.5 
mg of 2,3-Dipalmitoyl-sn-glycerol-1-phosphocholine (Sigma Aldrich) in an organic-
aqueous media of 800 µL hexane and 138 µL H2O (5.8:1 v/v) and was heated at 50°C 
for 10 min prior to the addition of Phospholipase A1 from Aspergillus oryzae (1 µL 
Phospholipase A1 per 1 mg of phospholipid). The reaction mixtures were heated at 50 
°C and stirred at 300 rpm for 48 h. The solvent was evaporated under vacuum and the 
reaction mixture was dissolved in 5 mL of water and extracted with chloroform 3 x 25 
mL. The aqueous phase was separated and the phospholipase A1 enzyme removed by 
ultrafiltration (Amicon, 10 kDa molecular weight cut off). The collected filtrate was 
freeze-dried.  
 
2.7.5 Characterisation of GPE, GPS and GPC enantiomer by NMR: 
GPE: 1H NMR (400MHz, D2O) δppm 3.99 – 4.08 (2H, m, POCH2CH2N), 3.75- 3.91 (3H, 
m, POCH2CHCH2), 3.49 – 3.63 (2H, m, POCH2CHCH2), 3.20 (2H, t, J = 5.0 Hz, 
POCH2CH2N). 13C NMR (100MHz, D2O) δppm 70.7 (CH), 66.5 (OCH2), 62.0 (OCH2), 
61.8 (OCH2), 40.0 (NCH2). 31P NMR (161 MHz, D2O) δppm 0.42.  
 
GPS: 1H NMR (400MHz, D2O) δppm 4.17 – 4.26 (2H, m, POCH2CHN), 4.01 – 4.08 (1H, 
m, POCH2CHN), 3.71 – 3.93 (3H, m, 3H, m, POCH2CHCH2), 3.48-3.65 (2H, m, 
POCH2CHCH2). 13C NMR (100MHz, D2O) δppm 178.5 (C=O), 70.6 (CH2CH(OH)CH2), 
66.5 (OCH2), 63.7 (POCH2CHN), 62.0 (OCH2), 54.4 (POCH2CHN). 31P NMR (161 MHz, 
D2O) δppm 0.08. 
 
GPC enantiomer: 1H NMR (400MHz, D2O) δppm  4.18 – 4.29 (2H, m, POCH2CH2N), 3.74 
– 3.90 (3H, m, POCH2CHCH2), 3.46 – 3.63 (4H, m, POCH2CHCH2 + POCH2CH2N), 
3.14 (9H, s, CH3). 13C NMR (100MHz, D2O) δppm  70.6 (CH2CH(OH)CH2), 66.5 (OCH2), 
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The expression and purification of soluble, correctly folded and physiologically active 
Mycobacterium tuberculosis (Mtb) proteins is a major challenge and a requirement to 
elucidate their biochemical structural properties. The bacterium Escherichia coli is the 
most widely used host for recombinant protein expression because it is well-studied, 
amenable to genetic methods and can be easily cultured (Rosano et al., 2014). The 
most widely used E. coli expression system uses the T7 RNA polymerase from the T7 
bacteriophage and the T7 promoter (Tabor et al., 1985). In the commonly used 
expression strain BL21 (DE3), the T7 RNA polymerase gene is inserted into the 
bacterial chromosome under the control of the inducible lacUV5 operon (Siebenlist et 
al., 1980). The gene of interest is cloned into a plasmid under the control of the T7 
promoter that can only be transcribed by the T7 RNA polymerase and is transformed 
into the bacteria. The lac repressor (lacI) binds to the operator sites (lacO) in the 
promoter of the lacUV5 operon and prevents the T7 RNA polymerase sequence from 
being transcribed. However, addition of the inducer isopropyl-β-D-1-
thiogalactopyranoside (IPTG), an analogue of allolactose that cannot be metabolised, 
releases lacI from the operator enabling the T7 RNA polymerase to be transcribed and 
to transcribe the gene of interest.  
 
However despite the advantages of E. coli for protein expression it is not always the 
most appropriate host to express mycobacterial proteins as they can be toxic (Melief et 
al., 2018) and have a tendency to form insoluble inclusion bodies (Baneyx, 1999). The 
molecular basis of the difficulties of expressing Mtb proteins in E. coli are not fully 
understood, however potential contributing factors are due to differences in the 
guanidine + cytosine (G+C) content of these organisms genomes. The G+C content of 
Mtb is 65.6 % (Cole et al., 1998) and for E. coli is 50.8 % (Blattner et al., 1997). Large 
differences in the G+C content of genes likely results in different codon usage and 
requirements for different cellular machinery to facilitate normal transcription and 
translation of the Mtb proteins (Bellinzoni et al., 2003). Additional important factors may 
be involved for example Mtb specific chaperones may be required for the correct 
folding of Mtb proteins and maintaining protein stability (Goldstone et al., 2008). Also 
differences in the composition of the mycobacterial cell membrane and cell wall may be 
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particularly important to successfully express Mtb membrane proteins. (Korepanova et 
al., 2009) 
 
3.1.2 Alternative host expression systems to E. coli 
Alternative host expression systems to E. coli have been developed to successfully 
express and purify Mtb proteins. These different host expression systems are diverse 
ranging from eukaryotic virus-infected-insect cells, yeast, bacterial Gram-positive and 
Gram-negative species and the closely related actinobacteria and mycobacterial 
species (Atkins et al., 1994) (Gurvitz et al., 2009) (Kieser et al., 1986) (Goldstone et al., 
2008). 
 
A baculovirus-insect cell eukaryote recombinant gene expression system was used to 
successfully express Mtb chaperonin 10 (Cpn1) and despite the high G+C content of 
the gene (64 %) the protein was purified to a high yield (Atkins et al., 1994). Other 
studies have also used similar systems to express Mtb NAD+ synthase (NadE) 
(Bellinzoni et al., 2002) and Mycobacterium bovis antigen P36 (Bigi et al., 1999). 
However this system is not routinely used because of practicalities associated with 
setting up an insect cell expression laboratory. Also non-physiological post-
translational modifications can be introduced into the expressed proteins because a 
prokaryote gene is being expressed in a eukaryote organism. Another eukaryote 
expression system that has been used to express Mtb proteins and investigate 
physiological function is Saccharomyces cerevisiae (Gurvitz et al., 2009). However this 
system can be disadvantageous because yeast has a longer growth time, doubling 
every 1.5-2 hours at 30 °C compared to every 20-30 minutes for E. coli and they can 
produce hyper-glycosylated proteins and introduce non-physiological post-translational 
modifications. Pseudomonas putida has a high G+C content genome of 61.5 % similar 
to the Mtb genome and its metabolism is versatile and tolerant to chemical agents and 
oxidative stress (Ramos-Gonzalez et al., 2005). Mtb cytosolic carbon-carbon hydrolase 
HsaD was successfully expressed in this system and its structure determined by X-ray 
crystallography (Lack et al., 2008). However this system is not routinely used because 
the vectors for the production of protein are not as well established. 
 
A potentially better approach is to express Mtb proteins in a more closely related 
bacterial species (Bashiri et al., 2015). For example Streptomyces are part of the 
actinobacteria family, and they also have a high G+C (>70 %) content similar to 
mycobacteria (Romero-Rodriguez et al., 2015). A study identified that Streptomyces 
lividans could efficiently use a high proportion of mycobacterial promoters and 
 Chapter 3: Cloning, expression and purification of Mycobacterium tuberculosis UgpB 	  
 
	   79 
translational signals suggesting that it could be adapted to express Mtb proteins 
(Kieser et al., 1986) and since this study the 45/47 kDa Mtb APA protein (Rv1860) was 
successfully expressed (Lammertyn et al., 1998). However in this system recombinant 
proteins are secreted directly into the culture medium and this can be a problem for 
producing proteins in the correct conformation at sufficient quantities. Many of these 
alternative hosts are not as convenient and practical to use compared to E. coli 
however a single solution system to express Mtb proteins does not exist and 
investigations often require trial and error.	   
 
3.1.3 Mycobacteria host expression systems 
Mycobacterium smegmatis is a closely related mycobacterial species sharing 
approximately 70 % of its genome with Mtb. It has the advantage of being non-
pathogenic and relatively fast growing as its doubling time is only approximately 4 
hours (Snapper et al., 1990). M. smegmatis has been widely adapted as a model 
organism to study Mtb and has also been adapted to express Mtb proteins (Goldstone 
et al., 2008). Its high G+C genome content and shared genes likely result in it having 
similar codon usage and myocbacterial specific heat shock, stress-induced and 
chaperones likely aid the correct folding, solubility and stability of expressed proteins 
(Poulsen et al., 2010). These effects may be further enhanced by mycobacterial 
specific metabolites and ligand cofactors as well as binding proteins (Bashiri et al., 
2012). Its cell membrane and cell wall also have a similar lipid composition that may be 
necessary to express Mtb membrane proteins (Etienne et al., 2005).  
 
To date 84 X-ray crystal structures of Mtb proteins expressed in M. smegmatis are 
available in the protein data bank (RSCB PDB 2019). However despite these 
advantages the yields of Mtb proteins expressed in M. smegmatis vary and sometimes 
result in slow cell growth (Saida et al., 2006). However the slower growth rate of M. 
smegmatis may be important for correct protein folding and for producing potentially 
toxic proteins. M. smegmatis mc2155 is available for efficient plasmid uptake (Snapper 
et al., 1990). A modified strain of mc2155 called M. smegmatis mc24517 is now 
available for protein expression. M. smegmatis mc24517 also expresses T7 RNA 
polymerase under the control of the acetamidase inducible promoter, in the vector 
pYUB1232 (Wang et al., 2010). M. smegmatis mc24517 is used to routinely express 
genes of interest in vectors controlled by the T7 promoter (Wang et al., 2010). A 
related mycobaterial species called Mycobacterium vaccae has also been utilised to 
successfully express and purify the tetrameric iron-dependent superoxide dismutase of 
Mtb and determine its structure by X-ray crystallography (J. B. Cooper et al., 1995). 
However M. vaccae is not routinely used because most mycobacterial vectors contain 
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a kanamycin resistance gene and some species of M. vaccae do not efficiently express 
the aminoglycoside phosphor-transferase genes involved in kanamycin resistance 
(Medeiros et al., 2002). As a result M. smegmatis has been routinely developed and 
used as a strain to produce Mtb proteins. 
 
3.1.4 Routes to optimise protein production 
Soluble protein expression and purification are major hurdles however genetically 
encoded tags are available to assist these processes. The poly-histidine tag is a very 
small tag consisting of a repeating sequence of 6-10 histidine residues. The poly-
histidine tag is easily incorporated into a plasmid at either the N or C-terminus of the 
protein of interest and when expressed has a high affinity for divalent metal cations 
(Bornhorst et al., 2000). The glutathione S-transferase (GST) tag is a larger 26 kDa 
protein tag inserted at the N-terminus of the protein of interest to enhance protein 
solubility and stability (Schafer et al., 2015). However, due to the large size of the GST 
tag it may affect protein crystallisation and require proteolytic cleavage. The small 
unbiquitin-like modifier (SUMO) tag is an 11 kDa protein from Saccaromyces 
cerevisiae Smt3 (Saitoh et al., 1997). Similar to the GST tag if SUMO is fused to the N-
terminus of a protein of interest it can result in enhanced soluble protein expression 
levels. However due to its large size it may interrupt normal protein function and 
therefore must be cleaved. The green fluorescent protein (GFP) is a 27 kDa protein 
and is used primarily as a fluorescent reporter. If GFP is inserted at the C-terminus of a 
gene of interest, GFP fluorescence can be used to monitor expression of correctly 
folded protein. GFP has also been successfully adapted as a reporter for Mtb protein 
expression in M. smegmatis (Radhakrishnan et al., 2018).  
 
3.1.5 What we know about Mtb UgpB protein expression 
Mtb ugpB (Rv2833c) encodes for the substrate binding protein Mtb UgpB and is 
located in a putative four-gene ugpABCE ATP-binding cassette (ABC) transporter 
operon. A previous study (Jiang et al., 2014) produced recombinant expressed UgpB 
as a N-terminal GST fusion protein in E. coli. In these studies the structure of UgpB in 
the ligand-unbound conformation was solved by X-ray crystallography to 1.5 Å and 
ligand binding to glycerol-3-phosphocholine (GPC) was identified by isothermal 
calorimetry (Jiang et al., 2014). However the diversity of the ligands tested was limited 
and the inability to solve a ligand bound structure prompted us to carry out a more 
extensive biochemical analysis starting by expressing Mtb UgpB.  
 
 
 Chapter 3: Cloning, expression and purification of Mycobacterium tuberculosis UgpB 	  
 
	   81 
3.2 Hypotheses and Aims 
The primary hypothesis of this chapter was that an N-terminal truncated Mtb UgpB 
substrate-binding protein could be expressed using the pYUB1062 vector in M. 
smegmatis mc24517. The protein could be purified to homogeneity using a combination 
of immobilised metal affinity, ion exchange and gel filtration chromatography, and its 
identity confirmed by mass spectrometry. An additional hypothesis was that alanine 
site directed mutants of the protein could be produced using the same method, and 
that the secondary structure profiles of these mutants would be similar to the apo 
protein. To test this hypothesis circular dichroism was used. 
 
The specific aims of the work presented in this chapter were: 
• To express and purify Mtb UgpB, the substrate-binding protein of the UgpABCE 
ATP-binding cassette transporter. 
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3.3 Results 
3.3.1 Identification of UgpB in Mycobacteria 
The ugpB gene is found in Mtb and Mycobacterium bovis the causative agents of 
tuberculosis in humans and primarily bovine mammals and shares 99.3 % amino acid 
sequence (NCBI BLAST). However in Mycobacterium bovis BCG the vaccine strain for 
Mtb (Calmette, 1922), the ugpB gene is frame shifted at nucleotide position 631 of the 
ugpB gene, where cytosine is replaced by thymine resulting in the formation of a TAG 
stop codon that truncates the translated sequence (Brosch et al., 2007). In contrast, 
from comparative genomics (Mycobrowser, 2019), the ugpB gene is not present in M. 
marinum the causative agent of tuberculosis in fish or M. leprae the causative agent of 
leprosy that is considered to have a core genome that is massively smaller compared 
to the Mtb genome (Vissa et al., 2001). Interestingly the ugpB gene is only found in 
pathogenic mycobacteria species whereas it is not found in the closely related fast 
growing and non-pathogenic M. smegmatis species therefore these differences may 
reflect the different physiological environments of these organisms.  
 
3.3.2 Operon organisation of Mycobacterium tuberculosis UgpABCE transporter 
The UgpABCE transporter is organised in a putative 4-gene operon (Figure 3.1). The 
ugpC gene is 1083 bp nucleotides and encodes the predicted nucleotide binding 
protein and is approximately 39.3 kDa. The ugpB gene is 1311 bp nucleotides and 
encodes the substrate binding protein and is approximately 46.7 kDa. The ugpA and 
ugpE genes are 912 bp nucleotides and 828 bp nucleotides and encode the membrane 
spanning proteins and are approximately 34.1 kDa and 30.7 kDa. Adjacent to the core 
transporter genes is echA16, a probable enoyl-CoA hydratase and dinF a possible 
DNA damage inducible protein. However, the genetic annotation of these surrounding 




Figure 3.1: Operon organisation of Mycobacterium tuberculosis Ugp transporter. Genes 
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3.3.3 Comparison with E. coli UgpB 
Multiple sequence alignment of Mtb UgpB and E. coli UgpB, which are the only known 
structures of UgpB (PDB ID 4MFI) (PDB ID 4AQ4) (Jiang et al., 2014) (Wuttge et al., 
2012) (Figure 3.2) revealed large differences at the amino acid level with only 26.4 % 
similarity over 83 % read. Based on these differences it is therefore possible that these 
proteins have evolved to carry out different physiological functions. Interestingly, the 
Mtb UgpB protein encodes a lipobox motif [Lys (Ala/Ser) (Gly/Ala) Cys] at the N-
terminus. The cysteine residue in this motif may enable the protein to be lapidated and 
attach to the cell membrane. In direct contrast, E. coli UgpB does not encode a lipobox 
motif at the N-terminus therefore the protein is unlikely to be lipidated. These 
differences may reflect the different cell wall structures of these organisms. The Gram 
–ve E. coli bacteria has an inner and outer membrane separated by the periplasm. The 
absence of a lipobox motif in E. coli UgpB suggests that the protein exists freely in the 
periplasm and is not bound to the lipid membrane. Conversely, Mtb is a pseudo Gram 
+ve bacteria and does not have a periplasm therefore the encoded lipobox motif may 
be required for the protein to be attached to the cell membrane or lipids found in the 
cell wall. This potential ability to attach to the cell wall may provide a mechanism 
through which the protein can acquire nutrients external to the cell wall. I have only 
attempted to express and purify the N-terminal truncated protein because it is likely to 
be more soluble and therefore more amenable to biochemical characterisation. 
However, this N-terminal region may be intergral for the transporters function within the 
cell. 
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Figure 3.2: Sequence alignment of UgpB from Mycobacterium tuberculosis with UgpB 
from Escherichia coli. The sequence alignment was generated using Clustal Omega and 
ESPript version 3. Identical residues are indicated by a red background and conserved residues 
by red characters. The secondary structure elements of Mtb UgpB are shown above the 




3.3.4 Cloning of ugpB-pYUB1062  
The Mtb ugpB (Rv2833c) gene was previously expressed with a GST tag (Jiang et al., 
2014) however attempts in our lab to replicate these results were unsuccessful. 
Various systems were tried within the lab including expressing the gene in 
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Pseudomonas putida (Lack et al., 2008). Eventually Mtb UgpB was successfully 
expressed in M. smegmatis mc24517. 
 
The Mtb ugpB (Rv2833c) gene was amplified and cloned into the vector pYUB1062 
with a C-terminal hexa-His tag (Figure 3.3) by Dr James Harrison, as described 
(Chapter 2, 2.3.3.1). In this construct the Mtb UgpB protein was truncated at the N-
terminus where residues 1-34 were removed. Residues 1-34 are predicted by TMpred 
(ExPASy) to form a single trans-membrane anchor helix and secreted signal sequence 
and lipobox motif that may decrease protein expression and solubility (Cuthbertson et 
al., 2005). Removal of the first 34 amino acids containing this lipobox motif was found 


















Figure 3.3: Mtb UgpB-pYUB1062 plasmid map. Abbreviations: HygR hygromycin resistance 
gene, f1 ori and ori origins of replication in E. coli and Mycobacteria. 
 
3.3.5 Expression and purification of UgpB-pYUB1062 
The truncated Mtb ugpB-pYUB1062 construct was electroporated into Mycobacterium 
smegmatis mc24517 electro-competent cells. The cells were incubated in 6 L of LBGT 
media at 37 °C until optical density 0.4 was reached. The cells were then induced by 
the addition of 0.2 % acetamide and expression was continued for 20 hours at 37 °C. 
This expression condition resulted in protein being produced and was used as the 
optimal condition for subsequent expressions and purifications. 
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After expression the cells were suspended in UgpB lysis buffer (500 mM NaCl, 20 mM 
NaH2PO4, 0.1 % (v/v) triton X-100, pH 7.4) (Chapter 2, Table 2.1) and lysed by 
sonication. The cell lysate was passed over a Co2+ immobilised metal affinity 
chromatography (IMAC) column. Following immobilisation of Mtb UgpB to the Co2+ 
column, the protein was purified through a series of wash-steps and eluted with a step-
wise imidazole gradient. The fractions were collected and analysed by SDS-PAGE 
(Figure 3.4A). The expected Mtb UgpB protein size is approximately 44 kDa and the 
gel indicated a large amount of correctly expressed protein in the 50-1000 mM 
imidazole fractions (Figure 3.4A). A high intensity protein band was also observed at 
approximately 65 kDa that is most likely to be the chaperone GroEL. The imidazole 
elution fractions (50-1000 mM) contained the largest amount of Mtb UgpB protein 
however it was not completely pure at this stage therefore ion-exchange 
chromatography was carried out. First, the 50-1000 mM imidazole fractions were 
combined and dialysed (150 mM NaCl, 25 mM HEPES, 10.0 % glycerol pH 7). The 
dialysed protein was passed over a QHP anion exchange chromatography column to 
separate the proteins based on overall charge. The theoretical pI of the Mtb UgpB 
protein is 5.64 (ExPASy ProtParam) (Wilkins et al., 1999) so the protein should have 
an overall negative charge and, in theory, would not bind to the negatively charged 
anion-exchange column. Under these purification conditions the Mtb UgpB protein did 
not bind to the QHP column and, instead, was collected in the flow through and 150 
mM NaCl wash (Figure 3.4B). The 70 kDa and 35 kDa contaminants observed from the 
first Co2+ column appeared to bind to the QHP column and were eluted with an 
increased concentration gradient of NaCl however, the 15 kDa and 11 kDa 
contaminants co-eluted with the Mtb UgpB protein (Figure 3.4B). The flow through and 
150 mM NaCl fractions were collected and concentrated by ultrafiltration (10 kDa cut-
off, Amicon Ultra) to approximately 2 mL and passed over a Superdex 200 gel filtration 
chromatography column to separate the proteins based on size (150 mM NaCl, 25 mM 
HEPES, 10.0 % glycerol pH 7). 1 mL fractions were collected, analysed by SDS-PAGE 
(Figure 3.4C) and Mtb UgpB eluted (83-103 mL) as a monomer at the expected size of 
44 kDa (Figure 3.4D). However the protein was still not completely pure as the 15 kDa 
and 11 kDa bands remained (Figure 3.4C) suggesting that they could be interacting 
with Mtb UgpB therefore the identities of these proteins were analysed by in-gel trypsin 
digest mass spectrometry (Figure 3.5). 
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Figure 3.4: SDS-PAGE analysis of the purification of Mtb UgpB from M. smegmatis. A) 
Elution of His6-tagged Mtb UgpB from a Co2+ IMAC-column. M = molecular weight marker in 
kDa, IS = insoluble fraction, S = soluble lysate, FT = flow through, numbers 5 – 1000 refer to the 
imidazole concentration in the elution buffer (units of mM). B) QHP anion exchange 
chromatography of Mtb UgpB following the Co2+ IMAC step. L = protein after dialysis, FT = flow 
through, numbers 150 – 1000 refer to NaCl concentration in the elution buffer (units of mM). C) 
Size exclusion chromatography of Mtb UgpB following anion exchange chromatography with the 
volumes shown as corresponding to D. D) Size exclusion trace of Mtb UgpB.  
  
3.3.6 Analysis of low molecular weight contaminants by mass spectrometry 
Both of the contaminant proteins were identified as rplU and rpsK (Figure 3.5) from M. 
smegmatis. The 11 kDa contaminant band was identified as the 50S ribosomal protein 
rplU, 22 exclusive unique peptides, 33 exclusive unique spectra, 152 total spectra, 
101/103 amino acids (598 % coverage). The 15 kDa contaminant band was identified 
as the 30S ribosomal protein rpsK, 10 exclusive unique peptides, 15 exclusive unique 
spectra, 41 spectra, 53/138 amino acids (38 % coverage). It is likely that these 
contaminants, as they are part of the ribosomal translational machinery are a result of 
expressing proteins in M. smegmatis and do not reflect any physiological interactions 
with Mtb UgpB. 
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Figure 3.5: In-gel trypsin digest mass spectrometry of low molecular weight 
contaminants. A refers to the 11 kDa rplU B refers to the 15 kDa rpsK. Sequences highlighted 
in yellow indicate coverage of the peptides identified. 
 
3.3.7 Optimisation of Mtb UgpB protein purification 
To optimise and increase the purity of Mtb UgpB the same expression procedure was 
carried out (3.3.5) and the purification steps were the same as before apart from the 
final size exclusion step. Instead a Superdex 75 gel filtration chromatography column 
was used to improve the separation of the low molecular weight contaminants (Figure 
3.6C). A Superdex 75 separates in the molecular weight range (3-70 kDa) whereas 
Superdex 200 separates in the molecular weight range (10-600 kDa). Following size-
exclusion chromatography with the Superdex 75 column in the same buffer (150 mM 
NaCl, 25 mM HEPES, 10 % glycerol pH 7.0) the fractions were analysed by SDS-
PAGE and found to be a higher purity (Figure 3.6C) compared to the Superdex 200 
column (Figure 3.4C). No contaminants were observed apart from in the final volume 
66-68 mL so this was not pooled with the pure UgpB protein. This separation difference 
was probably due to differences in the gel filtration chromatography pore size 
distribution. The fractions containing pure Mtb UgpB volumes 51-64 mL (Figure 3.6C) 
were combined concentrated by ultrafiltration to 2 mg/mL and stored at -80 °C prior to 
analyses. Therefore this was identified as the best method for optimisation and used in 
subsequent purifications. 
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Figure 3.6: SDS-PAGE analysis of the purification of Mtb UgpB from M. smegmatis. A) 
Elution of His6-tagged Mtb UgpB from a Co2+ IMAC-column. M = molecular weight marker in 
kDa, IS = insoluble fraction, S = soluble lysate, FT = flow through, numbers 5 – 1000 refer to the 
imidazole concentration in the elution buffer (units of mM). B) QHP anion exchange 
chromatography of Mtb UgpB following the Co2+ IMAC step. L = protein after dialysis, FT = flow 
through, numbers 150 – 1000 refer to NaCl concentration in the elution buffer (units of mM). C) 
Size exclusion chromatography of Mtb UgpB following anion exchange chromatography with the 
volumes shown as corresponding to D. D) Size exclusion trace of Mtb UgpB.  
 
3.3.8 Mass spectrometry of Mtb UgpB 
The identity of purified Mtb UgpB was confirmed by in-gel trypsin digest mass 
spectrometry of the approximate 44 kDa SDS-PAGE band (Figure 3.6C). The Mtb 
H37Rv and M. smegmatis mc24517 proteome databases were searched. 25 exclusive 
unique peptides, 39 exclusive unique spectra, 230 total spectra, 234/436 amino acids 
(54 % coverage) were identified, confirming the identity of Mtb UgpB. 
 
 
Figure 3.7: In-gel trypsin digest mass spectrometry of Mtb UgpB. 
Sequences highlighted in yellow indicate coverage of the peptides identified. 
 
 Chapter 3: Cloning, expression and purification of Mycobacterium tuberculosis UgpB 	  
 
	   90 
3.3.9 Generation of genetically modified derivatives of Mtb UgpB 
Single site point mutations were introduced into 9 individual amino acid residues based 
on my structure of Mtb UgpB in complex with its GPC ligand and the identification of 
specific residues involved in ligand binding interactions (Chapter 5). Mutations were 
introduced by site-directed mutagenesis, replacing each individual residue with alanine 
using primers designed to incorporate the codon change (Chapter 2, Table 2.4). The 
primers were designed to have 9-15 bp either side of the codon of interest that was 
altered to result in a codon change to alanine. The length of the primers was selected 
to minimise the G+C content to enable efficient extension. The codon sequence for 
alanine was selected to be either GCC or GCG depending on the most similar 
surrounding nucleotides and because GCC and GCG have the highest frequency in 
the M. smegmatis mc2155 proteome (NCBI GenBank) of 45 % and 42 % respectively. 
GCC and GCG are therefore most likely to successfully result in incorporation of the 
alanine amino acid. The site-directed mutagenesis used the specific primers (Chapter 
2, Table 2.4) and apo-ugpB-pYUB1062 as a template plasmid. Following thermocycling 
the methylated parental plasmid was digested by dpnI digest (1 µL, 37 °C, 3 hours), 
and the purified plasmid was transformed into E. coli Top 10 and plated onto LB agar 
containing hygromycin. For each mutant, 3 colonies were selected and the plasmid 
was isolated and sequenced with T7 F and T7 R primers (Chapter 2, Table 2.3) to 
confirm the correct site-directed mutant DNA sequence. 
 
3.3.10 Protein production and purification of Mtb UgpB site-directed mutants 
All of the Mtb UgpB site-directed mutants were expressed and purified using the same 
optimised methods and steps as for UgpB-pYUB1062 (3.3.5) (3.3.7). SDS-PAGE and 
chromatography traces of all mutants can be found (Chapter 3, Appendix, Figures 3.9-
3.17). All of the mutant derivatives of Mtb UgpB pYUB1062 (Table 3.1) were 
successfully expressed and purified however the yields of Asp102-Ala, Trp208-Ala and 
Gly306-Ala were markedly reduced compared to apo-UgpB. This could be due to the 
mutation altering the folding and stability of the protein. The fractions containing pure 
mutant derivatives of Mtb UgpB were combined, concentrated by ultrafiltration and 
stored in UgpB dialysis buffer 2 at -80 °C prior to analyses. Differences in the yields of 
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Table 3.1: Protein purification yields of Mtb UgpB mutants. 
 
Mutant derivative of Mtb 
UgpB  
Protein purification yield 












3.3.11 Circular dichroism analysis of Mtb UgpB mutants 
Circular dichroism spectroscopy was used to analyse the secondary structure profile of 
all of the UgpB mutants. The proteins were dialysed into a low salt buffer (Chapter 2, 
Table 2.1). All of the measured mutants spectra showed a similar molar elipticity profile 
from 198-260 nm suggesting that the secondary structures were similar and that the 
substituted alanine mutation was not detrimental to the correct protein folding (Figure 
3.8). 
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3.4 Discussion 
Mtb UgpB (Rv2833c) is the substrate binding protein of the Mtb UgpABCE transporter 
and was successfully purified to homogeneity with a yield of approximately 1 mg per L 
of culture. This was pivotal to carry out the biochemical and structural analyses as 
described (Chapter 4 and 5). In total 9 genetic variants of Mtb UgpB were also 
successfully expressed and purified with yields ranging from 0.2-2.6 mg per L of culture 
enabling further biochemical analyses (Chapter 4, 4.3.13). Lots of optimisations were 
previously attempted by members in the lab to express the Mtb UgpB protein including: 
different expression systems, vectors, host strains, full-length and truncated protein, 
homologues, different media and additives. However these were later found to not be 
successful and we found that Mtb UgpB needed to be expressed in M. smegmatis to 
produce soluble, non-aggregated protein. The levels of protein expression were 
comparable to other Mtb proteins expressed in M. smegmatis (Radhakrishnan et al., 
2018) (Singhal et al., 2015). However we found that for the genetic variants the yield 
varied. This could be due to problems with protein folding and instability caused by 
substituting the native binding site residue for alanine. 
 
Full length Mtb UgpB was expressed in E. coli in the pET28a vector under the control 
of the T7 promoter and containing a C-terminal hexa-histidine tag. Using this system 
Mtb UgpB could not be produced as soluble protein. This was probably because full 
length Mtb UgpB is predicted by TMpred (ExPASy) to form a single trans-membrane 
anchor helix and secreted signal sequence that may associate with the plasma 
membrane and cause it to be insoluble (Cuthbertson et al., 2005). In addition the 
potential lipobox motif may also contribute to the full-length protein being insoluble.  
Therefore to improve soluble expression of Mtb UgpB the first 34 amino acids at the N-
terminus were removed, however soluble expression did not improve. In the previous 
study (Jiang et al., 2014) full-length Mtb UgpB was successfully expressed in E.coli 
BL21 (DE3) pLysS under control of the tac promoter with an N-terminal GST tag. The 
GST tag is reported to improve soluble protein expression (Rabhi-Essafi et al., 2007). 
Also E. coli pLysS cells express T7 lysozyme to prevent leaky expression from the T7 
promoter (Rosano et al., 2014). We attempted to replicate this result however only 
found low levels of expression, the major product was free GST tag and most of the 
protein was insoluble. This data is not shown as a previous member in the lab group 
performed it. Therefore we decided to express both full length and truncated Mtb UgpB 
in pETSUMO together with the chaperone GroES (P. Gupta et al., 2006). The SUMO 
tag and GroES chaperone co-expression are reported to improve soluble expression 
and folding however, soluble expression was not obtained. 
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Different host organisms were used, including Pseudomonas putida (Ramos-Gonzalez 
et al., 2005) because it has a high G+C genome content similar to Mtb and may be 
particularly important for codon usage.  Using the Pseudomonas putida host, only low 
levels of soluble Mtb UgpB expression were observed. Changing the host organism did 
appear to slightly improve soluble expression therefore it was instead expressed in the 
pYUB1062 vector and the more closely related M. smegmatis species under the 
control of the acetamidase promoter (Daugelat et al., 2003). In this system high levels 
of truncated Mtb UgpB expression were observed and soluble protein was successfully 
purified based on affinity of the C-terminal hexa-histidine tag for Ni2+ resin, followed by 
QHP ion exchange chromatography and Superdex 200 gel filtration chromatography. A 
TALON resin could be used to purify the full length UgpB protein without clarifying the 
cell lysate as physiologically it is a potential lipo protein. 
 
Following the Ni2+ IMAC purification strategy, the protein was not completely pure and 
several low molecular weight contaminants remained. For biochemical and structural 
characterisation the protein needed to be as pure as possible therefore the purification 
steps had to be optimised.  Instead of using Ni2+ resin, Co2+ resin was used. Co2+ 
generally has a lower affinity for histidine tags, however this can be advantageous as it 
then binds to the histidine tag and not histidine tag like proteins, which can result in a 
higher protein purity (ThermoFisher, 2019). Co2+ resin was found to result in purer 
protein before the first purification step. We also needed better resolution to separate 
Mtb UgpB from the lower molecular weight contaminants therefore instead of using a 
Superdex 200 gel filtration column a Superdex 75 gel filtration column was used. This 
was because the Superdex 75 gel filtration column has a lower molecular weight 
separation range of 3-70 kDa compared to 10-600 kDa. The combination of these 
optimisation steps resulted in the successful removal of most of the low molecular 
weight contaminants and purification of Mtb UgpB. We also mutated binding site 
residues of Mtb UgpB by site-directed mutagenesis. Following this optimised strategy, 
the Mtb UgpB site directed mutagenesis were successfully produced. Importantly the 









 Chapter 3: Cloning, expression and purification of Mycobacterium tuberculosis UgpB 	  
 
	   94 
3.5 Appendix 
 
Figure 3.9: SDS-PAGE analysis of the purification of Tyr78Ala UgpB. A) Co2+ IMAC-
column. B) QHP anion exchange chromatography. C) Superdex 75 gel filtration 
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Figure 3.10: SDS-PAGE analysis of the purification of Asp102Ala UgpB. A) Co2+ IMAC-
column. B) QHP anion exchange chromatography. C) Superdex 75 gel filtration 






 Chapter 3: Cloning, expression and purification of Mycobacterium tuberculosis UgpB 	  
 
	   96 
 
Figure 3.11: SDS-PAGE analysis of the purification of Ser153Ala UgpB. A) Co2+ IMAC-
column. B) QHP anion exchange chromatography. C) Superdex 75 gel filtration 
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Figure 3.12: SDS-PAGE analysis of the purification of Leu205Ala UgpB. A) Co2+ IMAC-
column. B) QHP anion exchange chromatography. C) Superdex 200 gel filtration 
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Figure 3.13: SDS-PAGE analysis of the purification of Trp208Ala UgpB. A) Co2+ IMAC-
column. B) QHP anion exchange chromatography. C) Superdex 75 gel filtration 
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Figure 3.14: SDS-PAGE analysis of the purification of Ser272Ala UgpB. A) Co2+ IMAC-
column. B) QHP anion exchange chromatography. C) Superdex 75 gel filtration 
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Figure 3.15: SDS-PAGE analysis of the purification of Gly306Ala UgpB. A) Co2+ IMAC-
column. B) QHP anion exchange chromatography. C) Superdex 75 gel filtration 
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Figure 3.16: SDS-PAGE analysis of the purification of Tyr345Ala UgpB. A) Co2+ IMAC-
column. B) QHP anion exchange chromatography. C) Superdex 75 gel filtration 
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Figure 3.17: SDS-PAGE analysis of the purification of Arg385Ala UgpB. A) Co2+ IMAC-
column. B) QHP anion exchange chromatography. C) Superdex 75 gel filtration 
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Mtb UgpB is the substrate binding protein (SBP) that is part of the UgpABCE ATP-
binding cassette (ABC) transporter. As Mtb UgpB was successfully purified to 
homogeneity in Chapter 3 the next step was to biochemically characterise its ligand 
interactions. Only a limited number of molecules have been investigated for binding to 
Mtb UgpB (Jiang et al., 2014) therefore we set out to carry out a more extensive 
biochemical analysis.  
 
4.1.2 Ligand binding studies of Mtb substrate binding proteins 
The typical binding affinities of SBP’s range from nM to mM range (Berntsson et al., 
2010). As ligand binding to SBP’s can be difficult to measure, several different methods 
can be used. Methods to investigate SBP ligand binding include: radioactive assays 
(Pandey et al., 2016), surface plasmon resonance (SPR) (Kumar et al., 2019), intrinsic 
tryptophan fluorescence (Bhattacharyya et al., 2018), isothermal calorimetry (Wuttge et 
al., 2012), Forster resonance energy transfer (FRET) (Deuschle et al., 2005) and 
microscale thermophoresis (MST) (Brautigam et al., 2014). However only a limited 
number of studies have biochemically characterised Mtb SBP’s. 
 
Recently, the putative Mtb glutamine SBP, GlnH was biochemically investigated 
(Bhattacharyya et al., 2018). Despite being annotated as a glutamine binding protein 
Mtb GlnH was actually found to have the highest binding affinity to aspartate (Kd = 4.8 
µM compared to 15.2 µM) by isothermal calorimetry (ITC). In contrast, a GlnH 
homologue sharing only 43 % amino acid sequence similarity from Corynebacterium 
glutamicum had a significantly lower affinity to aspartate (Kd = 550 µM) and glutamate 
(Kd = 2,060 µM) by intrinsic tryptophan fluorescence (Bhattacharyya et al., 2018). 
Clearly this study demonstrates the requirement to functionally investigate SBP’s that 
are predicted by bioinformatics to have similar functions. Another example is the 
putative compatible solute-binding protein, Mtb ProX, which was predicted by 
bioinformatics to bind to the osmolytes: glycine and betaine however a functional study 
of Mtb ProX found that it actually binds to polyphenols and may be involved in the 
uptake of polyphenol analogues during infection (J. H. Zhao et al., 2018).  
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SBP’s that bind carbohydrates typically have lower binding affinities compared to 
amino acid or metal ion specific SBP’s (Phillips et al., 1976) (Cuneo et al., 2006) 
(Yatsunyk et al., 2008) (Pulido et al., 2015). The Mtb LpqY-SugABC transporter has 
been found to be involved in uptake of the disaccharide trehalose, however the binding 
affinity of trehalose to the SBP Mtb LpqY has not yet been determined, and other 
ligands may exist (Kalscheuer et al., 2010).  A predicted carbohydrate SBP, Mtb UspC 
was recently investigated for its ability to bind a panel of carbohydrates by a thermal 
shift assay and found to preferentially bind to amino-sugars: D-glucosamine-6-
phosphate (Kd = 27.7 mM) and chitobiose (Kd = 38.1 mM) (Fullam et al., 2016). 
Complementary NMR analysis revealed the structural basis of these carbohydrate 
interactions and highlighted a potential role of Mtb UspC in the uptake of peptidoglycan 
cell wall fragments (Fullam et al., 2016). Similarly this study highlights the importance 
of screening a wide range of potential substrates to investigate SBP function. 
Importantly, biochemical studies of Mtb SBP’s may reveal different nutrients and 
regulatory pathways utilised by Mtb during infection and could lead to the identification 
of novel targets for drug development. 
 
4.1.3 Ligand binding studies of Mtb UgpB and E. coli UgpB 
A previous study of Mtb UgpB (Jiang et al., 2014) identified binding to glycerol-3-
phosphocholine (GPC) (Figure 4.1), the head-group of the phospholipid 
phosphatidylcholine (Figure 4.1) by ITC. However the study (Jiang et al., 2014) was 
limited in scope as they only tested binding to four molecules: GPC, glycerol-3-
phosphate (G3P), glycerol-2-phosphate (G2P) and maltose, the structures are shown 
(Figure 4.1). The binding affinity to glycerol-3-phosphocholine (1:1 cadmium chloride 
adduct) was determined with a Kd of 27.3 µM however binding to the linear structurally 
related G3P, the branched G2P and structurally dissimilar maltose could not be 
detected. Despite the high affinity to GPC the authors were unable to co-crystallise Mtb 
UgpB with GPC (Jiang et al., 2014). In comparison, E. coli UgpB has a low amino acid 
sequence similarity (26.4 % similarity over 83 % read) (Chapter 3, Figure 3.2) 
compared to Mtb UgpB however for E. coli UgpB, binding was detected to both G3P 
with a Kd of 0.68 µM and also to GPC with a Kd of 5.1 µM by ITC (Wuttge et al., 2012). 
The observation of binding of GPC to both Mtb UgpB and E. coli UgpB was puzzling as 
both of these proteins do not have a choline-binding motif such as that found in the 
choline/acetylcholine binding protein aromatic box of S. meliloti ChoX (Oswald et al., 
2008). We therefore wanted to investigate if other potential ligands bind to Mtb UgpB 
and also determine the molecular basis of substrate recognition (Chapter 5). 
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Figure 4.1: Structures of glycerophosphodiester variations investigated for binding to 

















































































 Chapter 4: Characterisation of Mycobacterium tuberculosis UgpB   
 
	   106 
4.2 Hypotheses and Aims 
I hypothesised that the Mtb UgpB SBP binds to alternative ligands. The protein is 
predicted by comparative genomics to be a carbohydrate binding protein, and the aim 
here was to test binding to a range of different substrates. Many ABC transporters are 
promiscuous therefore I also tested binding to amino acids, anti-tubercular antibiotics 
and different components of glycerophosphodiesters. In order to test binding I used a 
thermal shift assay. A previous study found that the protein binds to a 
glycerophosphodiester called GPC. However I hypothesised that alternative 
glycerophosphodiesters that possess a glycerol tail and phosphate group, potentially 
derived from macrophage membranes could also bind. Finally, I hypothesised that site-
directed mtuants would have different glycerophosphodiester binding affinities 
compared to the apo protein. To test these hypotheses I synthesised alternative 
glycerophosphodiesters and tested binding by MST.  
 
The specific aims of the work presented in this chapter were:  
• To carry out a ligand binding screen to biochemically characterise Mtb UgpB.  
• To establish if alternative lipid head groups are recognised by Mtb UgpB. 
• To determine the binding affinities of Mtb UgpB for the ligands identified. 
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4.3 Results 
4.3.1 Introduction 
Mtb UgpB is known to bind to GPC (Jiang et al., 2014) To explore whether Mtb UgpB 
recognises other ligands Mtb UgpB was expressed as pure protein (Chapter 3, 3.3.7) 
and the biochemical characterisation is described in this chapter.  The ligands 
identified for Mtb UgpB in this chapter have subsequently been used to set crystal trials 
to investigate the structural determinants of these interactions (Chapter 5). 
 
4.3.2 Thermal shift assay of Mtb UgpB 
To investigate if other ligands bind to Mtb UgpB a thermal shift assay was carried out 
as described (Chapter 2, 2.5.8). The thermal shift assay works by measuring the 
excitation/emission wavelength profile of SYPRO Orange fluorescent dye (Niesen et 
al., 2007). The Tm is calculated by solving the first derivative of the fluorescence 
emission as a function of temperature and identifying the lowest point of the curve 
(Huynh et al., 2015). Comparing the Tm of a protein in the presence or absence of 
ligand is used to calculate the ΔTm. In this study, a panel of carbohydrates, amino 
acids, and anti-mycobacterial antibiotics were selected because they were readily 
available, some were known to be ligands based on previous studies (Jiang et al., 
2014) and carbohydrates were tested because of the bioinformatics sequence 
similarity of Mtb UgpB to other carbohydrate binding proteins (Niederweis, 2008).  
 
All of the carbohydrates were tested at a final concentration of 100 mM however the 
amino acids were tested at the highest soluble concentration. The anti-mycobacterial 
antibiotics were tested at a final concentration of 10 mM. In each assay, Mtb UgpB was 
tested at a final concentration of 22 µM in the buffer (150 mM NaCl, 25 mM HEPES, 10 
% glycerol pH 7.0). 15 X final concentration of SYPRO orange dye was added together 
with the ligand in a total volume of 20 µL and incubated at room temperature for 15 min 
prior to measurement.  
 
4.3.3 Thermal shift assay with Mtb UgpB and carbohydrates 
A total of 23 carbohydrate compounds were tested and the structures that were found 
to bind are shown (Figure 4.2). A range of different carbohydrates was tested including 
monosaccharides, disaccharides, amino-sugars and carbohydrates that resembled 
peptidoglycan cell wall components. Trehalose was tested because it is known to bind 
to a different Mtb substrate binding protein: LpqY that belongs to the LpqY-SugABC 
transporter (Kalscheuer et al., 2010). Amino-sugars were tested because one of the 
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other Mtb predicted carbohydrate transporters UspC was found to bind to D-




















































The results of the thermal shift assay with Mtb UgpB and carbohydrates (Figure 4.3) 
indicated that 8 amino sugars appeared to produce the highest thermal shifts: D-
mannosamine (+4.8 °C), D-galactosamine (+4.6 °C), D-glucosamine (+4.4 °C) and 
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ΔTm to the monosaccharide amino sugars therefore size of the sugar didn’t appear to 
be a determinant of binding. Other carbohydrates that produced only small positive 
thermal shifts were the amino sugars, muramic acid (+2.6 °C), chitobiose (+2.8 °C), 
chitotriose (+2.4 °C) and chitotetraose (-2.15 °C) which are all carbohydrates that 
resemble peptidoglycan cell wall components (Figure 4.2). Ligand binding to the most 
populated, lowest energy, native protein state will cause stabilisation and results in a 
positive thermal shift value. However, the protein is conformationally dynamic and 
exists in different energy states. If the ligand binds to a less populated, conformational 
state, ligand binding may result in a negative thermal shift value (Cimmperman et al., 
2008). Binding to amino-sugars was similar to a previous study of Mtb UspC that 
showed binding to D-glucosamine-6-phosphate (+3.0 °C) however the thermal shift for 
the disaccharide chitobiose was a lot higher for Mtb UspC (+6.7 °C) (Fullam et al., 
2016). 
 
Figure 4.3: Thermal shift assay with Mtb UgpB and carbohydrates. Bar graphs illustrating 
thermal shifts (ΔTm) defined as the difference in thermal shift of protein with ligand compared to 
without ligand. The different ligands were probed for binding at a final concentration of 100mM. 
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4.3.4 Thermal shift assay with Mtb UgpB and variations of glycerol-3-
phosphocholine 
Different variations of GPC were also tested because a previous study showed that 
Mtb UgpB binds to GPC:CdCl2 (1:1 cadmium chloride adduct) (Jiang et al., 2014). 
Structures of all the molecules tested are shown (Figure 4.4). A previous study of E. 
coli UgpB also identified that it binds to both G3P and GPC (Wuttge et al., 2012) so we 
wanted to see if this could be observed for Mtb UgpB using the thermal shift assay. 
Therefore GPC and G3P (Figure 4.4) were tested for binding as well as other 




Figure 4.4: Structures of glycerophosphodiesters and analogues probed by thermal shift 
assay. 
 
The results of the thermal shift assay with Mtb UgpB and variations of GPC (Figure 
4.5) indicated that GPC produced the highest thermal shift (+7.3 °C) which supports 
the previous study that revealed GPC bound with a high affinity Kd = 27.3 µM by 
isothermal calorimetry (Jiang et al., 2014). However, in our studies the GPC:CdCl2 (1:1 
cadmium chloride adduct) indicated a much lower thermal shift (-11.7 °C). The 
previous study (Jiang et al., 2014) also tested GPC:CdCl2 (1:1 cadmium chloride 
adduct) binding to Mtb UgpB and our thermal shift results suggest it may actually have 
a destabilising effect. This is further supported as when CdCl2 was tested it produced a 
large negative thermal shift (-28.0 °C). Therefore GPC that is available as a non-CdCl2 
adduct was tested, and it was found to produce the highest thermal shift (+7.3 °C). This 
suggests that GPC is binding, and CdCl2 is not binding. Other derivatives of GPC 
include phosphocholine (Figure 4.4) that lacks the glycerol moiety of GPC and G3P 
(Figure 4.4) that lacks the phosphocholine moiety of GPC therefore we wanted to test 
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Phosphocholine (Figure 4.5) only produced a small negative thermal shift (-1.4 °C) 
suggesting that the glycerol moiety of GPC is important for binding. G3P (Figure 4.4) 
was also tested because it showed binding to E. coli UgpB with a Kd of 0.68 µM by 
isothermal calorimetry (Wuttge et al., 2012). G3P has a glycerol tail and lacks a choline 
head-group (Figure 4.4). However G3P only showed a small negative thermal shift (-
1.4 °C) that contrasted with the previous study of E. coli UgpB however agreed with the 
Mtb UgpB study by isothermal calorimetry (ITC) (Jiang et al., 2014). We also wanted to 
investigate whether head group type was important. O-phospho-L-serine (Figure 4.4), 
the head-group of phosphatidyl-L-serine without a glycerol backbone only showed a 
small negative thermal shift of (-3.3 °C) whereas myo-inositol the head-group of 
phosphatidylinositol showed a very small negative thermal shift  (-0.2 °C) however 
myo-inositol does not contain a glycerol or phosphate group. Later we show that these 
head groups are recognised by Mtb UgpB (Chapter 4, 4.5) and that they require a 
glycerol moiety for binding recognition. Combined these results suggested that the 
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Figure 4.5: Thermal shift assay with Mtb UgpB and glycerophosphodiester variations. Bar 
graphs illustrating thermal shifts of ΔTm defined as the difference in thermal shift of protein with 
ligand compared to without ligand. The different ligands were probed for binding at a final 
concentration of 100mM. Data are shown from three independent repeats represented as mean 
± SD. 
 
4.3.5 Thermal shift assay with Mtb UgpB and amino acids 
To evaluate if Mtb UgpB binds to amino acids the thermal shift assay was carried out 
using the same conditions as described (4.3.2) (Chapter 2, 2.5.8). The amino acids 
were tested at the highest soluble concentration of 100 mM apart from those indicated 
(Figure 4.6) due to their low solubility in water. 
 
The results of the amino acid analysis (Figure 4.6) indicated that arginine produced the 
largest negative thermal shift (-3.8 °C). The structures of amino acids that indicated 
binding are shown (Figure 4.7). Arginine is frequently added to stabilise proteins from 
aggregation in refolding experiments and may explain this result as the thermal shift 
assay measures protein unfolding (Baynes et al., 2005). Histidine produced the largest 
positive thermal shift (+3.7 °C) and as well as arginine it has a positively charged side 
chain. As Mtb UgpB has a C-terminal hexa-histidine tag that was not removed following 
purification the histidine may be interacting with the intrinsic hexa-histidine tag, altering 
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Mtb UgpB to remove the C-terminal hexa-histidine tag therefore this hypothesis could 
not be tested. Two negatively charged amino acids, glutamate and aspartate produced 
the second largest thermal shifts, glutamate (+3.0 °C) and aspartate (+1.8 °C) whereas 
the other classes of amino acids did not produce any ΔTm > 2.0 °C therefore it appears 
that charged amino acids in particular affected the thermal shift.  
 
Figure 4.6: Thermal shift assay with Mtb UgpB and amino acids. Bar graphs illustrating 
thermal shifts of ΔTm defined as the difference in thermal shift of protein with ligand compared to 
without ligand.  The different compounds were probed for binding at the final concentrations in 
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4.3.6 Thermal shift assay with Mtb UgpB and antibiotics 
In order for antibiotics to be transported into cells they must either cross the lipid 
bilayer of the cell membrane directly or pass through protein transporters. However 
recent studies have indicated that there is little evidence of drug transport through the 
phospholipid bilayer and instead protein transporters mediate drug transport (Kell, 
2015) (Kell et al., 2013). Therefore we decided to test if a range of anti-mycobacterial 
antibiotics including some of those routinely used to treat tuberculosis could bind to 
Mtb UgpB by the thermal shift assay. 
 
The antibiotics were tested at a final concentration of 10 mM and the thermal shifts are 
shown (Figure 4.8). Interestingly three of the six antimycobacterial antibiotics produced 
large thermal shifts (Figure 4.8). Ethambutol produced the highest positive thermal shift 
(+3.7 °C). The structure of ethambutol resembles GPC (Figure 4.9) however 
ethambutol only has two hydroxyl groups instead of three hydroxyl groups in GPC. The 
two hydroxyl groups in ethambutol may be important for binding because based on our 
GPC bound structure the three hydroxyl groups of GPC are important for binding 
recognition (Chapter 5, 5.3.6). Hygromycin produced the largest negative thermal shift 
(-4.2 °C) however isoniazid and pyrazinamide only produced very small thermal shifts. 
As the antibiotics were tested at a final concentration of 10 mM, GPC was also tested 
at 10 mM and showed only a small thermal shift (+1.0 °C) compared to the large 
thermal shift (+7.3 °C) at 100 mM. Interestingly these results may indicate that Mtb 
UgpB binds to antibiotics and could have a role in the uptake of these compounds. 
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Figure 4.8: Thermal shift assay with Mtb UgpB and antibiotics. Bar graphs illustrating 
thermal shifts of ΔTm defined as the difference in thermal shift of protein with ligand compared to 
without ligand.  The different compounds were probed for binding at final concentrations of 10 






Figure 4.9: Structures of ethambutol and hygromycin that indicated binding to Mtb UgpB 
by thermal shift assay.  
 
 
4.3.7 Mtb UgpB phospholipid strips 
Based on the thermal shift results that indicated Mtb UgpB binds to GPC (Figure 4.5) 
we wanted to evaluate if other lipid head-groups could also bind to Mtb UgpB. A 
convenient method to do this is to measure binding to the phospholipids e.g. 
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strips are commercially available (Echelon Biosciences) and are nitrocellulose 




Figure 4.10: Structures of phospholipids that indicated the strongest binding to Mtb 
UgpB by phospholipid strip. The structure of glycerol-3-phosphocholine (GPC) is shown as it 
is derived from phosphatidylcholine. 
 
To determine the binding of Mtb UgpB to lipids the strips were treated as described in 
the methods (Chapter 2, 2.5.9). Mtb UgpB was incubated with the lipid strip and 
binding to the lipid spots was detected by incubating with penta-His primary antibody, 
followed by incubating with anti-mouse IgG-HRP secondary antibody. 
Chemiluminescence was used to detect the bound antibody. The membranes were 
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Figure 4.11: Phospholipid strip Mtb UgpB. A) Phospholipid strip probed with Mtb UgpB and 
anti-His/anti HRP secondary and ECL reagent. B) Schematic of phospholipid strip, black 
indicates strongest binding, grey weaker binding and white no binding. C) Quantitation of 
phospholipid strip binding calculated in ImageJ (n=1). 
 
The results of the phospholipid strip (Figure 4.11) indicated strongest binding of Mtb 
UgpB to inositol phosphate lipids containing a single phosphate group: Phosphatidyl-
inositol-3-phosphate (PtdIns(3)P), phosphatidyl-inositol-4-phosphate (PtdIns(4)P) and 
phosphatidylinositol-5-phosphate (PtdIns(5)P) (Figure 4.11). The results also indicate 
that Mtb UgpB binds to phosphatidylserine (PS). These results were intriguing as it 
suggested that potentially alternative phospholipid head-groups could also bind to Mtb 
UgpB. However no binding was observed to phosphatidylcholine (PC) despite it having 
the GPC head-group. These phospholipid strip assays are qualitative and were only 
carried out once. The assays would need to be repeated at least 3 times to show 
significance of the data. However these assays are renowned for false positives and 
negatives (Downes et al., 2005). It may be that as the glycerol moiety is ester bonded 
to two fatty acid tails in PC (Figure 4.10) this may inhibit binding recognition and based 
on the structure of GPC bound Mtb UgpB determined after this assay (Chapter 5, 



























































































	   	  
	   	  
	   	  
	   	  
	   	  
	   	  
	   	  
	   	  
A B 
C 
 Chapter 4: Characterisation of Mycobacterium tuberculosis UgpB   
 
	   118 
phosphorylated inositol phospholipids, phosphatidyl-inositol-3, 4-diphosphate 
(PtdIns(3, 4) P2), phosphatidyl-inositol-3, 5-diphosphate (PtdIns(3, 5) P2) and 
phosphatidyl-inositol-4, 5-diphosphate (PtdIns(4, 5) P2) however these lipids showed 
lower binding affinities compared to the mono phosphorylated inositol phospholipids. 
As the tri-phosphorylated phosphatidyl-inositol-3, 4, 5-triphosphate (PtdIns(3, 4, 5)P3) 
did not show binding it may suggest that size of the lipid head-group is a key 
determinant for binding. In hindsight overall this assay may not be the best to 
investigate lipid head-group binding based on the structures of these lipids and what 
we know about the binding recognition from the Mtb UgpB structure (Chapter 5, 5.3.6). 
 
4.3.8 Mtb UgpB phosphoinositide array 
To investigate the phospholipid interactions further a phosphoinositide array was tested 
using the same method as described previously (4.3.7) (Chapter 2, 2.5.9). The 
phosphoinositide array contains different concentrations (100-1.56 pmol per spot) of 
the inositol phospholipids and therefore concentration dependent binding could indicate 
the particular lipid binding preference. The results of the analysis showed that 
PtdIns(5)P had the highest binding as binding was found in the 12.5 pmol spot 
whereas the second highest binding was for PtdIns(4)P and the di-phosphorylated 
inositol phospholipid PtdIns(3, 5)P2 as lower binding was also observed in the 12.5 
pmol spot (Figure 4.12). The structures of the compounds that indicated strongest 
binding are shown (Figure 4.13) These results suggested that Mtb UgpB binding had a 
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Figure 4.12: Phosphoinositide array Mtb UgpB. A) Phosphoinositide array probed with Mtb 
UgpB and anti-His/anti HRP secondary and ECL reagent. B) Schematic of phosphoinositide 
array, black indicates strongest binding, grey weaker binding and white no binding. C) 
Quantitation of phosphoinositide array binding calculated in ImageJ (n=1). 
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Figure 4.13: Structures of phospholipids that indicated the strongest binding to Mtb 
UgpB by phosphoinositide array, 
 
4.3.9 Mtb UgpB sphingolipid strips 
Another strip containing sphingolipids was tested (Figure 4.14) using the same method 
as described previously (4.3.7) (Chapter 2, 2.5.9). In this strip binding was only 
observed for sulfatide, a structurally different lipid to phospholipids that is a sulphur 
containing glycolipid (Figure 4.15). Sulfatide is derived from a ceramide lipid however it 
has a sulphate group that replaces the 3-hydroxyl of galactose. Interestingly its head-
group does not have a phosphate group however sulfatides are important components 
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Figure 4.14: Sphingolipid strip Mtb UgpB. A) Sphingolipid strip probed with Mtb UgpB and 
anti-His/anti HRP secondary and ECL reagent. B) Schematic of sphingolipid strip, black 
indicates strongest binding, grey weaker binding and white no binding. C) Quantitation of 
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4.3.10 Microarray screen of ligand binding to Mtb UgpB 
To carry out a more extensive screen of ligand binding to Mtb UgpB a microarray 
analysis was carried out. The microarray screened for binding of 885 sequence-defined 
lipid-linked glycan probes to Mtb UgpB. Our collaborators Dr Lisete Silva and Dr Yan 
Liu at Imperial College London carried out the microarray analyses of Mtb UgpB. 
 
Two different assay conditions were used (Chapter 2, 2.5.10), either with or without 
pre-complexation of the hexa-histidine tagged Mtb UgpB protein and the primary 
mouse anti-His and secondary biotinylated anti-mouse IgG detection antibodies before 
the overlay. The pre-complexation procedure allowed for artificial oligomerization of the 
hexa-histidine tagged Mtb UgpB and can enhance avidities of binding of monomeric 
proteins, or proteins with low binding affinities (Otto et al., 2011). For the non-
precomplexed experiment, Mtb UgpB protein was overlaid followed by detection with 
primary monoclonal anti-polyHistidine antibody and secondary biotinylated anti-mouse 
IgG antibody. For the pre-complex experiment, protein-antibody complexes were 
prepared by pre-incubating primary antibody and secondary antibody, followed by 
addition of Mtb UgpB protein. For both the non-precomplexed and precomplexed 
protein, binding was detected with streptavidin-Alexa Fluor 647. However the 
microarray results found only non-specific binding to the probes and no significant 
binding signals were detected (Figure 4.16A and 4.16B).  
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Figure 4.16: Microarray analyses of Mtb UgpB and 885 sequence-define lipid-linked 
glycan probes. A) Precomplexed Mtb UgpB.  25 (µg/mL) precomplexed 1:2:2 (w/w/w). B) Mtb 
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4.3.11 BioLayer interferometry of Mtb UgpB 
We wanted to establish a high throughput screen to investigate if any other substrates 
or potential inhibitors bind to Mtb UgpB. Therefore we decided to evaluate the use of 
BioLayer interferometry (BLI) because BLI has previously been used for drug 
screening (Wartchow et al., 2011). BLI is capable of detecting small molecule 
interactions with a sensitivity down to a molecular weight of >150 Da (ForteBio) 
(Concepcion et al., 2009). In this study we chose to immobilise Mtb UgpB to Octet NHS 
reactive BLI sensors (ForteBio) that react with free amines. As a result the buffer for 
Mtb UgpB could not contain free amines and therefore Mtb UgpB was dialysed from 
HEPES buffer into three different buffers: buffer A (25 mM sodium acetate, 150 mM 
NaCl, 10 % glycerol pH 5.5) was selected because the commercial recommendations 
(ForteBio) for NHS reactive BLI sensors were to use 25 mM sodium acetate at pH 5.5. 
Buffer B  (25 mM NaH2PO4, 150 mM NaCl, 10 % glycerol pH 7.0) was selected 
because we wanted to keep the pH 7.0 and remove HEPES because it is a tertiary 
amine and may interfere with loading to the NHS reactive BLI sensors. Buffer C (25 
mM HEPES, 150 mM NaCl, 10 % glycerol pH 7) was selected because we wanted to 
see if the original protein buffer could be used to measure binding. A final 
concentration of 20 µg/mL of Mtb UgpB was used to immobilise the protein onto the 
sensors for each buffer tested. 
 
The sensorogram steps are shown (Figure 4.17) (Chapter 2, 2.5.11). Before 
immobilising Mtb UgpB to the sensor, the carboxylic acid surface was activated by 
reacting with 1-Ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride (EDC) (10 
mM) and N-hydroxysulfosuccinimide (NHS) (20 mM) to generate sulfo-NHS esters, that 
are reactive with primary amines located in the protein. After immobilising Mtb UgpB 
(20 µg/mL) the unreacted sulfo-NHS esters were quenched by addition of 
ethanolamine (1 M), that has free amines, and the sensor was washed in buffer to 
remove any excess ethanolamine. Association of GPC to Mtb UgpB was then tested at 
1 mM, this is approximately 36 times greater than the Kd of 27.3 µM determined by a 
previous study (Jiang et al., 2014).  
 
We found that Mtb UgpB was successfully immobilised onto the sensor because an 
increase in the binding signal was observed in the 360-960 s UgpB loading step 
(Figure 4.17). Of the buffers tested (A-C) the optimal buffer was found to be a variation 
of the commercially recommended sodium acetate pH 5.5 (buffer A) because this 
buffer showed the largest increase in signal of approximately 1.0 nm in the loading step 
(Figure 4.17). This was because the slightly acidic pH 5.5 of buffer A was necessary for 
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optimal protein binding to the activated carboxylic acid surface of the BLI sensor. 
Minimal dissociation of Mtb UgpB was identified in the 960-1260 s ethanolamine (1 M) 
quenching step and the 1260-1380 s buffer baseline was stable indicating that the 
protein was stably bound (Figure 4.17). 
 
Figure 4.17: BioLayer interferometry sensorogram of Mtb UgpB with selected buffers. 
Green line refers to buffer A. Orange line refers to buffer B. Magenta line refers to buffer C. 0-60 
s dH2O equilibration, 60-360 s 1-Ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride 
(20 mM) (EDC)/NHS (10 mM) activation, 360-960 s UgpB loading, 960-1260 s ethanolamine 
(1M) quenching of the excess sulfo-NHS esters, 1260-1380 s buffer baseline, 1380-1675 s GPC 
(1 mM) association and 1675-1980 s GPC dissociation. 
 
 
However association to GPC was not observed because there was no increase in the 
binding signal during the 1380-1675 s GPC (1 mM) association step or any decrease in 
the binding signal in the 1675-1980 s GPC dissociation step (Figure 4.17). The 
molecular weight detection limit for BLI is >150 Da and GPC approaches this limit, as 
its molecular weight is 257.22 Da, which may be why no association was observed. 
However it’s also possible that ethanolamine (1 M) added during the 960-1260 s sulfo-
NHS ester quenching step could be binding to Mtb UgpB and preventing GPC from 
binding to the binding site and hence why no signal was observed in the association 
step. Also as the buffer during the GPC association step was pH 5.5 this may have 
affected binding. 
 
Although association of GPC to Mtb UgpB couldn’t be detected using the conditions we 
tested, we wanted to see if the concentration of Mtb UgpB immobilised onto the sensor 
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could be lowered. As this would minimise the amount of protein used per assay. 
Therefore we tested different concentrations of Mtb UgpB: 5 µg/mL, 10 µg/mL and 20 
µg/mL in buffer A (Figure 4.18).  We found that 5 µg/mL of Mtb UgpB was sufficient for 
immobilisation as an increase in the binding signal to approximately 1.0 nm was 
observed in the 360-960 s UgpB loading step (Figure 4.18) 
 
Figure 4.18: BioLayer interferometry sensorogram of Mtb UgpB loading optimisation. 
Green line refers to 20 µg/mL protein. Orange line refers to 10 µg/mL protein. Magenta line 
refers to 5 µg/mL. 0-60 s dH2O equilibration, 60-360 s 1-Ethyl-3-[3-dimethylaminopropyl] 
carbodiimide hydrochloride (20 mM) (EDC)/NHS (10 mM) activation, 360-960 s UgpB loading, 
960-1260 s ethanolamine (1 M) quenching of the excess sulfo-NHS esters, 1260-1380 s buffer 
baseline, 1380-1675 s GPC (1 mM) association and 1675-1980 s GPC dissociation. 
 
In the future it may be better to biotinylate Mtb UgpB and load it onto super streptavidin 
biosensors, which are designed for the analysis of small molecule interactions 
(ForteBio). In particular super strepatavidin biosensors would also avoid using the 
coupling agent ethanolamine that is potentially remaining and binding to Mtb UgpB. 
Additionally, super streptavidin biosensors are compatible with buffers at a range of 
different pH. As pH may influence binding to GPC, the original purification buffer could 
be used instead. However, instead of optimising BLI for ligand screening we chose to 
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4.3.12 Binding affinity analysis of Mtb UgpB with GPC by microscale 
thermophoresis 
To investigate the interactions of Mtb UgpB with the potential ligands identified from the 
thermal shift analysis (4.3.2) and lipid strips (4.3.7), MST was used.  
 
The Mtb UgpB protein was labelled with RED-Tris-NTA dye that binds to the C-terminal 
hexa-His tag. Full details of the method are described (Chapter 2, 2.5.12). Mtb UgpB 
was used at a final concentration of 50 nM in the assay and binding to compounds in 
the concentration range (0-0.5 M) was measured using the MonoLith NT.115 
instrument with medium laser power and 40 % LED power settings. The binding 
affinities were calculated and the Kd model was fitted in the built-in MST analysis 
software. The calculated Kd model was plotted in GraphPad Prism V8. All experiments 
were calculated in triplicate.  
 
Initial binding of Mtb UgpB to GPC was tested and a high binding affinity of 3.6 µM ± 
0.5 µM was determined (Figure 4.19) (Table 4.1). This result was comparable with a 
previous study that showed GPC had a binding affinity of 27.3 µM by ITC (Jiang et al., 
2014). However, as expected based on the thermal shift assay (4.3.5) and the 
structure of GPC bound Mtb UgpB determined later (Chapter 5, 5.3.6), binding to G3P 




Figure 4.19: Microscale thermophoresis Mtb UgpB and glycerol-3-phosphocholine. 
FNorm (%) is the normalised fluorescence signal of the change in MST signal. Error bars 
represent SD from at least three independent experiments. 
 
4.3.13 Binding affinity analysis of Mtb UgpB mutant derivatives by microscale 
thermophoresis 
Residues identified from the X-ray structure of the GPC bound Mtb UgpB binding site 
(Chapter 5, 5.3.6) were each mutated to alanine and the site-directed mutants of Mtb 
UgpB were successfully purified (Chapter 3, 3.3.9). MST was used to test the mutant 
derivatives of Mtb UgpB ability to bind to GPC. All of the mutants were prepared for 
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MST analyses as described previously (4.3.13) and (Chapter 2, 2.5.12). MST analysis 
indicated that six of the mutants tested (Table 4.1) did not bind to GPC. Two of the 
mutants, Ser153Ala and Leu205Ala had a lower binding affinity compared to apo-Mtb 
Leu205Ala was found to have a binding affinity of 161.7 µM and Ser153Ala was found 
to have a binding affinity of 309.8 µM, approximately 45-fold and 85-fold lower 
compared to apo-Mtb UgpB (Table 4.1). 
 
Table 4.1: Summary of Mtb UgpB MST binding affinity data. 
Protein Substrate Kd (µM) 
Mtb UgpB GPC 3.6 ± 0.5 
Mtb UgpB GPC* 27.3 
Mtb UgpB Y78A GPC - 
Mtb UgpB D102A GPC - 
Mtb UgpB S153A GPC 309.8 ± 56.1 
Mtb UgpB L205A GPC 161.7 ± 15.9 
Mtb UgpB W208A GPC - 
Mtb UgpB S272A GPC - 
Mtb UgpB Y345A GPC - 
Mtb UgpB R385A GPC - 
(-) = no binding detected, ± SD from three independent experiments. GPC: glycerol-3-
phosphocholine. GPC* is the binding affinity determined by ITC (Jiang et al., 2014). 
 
4.3.14 Binding of alternative glycerophosphodiesters to Mtb UgpB  
The GPC bound X-ray structure of Mtb UgpB (Chapter 5, 5.3.6) did not indicate any 
Mtb UgpB binding site interactions with the choline head-group of GPC. However it 
was possible that previously untested and physiologically relevant 
glycerophosphodiesters could also bind to Mtb UgpB. Two of these 
glycerophosphodiesters were commercially available: glycerophosphoinositol-4-
phosphate (GPI(4)P) and glycerophosphoinositol (GPI) however 
glycerophosphoethanolamine (GPE) and glycerophosphoserine (GPS) were not 
commercially available and had to be produced. To do this the following synthetic 
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4.4 Glycerophosphodiester synthesis 
4.4.1 Glycerophosphodiester synthetic route 
4.4.1.1 Glycerophosphodiester synthetic route 
A synthetic route was attempted to produce the glycerophosphodiesters: 
glycerophosphoethanolamine (1) (GPE) and glycerophosphoserine (2) (GPS). This 
was based on two previous studies (R.-R. Tang et al., 2005) (Gagnon et al., 2017) that 
successfully synthesised glycerophosphodiesters from the respective building blocks 
(3), (4) and (5) (Figure 4.20). Retrosynthetic analysis (Figure 4.20) indicates that the 
products (1) and (2) are split into three components: a glycerol group (3), phosphate 




Figure 4.20: Retrosynthetic analysis for the production of glycerophosphoethanolamine 
(GPE) and glycerophosphoserine (GPS). 
 
The precursors (Scheme 4.1) (7) and (9) or (10) could react via their un-protected 
hydroxyl groups with the phosphate group of precursor (8). As the other hydroxyl 
groups of (7) and (9) or (10) were protected the reaction could be directed to produce 
the protected glycerophosphodiesters (11) or (12). Therefore it was necessary to use 
protected versions of (3), (4) and (5). The protected reagents included: (S)-
isopropylideneglycerol (7), the glycerol precursor containing an acetonide protective 
group so that only a single hydroxyl was reactive. Phenyldichlorophosphate (8), the 
phosphate precursor containing a protective phenyl group and two reactive chloride 
atoms. N-Boc-ethanolamine (9) or N-Boc-L-serine methyl ester (10) are the 
ethanolamine and L-serine precursors containing an N-Boc protective group and 
reactive hydroxyl group. The reaction of (7) and (8) with (9) or (10) would produce the 
intermediates: protected glycerophosphoethanolamine (11) or protected 
glycerophosphoserine (12). Once this protected product was purified, removal of the 
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acetonide group with an acid such as TFA would produce the products 
glycerophosphoethanolamine (GPE) (1) and glycerophosphoserine (GPS) (2). The 




Scheme 4.1: Proposed overall reaction scheme for the synthesis of 
glycerophosphoethanolamine (GPE) and glycerophosphoserine (GPS). The different 
strategies attempted are described (Table 4.2). Red indicates the protecting groups. (i) refers to 
protected glycerophosphodiester synthesis. (ii) refers to deprotection of the protected 
glycerophosphodiester to produce the product. 
 
 
4.4.1.2 Glycerophosphodiester synthesis strategies 
The first step was to produce the protected glycerophosphodiesters (11) and (12) as 
detailed in the overall scheme (Scheme 4.1). Three different strategies were attempted 
to produce the protected glycerophosphodiesters (11) and (12) and these are detailed 
(Table 4.2). The strategies differed based on the order of reagent addition and the type 
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Table 4.2: Glycerophosphodiester synthesis strategies. 
Strategy First addition Second addition Base 









N-Boc-L-serine methyl  
ester  
(1.0 eq) 
Solvent: Chloroform  
(5 mL) 
Pyridine  



















Solvent: Chloroform  
(5 mL) 
Triethylamine  












N-Boc-L-serine methyl ester 
(1.0 eq) 




Solvent: Toluene  
(5 mL) 
Triethylamine 








4.4.1.3 Strategy 1 synthesis 
The reagents and scheme for this strategy are described (Table 4.2) (Scheme 4.2). In 
order to attempt to synthesise the protected intermediate products (11) and (12), we 
reacted (7) with (8) followed by the addition of either (9) or (10) (Scheme 4.2) (Table 
4.2). The reactions were carried out under N2 and with stirring. During the first reagent 
addition: (7) reacted with (8), we found it was essential to keep the temperature at -20 
°C to avoid the protected glycerol (7) reacting twice with the protected phosphate (8). 
The reagents were allowed to reach room temperature over 6 hours. For the second 
reagent addition: (9) or (10) were added and the reagents were allowed to react at 
room temperature overnight.  
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Scheme 4.2: Strategy 1 and 2 scheme for the synthesis of glycerophosphoethanolamine 
(GPE) and glycerophosphoserine (GPS) using either pyridine or triethylamine base. (7) 
was reacted with (8) first, followed by reacting with (9) or (10).  
 
The reaction mixture was worked up by washes with: 50 mL ethyl acetate, 70 mL 10 % 
HCl, 70 mL H2O, 70 mL NaHCO3 and 70 mL brine. The organic phase was collected, 
dried by addition of anhydrous MgSO4 and vacuum filtered. The crude product in the 
organic phase was analysed by NMR and mass spectrometry.  
 
In strategy 1 (Table 4.2), pyridine was used as the base. Strategy 1 did not produce 
much product, as by NMR the starting materials were not completely used therefore we 
decided to repeat the reaction in strategy 2 (Table 4.2) (Scheme 4.2) using 
triethylamine as the base instead of pyridine because triethylamine is a stronger base. 
Note that strategy 1 and 2 are identical except a different base is used. 
 
4.4.1.4 Strategy 2 synthesis 
The reaction was repeated as in (4.4.1.3) hence the scheme is identical (Scheme 4.2) 
however the base was changed from pyridine to triethylamine, which is a stronger 
base. Strategy 2 (Scheme 4.2) (Table 4.2) resulted in production of a mixture of the 
protected products GPE 454 m/z (11) and GPS 512 m/z  (12), the 2x glycerol reacted 
by-product 424 m/z (13) and the 2x ethanolamine reacted by-product 483 m/z (14) as 
determined by mass spectrometry (Figure 4.21). The starting materials were 
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completely used as determined by mass spectrometry and NMR, however the ratio of 
the desired products (11) and (12) to by-products (13) and (14) wasn’t particularly high 
therefore we decided change the order of reagent addition in strategy 3 (Table 4.2) 
(Scheme 4.3). 
 
Figure 4.21: Products and by-products identified by mass spectrometry. A) 
Glycerophosphoethanolamine synthesis. B) Glycerophosphoserine synthesis. 
 
4.4.1.5 Strategy 3 synthesis 
In strategy 3 (Scheme 4.3) (Table 4.2) we changed the order of reagent addition and 
reacted (9) or (10) with (8) followed by the addition of (7) using triethylamine as the 
base and the same procedures as previously described (Table 4.2) (Scheme 4.3). The 
crude products were analysed by NMR and mass spectrometry and revealed a better 
ratio of the desired products (11) and (12) compared to by-products (13) and (14) 
therefore we decided to use strategy 3 moving forwards.  
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Scheme 4.3: Strategy 3 scheme for the synthesis of glycerophosphoethanolamine (GPE) 
and glycerophosphoserine (GPS) using triethylamine base and changing the order of 
reagent addition. (9) or (10) was reacted with (8) first, followed by reacting with (7). The base 
used throughout was triethylamine. 
 
To conclude, in strategy 2 and 3 (Table 4.2), there was complete conversion of starting 
materials (7), (8) and (9) or (10) to the products (11) and (12) and by-products (13) and 
(14). Based on the crude NMR and mass spectrometry we concluded that strategy 3 
was optimal therefore the next step was to separate the crude protected product (11) 
and (12) from the by-products (13) and (14) (Scheme 4.3). 
 
Column chromatography was used to separate the protected glycerophosphodiesters 
(11) and (12) from the by-products (13) and (14). We used the solvent 2:1 
(hexane/ethyl acetate v/v) and found that the protected GPS (12) did not separate well 
on the column despite trying several different polarities of solvent systems. This was 
potentially because the polarities of the GPS product (12) and the by-product (13) were 
more similar in the case for GPS therefore we were unable to separate them and did 
not do any further experiments for GPS. In contrast, GPE (11) separated better 
however NMR and mass spectrometry of GPE (11) after column chromatography 
indicated that there were still some by-products (13) and (14) present. The fractions 
containing the highest abundance of protected GPE (11) product were combined and 
we proceeded to remove the protecting groups (4.4.1.6). 
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4.4.1.6 Deprotection of glycerophosphoethanolamine (GPE) 
The overall deprotection scheme starting with the mixture of protected GPE product 
(11) and by-products (13) and (14) are described (Scheme 4.4). The aim of 
deprotection was to remove the acetonide group, phenyl group and N-Boc group to 
result in the correct GPE product (1) and a small amount of de-protected by-products 
(15) and (16). 
 
 
Scheme 4.4: Overall scheme for the deprotection of glycerophosphoethanolamine 
including by-products. 
 
To deprotect the phenyl group of protected GPE (11) we first used the base NaOH 
(Scheme 4.5). We found it required the addition of 2.2 eq NaOH in tetrahydrofuran 
solvent with overnight incubation at room temperature to completely remove the phenyl 
group (17). This was analysed using mass spectrometry (Figure 4.22) by the presence 
of phenyl removed GPE 354 m/z (17) and also some of the phenyl removed 2x 
ethanolamine by-product 383 m/z (18).  
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Scheme 4.5: Removal of the phenyl group. (i) Addition of 2.2 eq NaOH in tetrahydrofuran 
incubated overnight at room temperature produced the phenyl-removed product (17) and phenyl 





Figure 4.22: Mass spectrometry confirms removal of the phenyl group. Produced the 
phenyl-removed product (17) 354 m/z and phenyl removed 2x ethanolamine by-product (18) 
383 m/z. 
 
Next, removal of the acetonide and N-Boc groups from (17) required addition of acid 
(Scheme 4.6). We first added 5.0 eq TFA in tetrahydrofuran solvent however after 
overnight incubation at room temperature and mass spectrometry analysis (Figure 
4.23) it revealed two major peaks at 314 m/z (19) and (383 m/z) (18) suggesting the 
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phenyl and acetonide groups were successfully removed however the N-Boc group 




Scheme 4.6: Removal of the acetonide group. (i) addition of 5.0 eq TFA in tetrahydrofuran 




Figure 4.23: Mass spectrometry confirms removal of the acetonide group. Produced the 
acetonide-removed product (19) 314 m/z and also some of the phenyl removed 2x 
ethanolamine by-product (18) 383 m/z. 
 
We finally found that addition of 6.0 eq NaOH in tetrahydrofuran solvent to compound 
(11) and overnight incubation at room temperature, followed by the addition of 10.0 eq 
TFA in dichloromethane and overnight incubation at room temperature successfully 
removed all of the protecting groups including N-Boc to produce the GPE product (1) 
(Scheme 4.7). However now as the protecting groups were removed the product (1) 
and by-products (15) and (16) (Figure 4.24) did not fly well in the mass spectrometer 
and therefore could not be detected by mass spectrometry.  
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Scheme 4.7: Removal of the N-Boc group. (i) addition of 10.0 eq TFA in dichloromethane 






Figure 4.24: Structures of deprotected glycerophosphoethanolamine product (1) and by-
products (15) and (16). 
 
After successfully removing the protective groups, the product (1) and by-products (15) 
and (16) were now soluble in H2O, which enabled the organic soluble products to be 
removed by extraction. This resulted in a mixture of products (1), by-products (15) and 
(16) and TFA inorganic salts. To remove the TFA inorganic salts an amberlite IR120 
cation exchange resin was prepared. The deprotected products were loaded onto the 
column and eluted with dH2O however only a small amount of product (1) and by-
products (15) and (16) eluted. We thought the product (1) and by-products (15) and 
(16) were binding to the column due to the addition of acid during the deprotection 
conditions that may have protonated the NH2 of ethanolamine to NH3+. Ammonia water 
was added to deprotonate the product (1) and by-product (16) however they could not 
be successfully eluted. 
 
Instead we found that dissolving the deprotected products in a minimal amount of 
acetone successfully removed the TFA inorganic salts.  Subsequent NMR analysis 
indicated that the acetone soluble products included the correct GPE product (1) 
however it also contained several contaminants most likely carried over due to the 
inability to completely separate the protected GPE (11) from by-products (13) and (14). 
 
To conclude we found that protected synthesis of glycerophosphodiesters from the 
individual building blocks was not very successful. We found we were losing product 
during removal of the inorganic impurities and we still had a mixture of by-products. 
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Therefore we decided to use a different method, starting with phospholipids and using 
either chemical or enzymatic methods to hydrolyse the lipid tails in order to produce the 
glycerophosphodiesters. After removal of the lipid tails, the lipids tails would be soluble 
in organic chloroform solvent whereas the head-group would be soluble in H2O. 
 
4.4.2 Base hydrolysis of phosphatidyl-L-serine 
We attempted a chemical method based on the following studies that used the base 
NaOH to hydrolyse the fatty acid tails from phospholipids (Figure 4.25) (Kopp et al., 
2010) (Nishihara et al., 1988). We started with a commercially available phospholipid, 





Figure 4.25: Base hydrolysis of phosphatidyl-L-serine (20) to produce 
glycerophosphoserine (1). (i) Addition of 2 M NaOH in 2:1 (chloroform/methanol v/v). 
 
We dissolved 100 mg of phosphatidyl-L-serine (20) in 2:1 (chloroform/methanol v/v). 2 
M NaOH was added and incubated for 2 hours at room temperature to hydrolyse the 
fatty acid tails. The reaction was neutralized by the addition of 2 M HCl and an organic 
aqueous extraction using chloroform and dH2O was used to separate the fatty acid tails 
from the head-group. The aqueous fraction of the reaction was analysed by TLC in 
5:4:2:1 (butan-1-ol/methanol/ammonia/dH2O v/v/v/v) solvent. The TLC plates were 
stained with ninhydrin to detect the amine group of glycerophosphoserine (2) and also 
stained with sulphuric acid to compare any differences in staining. TLC analysis 
indicated at least two ninhydrin and sulphuric acid stained spots that may correspond 
to the glycerophosphoserine (2) and phosphoserine (22) products (Figure 4.26) 
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Figure 4.26: TLC analysis of the aqueous fraction of phosphatidyl-L-serine base 
hydrolysis products following aqueous/organic extraction. A) 10 % sulphuric acid in 
ethanol stain. B) Ninhydrin stain. 
 
We submitted the aqueous fraction for high-resolution mass spectrometry analysis and 
the analysis indicated the correct glycerophoserine product (2) size (M-1 258.0384 
m/z) (Figure 4.27) however glycerol-3-phosphate (21) (M-1 171.00061 m/z and 2M-1 






Figure 4.27: Analysis of base hydrolysis products of phosphatidyl-L-serine by high-
resolution mass spectrometry. Glycerophoserine (GPS) (2) was identified (M-1 258.0384 
m/z) 
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Figure 4.28: Analysis of base hydrolysis products of phosphatidyl-L-serine by high-
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Hydrolysis of the phosphodiester bond using the base NaOH likely resulted in the 
formation of by-products (21) and (22) (Figure 4.29) therefore instead we decided to 
attempt a more specific enzymatic method. 
 
 
Figure 4.29: By-products produced from base hydrolysis of phosphatidyl-L-serine (20). 
Glycerophoserine (GPS) (2) was identified (M-1 258.0384 m/z) however also glycerol-3-
phosphate (G3P (21) was identified (M-1 171.00061 m/z and 2M-1 343.0202 m/z). 
Phosphoserine (22) may have been produced however could not be detected. 
 
4.4.3 Enzymatic production of glycerophosphodiesters 
As all the previous routes did not result in the correct products we resorted to using an 
enzymatic method based on a previous study (Bang et al., 2016). The enzyme used 
was phospholipase A1 from Aspergillius oryzae that specifically cleaves the fatty acid 
tail at the sn-1 position of phospholipids (Chapter 1, 1.1.23). This leaves the fatty acid 
tail at position sn-2 intact. However in the previous study (Bang et al., 2016) it was 
found that if the phospholipid and enzyme mixture was incubated at 50 °C the fatty acid 
tail at position sn-2 migrates to sn-1 thereby enabling both fatty acid tails to be cleaved 
using the same enzyme (Bang et al., 2016). The enzymatic reaction is described 
(Figure 4.30). Similar to the base hydrolysis method the fatty acid tails are soluble in 
chloroform whereas the glycerophosphodiester product is soluble in H2O therefore no 
further purification steps would be required.  
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Figure 4.30: Phospholipase A1 hydrolysis of 1,2-Dipalmitoyl-sn-glycero-3-
phosphoethanolamine (20) and 1,2-Diacyl-sn-glycero-3-phospho-L-serine (23). R refers to 
the fatty acid tail at position sn-1 or sn-2 and X refers to the lipid head-group. X refers to the 
head-group. At 50 °C the fatty acid tail at position sn-2 (24) and (25) migrates to sn-1 (26) and 
(27). 
 
The following commercially available phospholipids were digested: 1,2-Dipalmitoyl-sn-
glycero-3-phosphoethanolamine (20) (50 mg) and 1,2-Diacyl-sn-glycero-3-phospho-L-
serine (23) (25 mg) (Figure 4.30). We also digested 2,3-Dipalmitoyl-sn-glycero-1-
phosphocholine (28) (12.5 mg) to produce the unnatural glycerophosphocholine 
enantiomer (Figure 4.31). 
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Figure 4.31: Phospholipase A1 hydrolysis of, 3-Dipalmitoyl-sn-glycero-1-phosphocholine 
(28). R refers to the fatty acid tail at position sn-1 or sn-2 and X refers to the lipid head-group. At 
50 °C the fatty acid tail at position sn-2 (29) migrates to sn-1 (30). 
 
The phospholipids were dissolved in organic-aqueous media (800 µL hexane, 138 µL 
H2O: 5.8:1 ratio) and heated at 50 °C for 10 minutes prior to the addition of 
Phospholipase A1 from Aspergillus oryzae (1 µL Phospholipase A1 per 1 mg of 
phospholipid). The reaction mixtures were heated at 50°C and stirred at 300 rpm for 48 
hours. Following incubation the solvent was removed in vacuo, the reaction mixtures 
were dissolved in water (5 mL) and the reaction mixtures were extracted with 
chloroform (3 x 25 mL) to remove the chloroform soluble fatty acid tails from the H2O 
soluble glycerophosphodiesters. The aqueous fractions containing the 
glycerophosphodiesters and phospholipase A1 enzyme were passed over a centrifugal 
filter unit (Amicon, 10 kDa molecular weight cut off) to remove phospholipase A1. The 
products were concentrated and yielded a colourless oil: 9.4 mg 
glycerophosphoethanolamine (1), yellow oil: 3 mg glycerophosphoserine (2) and a 
colourless oil 1.5 mg glycerophosphocholine enantiomer (31). The products were 
characterised by proton, carbon and phosphate NMR (Appendix 4.7) (Chapter 2, 
2.7.5). By NMR glycerophosphoethanolamine (1) was 90 % pure, 
glycerophosphoserine (2) was 80 % pure and the glycerophosphocholine enantiomer 
(31) was 33 % pure. The only impurities appeared to be glycerol. 
 
Now that we had all of the ligands we were ready to test binding of the enzymatically 
produced alternative glycerophosphodiesters to Mtb UgpB by MST (4.5). 
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4.5 Alternative glycerophosphodiester binding 
4.5.1 Binding affinity analysis of Mtb UgpB with alternative 




Figure 4.32: Structures of the alternative glycerophosphodiesters tested for binding to 
Mtb UgpB by microscale thermophoresis. Glycerophosphoserine (GPS), 
glycerophosphoethanolamine (GPE) and the glycerophosphocholine enantiomer were 
enzymatically produced. Glycerol-3-phosphocholine (GPC), glycerophosphoinositol-4-
phosphate (GPI(4)P) and glycerophosphoinositol (GPI) were commercially available. 
 
The glycerophosphodiester compounds that were produced enzymatically were tested 
for the ability to bind to Mtb UgpB by MST (Figure 4.32): GPE (90 % pure), GPS (80 % 
pure) and GPC enantiomer (33 % pure). Mtb UgpB was prepared for MST analyses as 
described previously (4.3.12) (Chapter 2, 2.5.12). Both of the alternative 
glycerophosphodiesters were found to bind and the highest affinity was for GPS with a 
Kd of 14.9 µM (Figure 4.33A) (Table 4.3) and a slightly lower binding affinity for GPE 
with a Kd of 74.7 µM (Figure 4.33B) (Table 4.3). Binding of Mtb UgpB to the 
commercially available glycerophosphodiesters: GPI(4)P and GPI was also 
investigated by MST. These compounds were selected because the lipid strips 
indicated that Mtb UgpB binds to PtdIns(4)P (4.3.8). GPI(4)P had a Kd of 289.8 µM 
(Figure 4.33C) (Table 4.3) and was slightly higher compared to the binding affinity of 
GPI with a Kd of 1053.2 µM (Figure 4.33D) (Table 4.3). Together these results 
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highest binding affinities were for GPS and GPE. The result of Mtb UgpB binding to 
GPI(4)P with a higher affinity compared to GPI also indicated that the larger 
phosphorylated inositol head-group was preferred.   
 
 
Figure 4.33: Microscale thermophoresis of Mtb UgpB and alternative 
glycerophosphodiesters. FNorm (%) is the normalised fluorescence signal of the change in 
MST signal. Error bars represent standard deviations from at least three independent 
experiments. A) Glycerophosphoserine (GPS). B) Glycerophosphoethanolamine (GPE). C) 
Glycerophosphoinositol-4-phosphate (GPI(4)P). D) Glycerophosphoinositol (GPI). 
 
 
We also wanted to investigate the importance of the stereo-configuration of the glycerol 
group of GPC by testing the unnatural enantiomer of GPC. As based on the structure 
of GPC bound Mtb UgpB (Chapter 5, 5.3.6), the 2-hydroxyl of the glycerol group 
interacts with Asp102 in the binding pocket. Therefore if the orientation of the 2-
hydroxyl of the glycerol group is altered it may exhibit an altered binding affinity. The 
structures of the unnatural enantiomer of GPC and natural GPC are shown (Figure 
4.34).  
 







































































































 Chapter 4: Characterisation of Mycobacterium tuberculosis UgpB   
 
	   147 
 
 
Figure 4.34: Structure of the unnatural glycerophosphocholine (left) enantiomer 
compared to GPC (right). 
 
 
The GPC enantiomer was found to bind to Mtb UgpB by MST with a Kd of 1.1 mM 
(Figure 4.35), approximately 300-fold lower compared to the standard GPC Kd of 3.6 
µM.  This result is likely to reflect the importance of the orientation of the 2- hydroxyl of 
the GPC glycerol group for binding to Asp102 in the Mtb UgpB binding pocket. This is 
further supported because when Asp102 is mutated to Ala, binding to the standard 
GPC is also abolished (4.3.13). 
 
 
Figure 4.35: Microscale thermophoresis Mtb UgpB and glycerophosphocholine 
enantiomer. FNorm (%) is the normalised fluorescence signal of the change in MST signal. 
Error bars represent standard deviations from at least three independent experiments. 
 
A summary of the Mtb UgpB MST binding affinity results is shown (Table 4.3). Overall 
GPC had the highest affinity with a Kd of 3.6 µM. This was closely followed by GPS that 
had a Kd of 14.9 µM and suggests that the serine head-group is well tolerated. GPE 
had a slightly weaker binding affinity with a Kd of 74.7 µM, approximately 20-fold lower 
compared to GPC. This is potentially because the ethanolamine head-group is smaller 
and Mtb UgpB appears to have a preference for larger head-groups. GPI(4)P also 
bound with a Kd of 289.8 µM, approximately 80-fold lower compared to GPC. GPI(4)P 
binding is also supported by STD-NMR data (Chapter 5, 5.3.13) that interestingly 
revealed that regions of the inositol phosphate head-group are involved in binding 
recognition. In comparison, GPI, which is smaller and lacks a phosphorylated inositol 
group had a weaker affinity with a Kd of 1053.2 µM, approximately 290-fold lower 
compared to GPC. However the weakest affinity was for the GPC enantiomer with a Kd 
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glycerol group. Of the mutants tested, Tyr78Ala and Asp102Ala did not bind to either 
GPS or GPE and this result was identical to the result found previously (4.3.13) for 
GPC, and clearly suggests that Tyr78 and Asp102 are important for 
glycerophosphodiester binding recognition. However, Ser153Ala was found to bind to 
GPS with a Kd of 102.5 µM approximately 7-fold lower compared to apo-Mtb UgpB. 
Ser153Ala also had a weaker affinity for GPC with a Kd of 309.8 µM (4.3.13), yet 
surprisingly Ser153Ala did not bind to GPE. This was potentially due to the smaller 
ethanolamine head-group.  
 
Table 4.3: Summary of all Mtb UgpB MST binding affinity data. 
Protein Substrate Kd (µM) 
Mtb UgpB GPC 3.6 ± 0.5 
Mtb UgpB GPC* 5.2 ± 1.6 
Mtb UgpB GPC enantiomer 1080 ± 188.3 
Mtb UgpB GPS 14.9 ± 1.6 
Mtb UgpB GPE 74.7 ± 13.9 
Mtb UgpB GPI(4)P 289.8 ± 54.1 
Mtb UgpB GPI 1053.2 ± 313.4  
Mtb UgpB Y78A GPS - 
Mtb UgpB Y78A GPE - 
Mtb UgpB D102A GPS - 
Mtb UgpB D102A GPE - 
Mtb UgpB S153A GPS 102.5 ± 16.4 
Mtb UgpB S153A GPE - 
 
(-) = no binding detected, ± SD from three independent experiments. GPC: glycerol-3-
phosphocholine, GPS: glycerophosphoserine, GPE: glycerophosphoethanolamine, GPI(4)P: 
glycerolphosphoinositol-4-phosphate, GPI: glycerophosphoinositol. * refers to the GPC 
competition experiment. 
 
In conclusion, Mtb UgpB has demonstrated broad substrate selectivity and was found 
to be promiscuous for binding to a wide range of glycerophosphodiester substrates.  
 
4.5.2 Microscale thermophoresis competition experiment 
To investigate if the presence of G3P altered GPC binding a competition experiment 
was carried out (Figure 4.36). As it wasn’t clear why GPC bound to Mtb UgpB however 
G3P did not bind to Mtb UgpB. Even though both compounds have a glycerol and 
phosphate moiety and glycerol is the main recognition element. In this experiment 100 
µM of G3P was included in each assay and the concentration of GPC was varied from 
0.1-11 µM. The binding affinity for GPC in the presence of G3P was 5.2 µM (Figure 
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4.36) (Table 4.3) and was comparable to GPC only of 3.6 µM (4.3.12). This result 
further suggested that GPC binds preferentially to Mtb UgpB as the presence of G3P 
did not alter the binding affinity to GPC. This experiment also supports previous 
thermal shift assay data (4.3.4) that indicated GPC binds however G3P does not bind 
to Mtb UgpB. 
 
 
Figure 4.36: Microscale thermophoresis Mtb UgpB and 100 µM glycerol-3-phosphate and 
glycerophosphocholine. FNorm (%) is the normalised fluorescence signal of the change in 
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4.6 Discussion 
A thermal shift assay testing a panel of carbohydrates, amino acids, 
glycerophosphodiester variations and antibiotics found GPC to have the highest 
thermal shift (+7.3 °C) (4.3.4) Binding to GPC was determined by MST to have a Kd of 
3.6 µM (4.3.12) and was comparable to other substrate binding proteins of the ATP-
binding cassette family (Berntsson et al., 2010). The MST result was also similar to a 
previous study that measured binding of Mtb UgpB to GPC by isothermal calorimetry 
(ITC) and found GPC to have a Kd of 27.3 µM (Jiang et al., 2014). By MST, binding to 
G3P or phosphocholine could also not be detected and is in good agreement with the 
previous study (Jiang et al., 2014). Together, our MST data suggested that the 
combined glycerol, phosphate and choline moieties were required for binding 
recognition.  
 
The GPC bound Mtb UgpB X-ray crystal structure was later determined (Chapter 5, 
5.3.6) and revealed 8 binding site residues that interacted with GPC. Based on our 
structure, the 8 binding site residues of Mtb UgpB were individually mutated to alanine 
by site directed mutagenesis and mutant derivatives of Mtb UgpB were successfully 
purified (Chapter 3, 3.3.10). MST analysis found that all of the mutant derivatives of 
Mtb UgpB either did not bind to GPC or had a lower binding affinity compared to apo-
Mtb UgpB. Leu205Ala and Ser153Ala had reduced binding affinities with a Kd of 161.7 
µM and a Kd of 309.8 µM respectively (4.3.13). This result contrasted with the previous 
study (Jiang et al., 2014) that did not identify binding of Leu205Ala to GPC. 
 
Interestingly, based on the GPC bound Mtb UgpB structure (Chapter 5, 5.3.6), the 
choline head-group of GPC did not appear to interact with Mtb UgpB. We therefore 
hypothesised that alternative glycerophosphodiester head-groups could also bind. 
Glycerophosphodiesters could potentially be derived from phospholipids of the 
macrophage membrane or lung surfactant (Sahu et al., 1977) (Fessler et al., 2016). 
We initially investigated binding to lipid strips containing phospholipids with different 
head-groups. The results of the lipid strips found that Mtb UgpB had a preference for 
phosphoinositides, phosphatidylserine (4.3.7) and sulfatide (4.3.9). However, 
surprisingly binding to phosphatidylcholine or phosphatidylinositol was not found. In 
hindsight the lipid strips may have not been the best assay to use because the fatty 
acid tail was ester bonded to the glycerol group and therefore blocked access to the 
glycerol moiety. 
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Instead, we decided to directly investigate the interactions of alternative 
glycerophosphodiesters to Mtb UgpB. Therefore we tested GPI, GPI(4)P, GPE and 
GPS. We tested GPI because GPI is the head-group of phosphatidylinositol and 
phosphatidylinositol mannosides (PIMs), which are found in abundance in the 
Mycobacteria inner membrane (Bansal-Mutalik et al., 2014). We also tested GPE 
because phosphatidylethanolamine is also found in the Mycobacteria inner membrane 
(Bansal-Mutalik et al., 2014). All of the lipids of which these head-groups are derived 
are also found in macrophage membranes (Sahu et al., 1977) and therefore could be 
produced by the activities of Mtb or host derived phospholipase A1 and A2 enzymes 
(Brust et al., 2011) (Schue et al., 2010) (B. E. Schneider et al., 2014).  
 
GPI and GPI(4)P were commercially available however we had to produce GPS and 
GPE. To produce GPS and GPE we decided to use a synthetic route based on 
previous studies (R.-R. Tang et al., 2005) (Gagnon et al., 2017). In order to direct the 
reaction to produce the glycerophosphodiesters we had to use protected reagents:  
(S)-isopropylideneglycerol, phenyldichlorophosphate, N-Boc-ethanolamine and N-Boc-
L-serine methyl ester. We optimised the reaction by altering the base and the order of 
reagent additions however in all cases we produced several by-products that could not 
be effectively separated by column chromatography. Therefore we decided instead to 
start with the intact phospholipid and use a chemical or enzymatic method to cleave 
the fatty acid tails leaving the glycerophosphodiester intact. The base hydrolysis 
method (Kopp et al., 2010) produced the correct glycerophosphodiester products 
however it also produced several by-products therefore we decided to use a more 
specific enzymatic route (Bang et al., 2016). The glycerophosphodiesters, GPS and 
GPE were successfully produced enzymatically and we also produced the unnatural 
enantiomer of GPC by enzymatically digesting 2,3-Dipalmitoyl-sn-glycero-1-
phosphocholine.  
 
The alternative glycerophosphodiesters were also found to bind by MST (4.5.1). GPS 
was found to bind with a Kd of 14.9 µM, similar to GPC and GPE was found to bind with 
a Kd of 74.7 µM approximately 5-fold lower compared to GPC. The GPC enantiomer 
indicated a considerably lower binding affinity compared to the standard GPC, with a 
Kd of 1.08 mM and suggested that the stereo-configuration of the 2-hydroxyl of the 
glycerol moiety was important for binding recognition. GPI(4)P bound with a Kd of 289.8 
µM, approximately 80-fold less compared to GPC and GPI bound with a Kd of 1053 
µM. These results clearly suggested that Mtb UgpB is able to bind and recognise a 
broad range of glycerophosphodiester substrates containing different head-groups. 
The order of binding preference is: GPC>GPS>GPE>GPI(4)P>GPI>GPC enantiomer. 
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Interestingly by metabolic profiling, GPC is increased in Mtb infected guinea pig 
granuloma (Somashekar et al., 2011) therefore this places the Mtb bacilli in close 
proximity to a potential nutrient source and substrate of Mtb UgpB. However we have 
also found that Mtb UgpB may also be adapted to bind and recognise alternative 
glycerophosphodiesters that are potentially derived from macrophage membranes in 
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4.7 Appendix 
 
Figure 4.37: GPS 1H NMR. (400MHz, D2O) δppm 4.17 – 4.26 (2H, m, POCH2CHN), 4.01 – 4.08 




































 Chapter 4: Characterisation of Mycobacterium tuberculosis UgpB   
 
	   154 
 
Figure 4.38: GPS 13C NMR. (100MHz, D2O) δppm 178.5 (C=O), 70.6 (CH2CH(OH)CH2), 66.5 
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Figure 4.40: GPE: 1H NMR. (400MHz, D2O) δppm 3.99 – 4.08 (2H, m, POCH2CH2N), 3.75- 3.91 
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Figure 4.41: GPE 13C NMR. (100MHz, D2O) δppm 70.7 (CH), 66.5 (OCH2), 62.0 (OCH2), 61.8 
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Figure 4.43: GPC enantiomer: 1H NMR. (400MHz, D2O) δppm  4.18 – 4.29 (2H, m, 
POCH2CH2N), 3.74 – 3.90 (3H, m, POCH2CHCH2), 3.46 – 3.63 (4H, m, POCH2CHCH2 + 
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Figure 4.44: GPC enantiomer 13C NMR. (100MHz, D2O) δppm  70.6 (CH2CH(OH)CH2), 66.5 
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Structural determination of proteins is a powerful method to elucidate their functions. It 
reveals details about the secondary, tertiary and quaternary structures, information 
about how the protein folds, alters conformational state and can identify regions that 
interact with other macromolecules and small molecule ligands. To date, 2440 
Mycobacterium tuberculosis (Mtb) protein structures are available (RCSB, 2019) that 
have been solved by four different methods. X-ray diffraction is the most widely used 
method and is responsible for 2365 structures whereas cryo-electron microscopy, 
solid-state NMR and solution NMR, combined are responsible for only 75 
structures/partial structures. Investigating how small molecule ligands target, alter the 
activity or inhibit proteins is particularly useful because they are widely used as drugs 
and antibiotics to treat bacterial infections. Solving the structures of ligand bound 
targets is therefore a powerful method to identify new drug targets and investigate how 
to modify and improve existing small molecules. It also provides a functional insight to 
understand the underlying biochemistry. 
 
Various methods are available to study the structures of molecules. X-ray 
crystallography is capable of producing the highest atomic resolution structures 
however obtaining the crystals and solving the structures can be challenging. With the 
recent development of new algorithms and direct electron detectors, cryo-electron 
microscopy is now approaching the resolution levels of X-ray diffraction (Lyumkis, 
2019) however the highest resolution structures are still limited to complexes or large 
molecules ≥ 200 kDa. Solid-state NMR has been developed to determine the structure 
and conformational dynamics of membrane proteins within the native membrane 
environment (X. Zhao, 2012). For proteins that are difficult to crystallise, solution NMR 
methods are also available, however the size limit is approximately 30 kDa (Billeter et 
al., 2008). More recently, saturation transfer difference NMR (STD-NMR) has been 
developed to elucidate protein-glycan interactions (Blaum et al., 2018) and differential 
epitope mapping (DEEP) STD-NMR (Monaco et al., 2017) has been developed to 
reveal information about how protein amino acid residues interact with particular ligand 
moieties.  
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5.1.2 Structures of ABC transporter SBP’s 
Substrate binding proteins (SBP’s) of ATP-binding cassette transporters (ABC) vary in 
size from around 25-70 kDa (Quiocho et al., 1996). All are made of two globular α/β 
domains connected by flexible hinge regions that enable them to exist in at least four 
possible conformational states, open un-liganded, open liganded, closed un-liganded 
and closed liganded (C. Tang et al., 2007). SBP’s are able to bind to ligands via a 
flexible hinge resulting in a conformational closure of the two α/β domains around the 
ligand by a mechanism termed the Venus Fly-trap (Mao et al., 1982). SBP’s were 
previously classified as either class I, II or III due to sequence similarity and core β 
sheet topology in the two α/β domains (Fukami-Kobayashi et al., 1999). Generally in 
class I SBP’s there are 3 connecting strands whereas there are only 2 connecting 
strands in class II SBP’s.  Class III SBP’s are different as they instead have a single α-
helix linking the two-α/β domains. However based on the huge increase in available 
SBP structures they were reclassified based on structural alignment to six different 
clusters A-F (Figure 5.1) (Berntsson et al., 2010). Cluster A (class III) have a single α-
helix functioning as the hinge and they are part of ABC importers. Cluster B (class I) 
have three interconnecting strands between the two-α/β domains. Cluster C (class II) 
have an additional domain between the two-α/β domains. Cluster D (class II) have a 
very short hinge region consisting of two strands 4-5 amino acids long. Cluster E (class 
II) associate with TRAP or TT transporters that use electrochemical ion gradients for 
transport. Cluster F (class II) have a longer 8-10 amino acid hinge region containing 
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Figure 5.1: Structural classification of substrate binding proteins. Cluster A-F, the distinct 
structural feature is labelled orange. Clusters A–F were BtuF (PDB 1N2Z), RBP (PDB 1DRJ), 
OppA (PDB 3DRF), ModA (PDB 1ONR), UehA (PDB 3FXB) and HisJ (PDB 1HSL), respectively 
(Berntsson et al., 2010). The substrate-binding protein structures differ by the number of 
interconnecting segments, the length of the flexible hinges and the number of domains. 
 
To date, all SBP’s have a highly similar three-dimensional fold despite differences at 
the amino acid sequence level and this makes it very difficult to infer function based 
solely on sequence homology. The first SBP crystal structure to be solved was the L-
arabinose binding protein of E. coli (PDB ID 1ABE) (Quiocho et al., 1974) however now 
501 structures have been solved that range from different bacterial species and bind to 
a wide variety of ligands including carbohydrates, metals, vitamins, amino acids, 
peptides and alternative metabolites (Scheepers et al., 2016). 
 
5.1.3 Structures of Mtb ABC transporter SBP’s 
To date of the predicted 37 ABC transporters in the Mtb genome, including 16 
importers and 21 exporters (Braibant et al., 2000), only five Mtb SBP structures are 
available: UspC (Rv2318) (PDB ID 5K2X/5K2), GlnH (Rv0411c) bound to aspartate, 
asparagine and glutamate (PDB ID 6H1U, 6H20, 6H2T) and UgpB (Rv2833c) (PDB ID 
4MFI). Rv2318 encodes Mtb UspC the SBP of the Mtb UspABC transporter. The 
structure of Mtb UspC with no ligand bound was solved by X-ray diffraction to 1.5 Å 
resolution and it has the overall architecture characteristic of SBP’s with two-α/β 
domains (Fullam et al., 2016). Although the ligand bound structure could not be 
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determined a ligand-binding pocket between the two domains was identified to consist 
of the aromatic side chains of: Trp46, Tyr77, Phe81, Tyr103, Tyr292 and Phe402 that 
potentially form π-stacking interactions with carbohydrate ligands. High thermal shifts 
and STD-NMR signals were also identified for D-glucosamine-6-phosphate and 
chitobiose indicating that Mtb UspC had a preference for amino-sugars leading the 
authors to propose it may be involved in peptidoglycan cell wall fragment recycling 
(Fullam et al., 2016). 
 
The structure of Mtb GlnH in complex with the ligands aspartate, asparagine and 
glutamate was determined by X-ray crystallography to 1.4-1.7 Å resolution. All 
structures of Mtb GlnH revealed a similar binding mode to the different ligands 
(Bhattacharyya et al., 2018). The overall architecture of Mtb GlnH was similar to other 
SBP’s as the two-α/β domains enclosed the aspartate ligand in a Venus Fly-trap 
mechanism. The asparate ligand was buried in the centre and made contacts with the 
two lobes by interactions of Ser164, Arg169 and Asp250 with the amine and carboxyl 
groups of the aspartate ligand. Arg147, Trp232 and Thr162 interacted with the carboxyl 
side chain of the aspartate ligand by hydrogen bonding and Lys161 contacted the 
aspartate ligand via a single water molecule. Mtb GlnH was also co-crystallised with 
lower-affinity amino acids. Interestingly the authors proposed that Mtb GlnH senses 
amino acid concentrations in the periplasm in order to adjust cellular nutrient 
responses to availability (Bhattacharyya et al., 2018). 
 
The structure of Mtb UgpB was previously solved by X-ray crystallography to 1.5 Å 
resolution in the open ligand unbound conformation (Figure 5.2) (Jiang et al., 2014). As 
the ligand was not bound the molecular mechanisms of binding are still not known. As 
there are no structures available that have high homology to Mtb UgpB additional 
investigations are required to understand the molecular basis of ligand binding. From 
the previous study (Jiang et al., 2014) Mtb UgpB was identified to bind to glycerol-3-
phosphocholine (GPC) but not glycerol-3-phosphate (G3P) by isothermal calorimetry 
however the authors were not able to obtain co-crystals of Mtb UgpB bound to either 
GPC or G3P. In comparison, a structure of G3P bound E. coli UgpB was previously 
solved by X-ray crystallography to 1.8 Å resolution (Wuttge et al., 2012) and it revealed 
that G3P interacted with the residues Trp169 and Trp172 via the glycerol backbone. 
Further stabilisation is provided by hydrogen bonding between Arg374, Glu66 that 
interact with the 1-hydroxyl and 2-hydroxyl of the glycerol group and Ser247, Tyr42 and 
Tyr323 that hydrogen bond with the phosphate group. The structures of GPC 
compared to G3P (Figure 5.3) indicate that both compounds have a glycerol backbone 
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and phosphate group however GPC also has a 2 additional CH2 groups and a 
positively charged choline group which may be key determinants for binding to Mtb 
UgpB. We wanted to attempt to co-crystallise Mtb UgpB with GPC and the alternative 




Figure 5.2: The X-ray crystal structure of ligand unbound apo Mtb UgpB (PDB 4MFI) 
(Jiang et al., 2014). A) Cartoon representation identifying the secondary structure elements 
domain I (magenta), domain II (orange). B) Surface representation where the two domains are 







Figure 5.3: Structures of glycerol-3-phosphocholine (GPC) (left) and glycerol-3-
phosphate (G3P) (right). 
 
 
Figure 5.4: Structures of compounds to co-crystallise with Mtb UgpB. From left to right 
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5.2 Hypotheses and Aims 
I hypothesised that the Mtb UgpB substrate-binding protein could be co-crystallised 
with GPC and alternative glycerophosphodiesters and the structures could be solved 
by X-ray crystallography. I also hypothesised that an in-solution method using STD 
NMR may reveal additional insights into the specific ligand binding recognition mode 
that could not be found in the solid state. As these potential ligands have a glycerol tail 
and phosphate group I hypothesised that these groups were the main ligand 
recognition sites, however that the head-group may also have a role in determining the 
affinity of the binding site interaction.  
 
The specific aims of the work presented in this chapter were:  
• To determine the X-ray co-crystal structure of GPC bound to Mtb UgpB. 
• To determine the X-ray co-crystal structure of alternative 
glycerophosphodiesters bound to Mtb UgpB. 
• To investigate Mtb UgpB ligand interactions in the solution state by STD-NMR 
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5.3 Results 
5.3.1 Protein production 
Mtb UgpB protein was produced as described (Chapter 3, 3.3.5 and 3.3.7). The protein 
was concentrated by ultrafiltration (10 kDa cut-off, Amicon Ultra) to 7.4 mg/mL. It is 
usually preferred to remove the hexa-his tag prior to setting down crystal trials (Majorek 
et al., 2014) however in the UgpB-pYUB1062 construct there is no cleavage site 
between the C-terminus and the hexa-His tag therefore crystal trials were set with the 
hexa-His tag intact. 
 
5.3.2 Crystallisation studies of Mtb UgpB 
For co-crystallisation experiments Mtb UgpB (7.4 mg/mL) and 10-100 mM of GPC were 
first incubated at 4 °C for 30 minutes. Crystal trials were set by using the sitting-drop 
vapour diffusion method in 96-well plates and a Mosquito liquid handling system (TTP 
LabTech). The crystallisation screens JCSG-plus and Morpheus were used for initial 
screening with drop sizes varying from 0.3-0.45 µL. Ratiometric volumes of 1:1, 1:2 
and 2:1 volumes of protein with reservoir solution were mixed using the Mosquito liquid 
handling system. From these screening conditions, no crystals of Mtb UgpB formed. A 
previous study (Jiang et al., 2014) also attempted to co-crystallise GPC and Mtb UgpB 
however they were unsuccessful. Other attempts in the lab previously resulted in 
crystals of Mtb UgpB however they were always in the open conformation without 
ligand bound.  
 
5.3.3 Chemical methylation of Mtb UgpB 
In order to enhance co-crystallisation of GPC with Mtb UgpB we modified Mtb UgpB by 
reductive methylation using formaldehyde and dimethyamine borane complex (DMAB) 
(Walter et al., 2006). Reductive methylation of the surface-exposed lysine residues is 
used to improve the ability for proteins to crystallise because methylation of lysine 
residues alters the hydropathy, solubility and pI of the protein. These changes alter 
interactions between the protein-protein, protein-solvent and crystal lattice interfaces 
and in most cases the biological function is not affected (Walter et al., 2006). Following 
the methylation procedure crystal trials were repeated using the same concentrations 
and ratios (5.3.2) and the commercially available JCSG-plus screen. Mtb UgpB crystals 
typically grew within three days at 22 °C in the 1:1 ratiometric volume of protein with 
reservoir solution in the condition: 0.2 M MgCl2, 0.1 M Tris-HCl pH 8.5, 20% w/v PEG 
8,000. The crystals appearance was plate-like (Figure 5.5).  
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Figure 5.5: Mtb UgpB co-crystallised with glycerol-3-phosphocholine (GPC). Crystals 
formed with methylated Mtb UgpB and 10 mM GPC in the JCSG-plus screen and typically grew 
within three days at 22 °C in the condition 0.2 M MgCl2, 0.1 M Tris-HCl pH 8.5, 20% w/v PEG 
8,000. 
 
5.3.4 Crystal structure of Mtb UgpB bound to glycerol-3-phosphocholine 
The Mtb UgpB crystals that formed were cryoprotected with 20 % glycerol to reduce ice 
crystal formation (Pflugrath, 2015) and flash frozen in liquid nitrogen prior to diffraction 
data collection at the I04 beamline (Diamond Light Source). The diffraction data were 
indexed, integrated and scaled with XDS (Kabsch, 2010) through the XIA2 pipeline and 
the CCP4 suite of programmes (Collaborative Computational Project, 1994).	    Initially 
the ligand unbound Mtb UgpB structure (PDB ID 4MFI) was used as a search model to 
solve the phases by molecular replacement, however this failed. As SBP’s are known 
to be very flexible the two-α/β domains were used as separate search models 
specifying (PDB ID 4MFI), residues 34-153 and 305-378 as domain I and residues 
154-304 and 379-424 as domain II. A single molecule of 4MFI was searched for in the 
asymmetric unit however significant density was not fitted therefore the number of 
molecules searched for was increased. Four molecules were identified in the 
asymmetric unit with a Matthew’s coefficient of 2.18 Å3/Da and the space group was 
orthorhombic P 21 21 21. The structure was initially built using Autobuild (Terwilliger et 
al., 2008) followed by iterative cycles of alternating manual rebuilding in COOT 
(Emsley et al., 2004) and reciprocal space crystallographic refinement with PHENIX-
REFINE (Afonine et al., 2012) assigning each domain as a separate TLS group. 
Residues 37-354 and 367-403 were clearly defined in all chains. However as residues 
355-366 in chain C and D were not well defined they were deleted from the model. A 
single methylated lysine was confidently fitted in all chains at residue Lys161 out of a 
total of 13 lysine residues however due to the small size of the methyl group (15.03 
g/mol) these were difficult to accurately fit as there was no clear density. In all four 
chains between the two-α/β domains, a central electron dense region was identified to 
be the bound ligand and glycerol-3-phosphocoline was manually fitted and the 
molecular restraints were calculated (eLBOW) (Adams et al., 2010). To finally refine 
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the model a single glycerol molecule was fitted in chains A and C and 2 glycerol 
molecules were fitted in chain B.  A single Mg2+ ion was fitted in chains A, C and D and 
two Mg2+ ions were fitted in chain B. A total of 259 H2O molecules were also fitted. All 
residues were found in the Ramachandran allowed regions (Davis et al., 2004) and no 
outliers were identified. The resolution of the final structure was 2.3 Å and the Rwork was 
20.6 % and Rfree was 25.6 %. Crystallography parameters are listed (Table 5.1). 
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aNumbers in parentheses refer to the highest-resolution shell. 
bRamachandran plot statistics were calculated by MolProbity. 
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5.3.5 Comparison of the four chains of Mtb UgpB 
The four molecules of Mtb UgpB were aligned using PDBeFOLD (Hayward et al., 
2002) and found an r.m.s.d of 0.35-0.44 Å for 394-395 residues indicating that the 
molecules in the asymmetric unit were equivalent (Figure 5.6A). PDBePISA (Krissinel 
et al., 2007) was used to analyse crystal packing interfaces and did not suggest that 
Mtb UgpB forms dimers or larger oligomers and is therefore consistent with substrate 
binding proteins of other ABC-transporters that also form monomers (Locher, 2009) 
(Scheepers et al., 2016). This also supports the size-exclusion chromatography studies 
(Chapter 3, 3.3.7) that demonstrate Mtb UgpB exists in solution as a monomer and the 
apparent molecular weight is 44 kDa therefore the physiologically relevant unit is most 
likely a monomer. 
 
 
Figure 5.6: Overall structure of Mtb UgpB in complex with GPC. A) Alignment of the 4 
chains of Mtb UgpB bound to glycerol-3-phosphocholine in the asymmetric unit. B) Cartoon 
representation identifying the secondary structure elements domain I (blue), domain II (orange). 
The GPC ligand is represented as spheres with yellow carbon atoms. C) Surface representation 
where the two domains are highlighted, domain I (blue) and domain II (orange). The GPC ligand 
is represented as spheres with yellow carbon atoms. D) Superposition of domain I of GPC Mtb 
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5.3.6 Overall structure of Mtb UgpB bound to glycerol-3-phosphocholine 
The overall structure of Mtb UgpB (Figure 5.6B and 5.6C) consists of two-α/β domains 
connected by two flexible hinges between the residues Arg152-Pro155 and Ala290-
307. Domain I is made of a five-stranded β-sheet (residues 1-154 and 307-365) 
surrounded by 11 α-helices whereas domain II is made of a four-stranded β-sheet 
that’s enclosed by 9 α-helices. This classifies Mtb UgpB as a class II cluster D 
substrate binding protein (Berntsson et al., 2010) (Fukami-Kobayashi et al., 1999). The 
structure of ligand bound Mtb UgpB was compared to the unbound structure (PDB ID 
4MFI) and revealed a 21.8 o rotation of domain I relative to domain II about the 
interdomain screw-axis from DynDom analysis (Table 5.2) (Hayward et al., 2002). 
Hinge-bending residues were identified as residues 152-153, 304-306 found in the two 
inter-domain connecting regions and also from residues 362-372 that are separate to 






















Figure 5.7: Flexible hinges and hinge-bending residues of Mtb UgpB. Flexible hinges 
between the two-α/β domains are residues Arg152-Pro155 and Ala290-Ala307 coloured green. 
The flexible hinge bending residues measured by DynDom analysis Arg152-Ser153 and 
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Table 5.2. DynDom analysis of Mtb UgpB (pdb 4MFI) and Mtb UgpB in complex with GPC 
Backbone RMSD 
(Å) 
Bending region Rotation angle Translation 
(Å) 
Closure (%) 
0.47 (Domain I) 




21.8o 0.8 98.7 




Mtb UgpB appeared to follow the Venus Fly-trap mechanism where the substrate 
binding protein closes upon ligand binding (Locher, 2009) (Scheepers et al., 2016). 
Ligand binding resulted in a bending movement that reduced the binding pocket 
volume almost two-fold from 1986 Å3 to 791 Å3 as measured by CAVER (Figure 5.8) 
(Kozlikova et al., 2014).  
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Figure 5.8: Binding pocket cavity volume of Mtb UgpB as determined by Caver. A) The 
measured binding pocket cavity volume of apo Mtb UgpB was 1986 Å3. B) The measured 
binding pocket cavity volume of glycerol-3-phosphocholine bound Mtb UgpB was 791 Å3. C) 
Rotation angle of 21.8 o between the domains of glycerol-3-phosphocholine bound Mtb UgpB 
(blue and orange) compared to apo Mtb UgpB (white), rotational axis (magenta). 
 
The closed ligand bound conformation appeared to be stabilised by Arg385 of domain 
II forming interdomain hydrogen bonds with Asp102 of domain I and Gln381 from 
domain II. Alignment of GPC bound Mtb UgpB to the unbound structure (PDB ID 4MFI) 
(PDBeFOLD) found an r.m.s.d of 2.2 Å (over 385 residues) whereas alignment of the 
individual domains of the ligand bound structure and unbound structure (Figure 5.6D) 
found an r.m.s.d of 0.57 Å and 0.75 Å for domains I and II respectively (over 178 atoms 
(domain I) and over 216 atoms (domain II) (PDBeFOLD) (Hayward et al., 2002) 
indicating the importance of interdomain flexibility for ligand binding. 
	   	   
A B 
C 	   21.8° 
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5.3.7 The glycerol-3-phosphocholine binding site in Mtb UgpB 
The GPC ligand was manually fitted into the central electron dense region between the 
two-α/β domains identified in all four molecules of the asymmetric unit (Figure 5.9A). 
The GPC electron density map was contoured at 0.38 electrons/Å3 (CCP4mg). GPC 
from chains A-D were aligned (PyMOL) and appeared to be orientated identically in 




Figure 5.9: Glycerol-3-phosphocholine electron density. A) Electron density for the GPC 
substrate. Electron density map contoured at 0.38 electrons/Å3. Carbon atoms are shown in 
green, oxygen atoms are shown in red, nitrogen atoms in blue and phosphate atom in purple. 
The figure was prepared using CCP4mg. The mtz file was loaded directly with the default 
settings and clipped to select for the GPC atoms. B) Alignment of the glycerophosphocholine 
ligand from each Mtb UgpB subunit. Superposition of GPC from each Mtb UgpB subunit in the 
asymmetric unit. The GPC ligand is shown with green carbon atoms (subunit A), light blue 
carbon atoms (subunit B), wheat carbon atoms (subunit C) and grey carbon atoms (subunit D). 
In all subunits oxygen atoms are coloured red and the phosphorous atom is coloured orange.  
 
5.3.7.1 The electrostatic surface of GPC bound Mtb UgpB 
The electrostatic surface of Mtb UgpB (CCP4mg) (Figure 5.10A) was analysed 
because it could be a determinant for ligand binding. The electrostatic surface 
indicated an acidic interface between the two-α/β domains of Mtb UgpB. The glycerol 
moiety of GPC is located at the base of this acidic cavity in close proximity to Arg385 
and appears to stabilise domain closure whereas the choline moiety is pointing 
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Figure 5.10: The binding pocket electrostatic surface of Mtb UgpB (CCPMG). A) 
Electrostatic surface representation of Mtb UgpB GPC. B) Close-up illustration of the Mtb UgpB 
binding pocket with the GPC ligand in stick representation. Electrostatic surface was generated 
in CCP4mg (Collaborative Computational Project, 1994) red represents negative potential, blue 
represents positive potential.  
 
5.3.7.2 Ligand binding site interactions of Mtb UgpB 
The interactions of the GPC ligand with Mtb UgpB were now investigated in detail. The 
side chains of Leu205 and Trp208 from domain II form hydrophobic contacts with the 
glycerol moiety (Figure 5.11A and 5.11B). Parallel to the plane formed by these atoms: 
C1, C2 and the 2-hydroxy group of the glycerol moiety is Trp208 where its indole ring 
system enables π-stacking interactions. Perpendicular to the same plane there is 
additional stabilisation provided by the aliphatic residue, Leu205 although it is 
approximately 4 Å distance away from the glycerol backbone. Within the binding 
pocket multiple hydrogen bonding interactions provided by 7 additional residues fix the 
GPC ligand in place. From domain I, direct hydrogen bonding occurs between Asp102 
and the 1- and 2-hydroxyl groups of the glycerol moiety. Two residues of the flexible 
hinge region bind to the GPC ligand and may be important to stabilise the ligand bound 
closed conformation: Arg385 (domain II) hydrogen bonds to the 1-hydroxy of the 
glycerol moiety and Gly306 (domain I) also hydrogen bonds with the 2-hydroxy of the 
glycerol moiety via its backbone amide nitrogen atom. Further ligand binding 
interactions are stabilised via the phosphate moiety of GPC and hydrogen bond 
interactions between the side chains of Tyr78, Tyr345 and Ser153 (domain I) and the 
Ser272 (domain II) side chain and Gly306 amide backbone (domain I). Interestingly no 
interactions appeared to occur between Mtb UgpB and the positively charged choline 
moiety despite its well-defined density and the choline group being a key requirement 
for binding based on ligand binding studies (Chapter 4, 4.3.12). Therefore it could be 
combination of ligand charge and size that are required for recognition. Based on the 
	   A B 
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lack of interactions with the choline group, other ligands could potentially be recognised 

















































Figure 5.11: The GPC binding site in Mtb UgpB. A) Illustration showing GPC with yellow 
carbon atoms and selected Mtb UgpB amino acid residues in stick representation (coloured 
blue for residues within domain I, and orange for residues within domain II. B) Schematic 
diagram of the interactions of Mtb UgpB with GPC. Dashed lines (black) represent hydrogen 
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5.3.8 Identification of an additional glycerol in the Mtb UgpB binding site 
Interestingly in chain B of GPC bound Mtb UgpB an additional glycerol was identified 
(Figure 5.12A). This could be a result of cryo-protecting the crystals with glycerol and 
also because glycerol is included in the purification buffer. The glycerol molecule was 
found in the Mtb UgpB binding pocket and within 4 Å close proximity to the choline 
moiety of the GPC ligand (Figure 5.12B). This is similar to the G3P bound E. coli UgpB 
structure (Wuttge et al., 2012) where a glycerol molecule is also present in the binding 
pocket although at a different position and therefore indicates that the binding pockets 
of both UgpB proteins are larger than the GPC ligand. This may be functionally 




Figure 5.12: Location of additional glycerol moiety in the Mtb UgpB binding pocket. A) 
Surface representation of Mtb UgpB. The GPC ligand is represented by yellow spheres and a 
solvent glycerol moiety as cyan spheres. B) Close-up of the Mtb UgpB binding pocket. The GPC 
ligand and glycerol moiety are shown in stick representation. 
 
5.3.9 Comparison of Mtb UgpB and E. coli UgpB 
The only other available structure of a UgpB substrate-binding protein is from E. coli 
and it is bound to glycerol-3-phosphate (G3P). The binding profiles of E.coli UgpB and 
Mtb UgpB are different because Mtb UgpB did not show binding to G3P by microscale 
themophoresis (Chapter 4, 4.3.12) or by isothermal calorimetry (Jiang et al., 2014). 
However when the overall structures of G3P bound E. coli UgpB (Wuttge et al., 2012) 
and GPC bound Mtb UgpB were compared they were found to be highly similar with a 
r.m.s.d. of 2.1 Å (PDBeFold, target residues: 394, sequence identity 25 % (Figure 
5.13A) (PDB ID 4AQ4) (Krissinel et al., 2007). It appears that despite the inability of 
Mtb UgpB to recognise the smaller G3P ligand, the binding mode of the G3P core of 
GPC resembles the G3P E. coli UgpB bound structure (Wuttge et al., 2012) and the 
ligand-binding pocket of Mtb UgpB is very similar to E. coli UgpB (Figure 5.13B and 
A B 
 Chapter 5: Structural studies of Mycobacterium tuberculosis UgpB   
 
	   178 
5.13D). However despite these overall similarities, important differences exist between 
the two UgpB structures. In Mtb UgpB Leu205 is replaced by the larger indole side 
chain of Trp269 in E. coli UgpB and Asp102 in Mtb UgpB is replaced by the longer and 
more acidic side chain of Glu66 in E. coli UgpB. These different residues may influence 
the different ligand selectivity. The two substrate-binding proteins may have also 
evolutionary diverged because the conserved Arg385 in Mtb UgpB and Arg374 in E. 




Figure 5.13: Comparison of glycerol-3-phosphocholine bound Mtb UgpB to glycerol-3-
phosphate bound E. coli UgpB. A) Comparison of Mtb UgpB with E. coli UgpB. Superposition 
of the Mtb UgpB GPC complex structure (blue/orange) with E. coli UgpB in complex with G3P 
(PDB 4AQ4) (white). Loop regions that differ are highlighted in green and magenta. B) Close-up 
of the overlay of the binding-sites of GPC (Mtb) and G3P (E. coli). Selected residues are shown 
as sticks (Mtb blue/orange, E. coli white) and the font labeled in black (Mtb) and blue (E. coli). 
C) Close-up illustration showing the binding orientation of the GPC ligand and G3P ligand in 
stick representation (yellow carbon atoms, GPC, white carbon atoms G3P). D) Close up overlay 
of GPC and G3P. 
 
 
Overall the substrate-binding pocket is much narrower in E. coli UgpB (Figure 5.14) 
compared to Mtb UgpB. This is partly due to two different loop regions in E. coli UgpB 
from residues Gly221-Asp230 (domain II) and residues Gly12-Pro30 (domain I). 
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narrows the substrate-binding pocket. A second loop His8-Gly12 causes the first α-
helix (residues 12-30) to translate by 6 Å towards α-helix 11. Furthermore, compared to 




Figure 5.14: Comparison of the binding pocket electrostatic surface of Mtb UgpB and E. 
coli UgpB. A) Electrostatic surface representation of Mtb UgpB GPC. B) Close-up illustration of 
the Mtb UgpB binding pocket with the GPC ligand in stick representation. C) Electrostatic 
surface representation of E. coli UgpB G3P. D) Close-up illustration of the E. coli UgpB binding 
pocket with the G3P ligand in stick representation. Electrostatic surface was generated in 
CCP4mg (Collaborative Computational Project, 1994) red represents negative potential, blue 
represents positive potential.   
 
5.3.10 Crystallisation studies of Mtb UgpB and glycerophosphoserine (GPS) 
Other glycerophosphodiesters have been identified as substrates of Mtb UgpB 
(Chapter 4) therefore we wanted to investigate how the binding recognition mode of 
these substrates compares to GPC, as they have different binding affinities. GPS was 
investigated because it has a similar binding affinity of 14.9 µM compared to the 
binding affinity for GPC of 3.6 µM. For co-crystallisation experiments Mtb UgpB was 
reductively methylated as described previously (5.3.2). 20 mM of 
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4 °C for 30 minutes before setting plates. Crystal trials were set using the sitting-drop 
vapour diffusion method in 96-well plates using a Mosquito liquid handling system (TTP 
LabTech). Ratiometric volumes of 1:1, 1:2 and 2:1 volumes of protein with reservoir 
solution were mixed producing drop sizes of 0.3-0.45 µL. The crystallisation conditions 
that were initially screened included JCSG-plus, Morpheus, Midas and Structure 
Screen I and II (Molecular Dimensions). A single crystal was identified in the 1:1 ratio 
drop of JCSG-plus condition D4 (0.1 M sodium acetate, 0.2 M lithium sulphate, pH 4.5, 
30 % w/v PEG8000) and diffracted at >4 Å resolution indicating that the crystal was 
protein however due to the low resolution further optimisation was required.  
 
The Hampton additive screen (Hampton Research) was used at the manufacturers 
guidance to give a final 10 % additive concentration to condition D4 from JCSG-plus 
(0.1 M sodium acetate, 0.2 M lithium sulphate, pH 4.5, 30 % w/v PEG8000) that had 
previously produced a low diffraction quality protein crystal. In the additive screen 
several crystals were identified after 2 weeks in the additives: ethylene glycol (3.0 %), 
acetone (4.0 %), ethyl acetate (0.5 %) and trimethylamine hydrochloride (0.01 M). The 
crystals were flash frozen in liquid nitrogen prior to diffraction data collection at the I-24 
beamline (Figure 5.15) (Diamond Light Source). No cryo-protection was added due to 
the high concentration of PEG8000 (30 % w/v) in the crystallisation condition. The 
crystal that produced high-resolution diffraction data (1.76 Å) grew in the additive 
ethylene glycol (3.0 %). Ethylene glycol is a polyol and has general structural 
stabilising properties as it increases the thermal denaturation temperature of proteins 
and may have induced order in the flexible Mtb UgpB protein to promote ordered 










Figure 5.15: Mtb UgpB co-crystallised with glycerophosphoserine (GPS). Crystals formed 
with methylated Mtb UgpB and 20 mM GPS in the JCSG-plus screen and Hampton additive. 
The crystal that diffracted was identified in the following condition: 0.1 M sodium acetate, 0.2 M 
lithium sulphate, pH 4.5, 30 % w/v PEG8000, 3.0 % ethylene glycol. 
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aNumbers in parentheses refer to the highest-resolution shell. 
bRamachandran plot statistics were calculated by MolProbity. 
 
 
5.3.11 Structure of Mtb UgpB co-crystallised with glycerophosphoserine  
To solve the phases molecular replacement (PHASER) (McCoy et al., 2007) was used 
specifying chain A of GPC bound Mtb UgpB as the single search model. Only one 
molecule was identified in the asymmetric unit with a Matthew’s coefficient of 2.2 Å3/Da 
and the space group was monoclinic P1211. A full list of the crystallography parameters 
is presented (Table 5.3). The calculated phases were well defined and the model was 
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visualised (COOT) (Emsley et al., 2004)  and appeared to be identical to GPC bound 
Mtb UgpB. However Mtb UgpB amino acids 90-93 did not fit well to the density and had 
to be manually adjusted. No methylated lysines were identified in the structure despite 
reductively methylating the protein prior to crystal trials. At the centre of the structure 
between the two-α/β domains an electron dense region was identified and we 
attempted to manually fit GPS. The glycerol and phosphate electron densities of GPS 
were clearly defined and GPS was manually fitted and the molecular restraints were 
calculated (eLBOW) (Adams et al., 2010). The putative GPS electron density map was 
contoured at 0.38 electrons/Å3 (CCP4mg) (Figure 5.17).  However the serine density of 
GPS was not well defined therefore we could not precisely confirm that GPS was 
bound and further studies are needed. In an attempt to improve the serine density we 
used different numbers of images and re-processed the data however the serine 
density did not improve. In addition, there was also an unknown density close to the 
putative GPS density. To finally build the model, H2O molecules were fitted into the 
appropriate densities. The final overall structure (Figure 5.16) was 1.76 Å resolution 
and the Rwork was 18.4 % and Rfree was 22.1 %. A single molecule of Mtb UgpB, 
putatively co-crystallised with glycerophosphoserine (GPS) was identified in the 
asymmetric unit.  
 
 
Figure 5.16: Overall structure of Mtb UgpB co-crystallised with GPS. A) Cartoon 
representation identifying the secondary structure elements domain I (blue), domain II (orange). 
The GPS ligand is represented as sticks with yellow carbon atoms. B) Surface representation 
where the two domains are highlighted, domain I (blue) and domain II (orange). The GPS ligand 
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Figure 5.17: Putative glycerophosphoserine bound electron density. A) Electron density for 
the GPS ligand. Electron density map contoured at 0.38 electrons/Å3. Carbon atoms are shown 
in green, oxygen atoms are shown in red, nitrogen atoms in blue and phosphate atom in purple. 
The figure was prepared using CCP4mg. The mtz file was loaded directly with the default 
settings and clipped to select for the GPC atoms. B) GPS ligand in stick representation showing 
green carbon atoms, red oxygen atoms, blue nitrogen atoms and orange phosphate atoms. 
 
5.3.12 Comparison of Mtb UgpB bound GPC with GPS 
Even though we were not completely sure if GPS is bound we compared the GPC 
bound Mtb UgpB structure with the putative GPS bound Mtb UgpB structure and found 
that they were almost identical (RMSD 0.335 over 392 residues). Comparisons of the 
residues involved in binding (Figure 5.18) revealed that the same residues were 
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Figure 5.18: Comparison of the putative GPS bound Mtb UgpB binding site to GPC bound 
Mtb UgpB. A) Comparison of the putative GPS bound Mtb UgpB binding site to GPC bound 
Mtb UgpB. Selected residues are shown as sticks (Mtb GPS orange/blue, Mtb GPC cyan). The 
GPS ligand carbon atoms are coloured yellow and the GPC ligand carbon atoms are coloured 
cyan. B) Close-up illustration showing the putative binding orientation of the GPS ligand and 
GPC ligand in stick representation (yellow carbon atoms, GPS, cyan carbon atoms GPC).  
 
 
The serine density of GPS was not well defined. However, no Mtb UgpB interactions 
could be identified with the serine group similar to how no interactions were identified 
with the choline head-group of the GPC bound structure (Figure 5.18A). The same 
residues were found to interact with the glycerol and phosphate group of GPS. The 
glycerol and phosphate group of the putative GPS ligand aligned almost identically with 
GPC (Figure 5.18B). Similar to GPC bound Mtb UgpB the glycerol C1 -hydroxyl group 
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hydroxyl group of GPS forms hydrogen bonds with Asp102 and the nitrogen amide 
backbone of Gly306. Trp208 and Leu205 also stabilise the glycerol backbone via π-
stacking interactions and Van der Waal’s forces. Tyr78, Tyr345, Ser153 and Ser272 
form hydrogen bonds with the phosphate hydroxyl groups of GPS. Asp102 (domain I) 
and Arg385 (domain II) were also identified to form a salt bridge that may be important 
for stabilising the closed conformation of the ligand bound structure and may be 
involved in enabling larger glycerophosphodiester ligands to bind.  
 
5.3.13 STD-NMR for Mtb UgpB with glycerol-3-phosphocholine 
Our collaborators Dr Ridvan Nepravishta and Dr Jesus Angulo at the University of East 
Anglia carried out all of the following STD-NMR experiments and analyses. 
 
As no interactions were identified by X-ray diffraction between the choline moiety of 
GPC and Mtb UgpB, and G3P did not show binding despite the lack of a choline 
moiety, the binding interaction was investigated using NMR. As this method is in the 
solution state, it’s anticipated that the protein is more conformational flexible and 
dynamic which may be important prior to contact with the ligand. Whereas protein 
crystals are in the solid state and tend to crystallise in a single conformation and are 
more dynamically restricted. To obtain quantitative epitope maps of the ligand-protein 
interaction in solution, STD-NMR was used (Mayer et al., 1999). Firstly, Mtb UgpB was 
buffer exchanged into deuterated PBS at pH 7.5 by ultrafiltration (10 kDa cut-off, 
Amicon Ultra) to a final concentration of 3.1 mg/mL (68 µM) and the ligands were also 
dissolved in deuterated PBS at 5 mM prior to the STD-NMR analyses. 
 
In the STD-NMR experiment binding was successfully detected to GPC and the STD 
NMR signals and GPC binding epitope maps were obtained (Figure 5.19A). The 
epitope map clearly indicated that the glycerol moiety of GPC was the main recognition 
site as it showed the highest normalised STD values. Of the protons identified the 
highest STD intensities were found in the glycerol moiety at position 2 and 3 (H2G, 100 
% and H3G, 100 %) (Figure 5.19A) whereas the proton at position 1 (H1G, 82 %) 
showed a slightly lower signal. The ligand-protein contacts appeared to be closer to the 
glycerol group compared to the choline group because the STD signals decreased 
from the glycerol group to the choline group. Protons at position 1 and 2 adjacent to the 
phosphate and choline group (H1C, 70 % and H2C, 50 %) showed intermediate STD 
signals and the lowest STD signals were observed for the methyl groups of the choline 
moiety (H3C, 26 %). 
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Figure 5.19: STD-NMR for Mtb with GPC. A) Structure of glycerol-3-phosphocholine. B) 
Experimental STD build up curves for the GPC/Mtb UgpB complex and the obtained epitope 
map of GPC/Mtb UgpB. C) STD in red bars obtained with a 4s saturation time while in blue bars 
the CORCEMA-ST calculated STD from the 3D crystallographic structure of the Mtb UgpB/GPC 
complex obtained for the same saturation time. RNOE factor 0.25. D) Differential epitope 
(DEEP)-STD factors showing the type of amino acid that the protons of the GPC ligand are 
orientated towards. Protons orientated towards aliphatic residues are highlighted in blue and 
protons orientated towards aromatic residues are highlighted in magenta. The figure was 
prepared by Dr Ridvan Nepravishta.  
 
As the X-ray structure of ligand unbound Mtb UgpB was available a quantitative 
comparison of the NMR solution data and X-ray data was carried out by complete 
relaxation and conformational exchange matrix (CORCEMA-ST) calculations 
(Jayalakshmi et al., 2002) and the newly developed method DEEP-STD NMR (Monaco 
et al., 2017). Comparing the CORCEMA-ST calculated solution data STD NMR 
intensities (Figure 5.19B) to the X-ray structure revealed a NOE R-factor (Xu et al., 
1995) of 0.25 and demonstrates very good data agreement as a NOE R-factor of 0.31-
0.39 is typical for accurate structures (Edmondson, 1992). However to probe for 
additional information about how the ligand is orientated in the binding site as well as 
indirect information about the types of amino acids (aromatic, polar or apolar residues) 
contacting the ligand, differential epitope mapping STD NMR (DEEP-STD NMR) was 
used (Figure 5.19C) (Nepravishta et al., 2019). The calculated DEEP-STD NMR 
factors indicated that protons in position 3 of the glycerol moiety of GPC (H3G) are 
orientated towards aliphatic amino acids whilst the protons in position 1 adjacent to the 
phosphate and choline moiety (H1C) are oriented toward aromatic residues and these 
were mapped to the crystal structure of Mtb UgpB as the aliphatic Leu205 and 
aromatic Tyr78 and Tyr345 amino acid residues. This data correlates well with the 
ligand recognition mode obtained for the GPC Mtb UgpB complex (Figure 5.11) in the 
solid-state structure showing the side chains of Leu205 from domain II forming 
hydrophobic contacts with the glycerol moiety and Tyr78 and Tyr345 from domain I 
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5.3.14 STD-NMR for Mtb UgpB with glycerolphosphoinositol-4-phosphate 
As binding to the alternative glycerophosphodiester, glycerophosphoinositol-4-
phosphate (GPI(4)P) was identified by microscale thermophoresis with a Kd of 298.8 
µM (Chapter 4, 4.5.1), STD-NMR spectroscopy was used to investigate the binding 
interaction with Mtb UgpB. Crystal trials of GPI(4)P and Mtb UgpB were not set 
because of its limited commercial availability and high purchase cost. The results 
indicated similarly that the glycerol moiety of GPI(4)P was the main recognition site as 
the strongest STD signals were at position 1, 2 and 3 (H1G, 93 % and 88.7 %), (H2G, 
100 %) and (H3G, 82 % and 77 %). However also high STD signals were observed for 
protons located in the inositol ring at position 1 and 2 (H1I, 71%) and (H2I, 91 %) 
(Figure 5.20A). Intermediate STD signals were identified for protons located in the 
inositol ring at positions 3 and 4 (H3I, 65 %) and (H4I, 67 %) whereas protons at 
position 5 and 6 showed the lowest STD signals (H5I, 46 %) and (H6I, 42 %). This 
contrasts with GPC where only low STD signals were observed for the choline head-
group (Figure 5.20A).  
 
 
Figure 5.20: STD NMR of Mtb UgpB with GPI4P. A) Structure of glycerophosphoinositol-4-
phosphate and experimental STD build up curve for the Mtb UgpB/GPIP4 complex and the 
obtained epitope map of GPI4P/Mtb UgpB. B) Differential epitope (DEEP)-STD factors showing 
the type of amino acid that the protons of the GPI4P ligand are orientated towards. Protons 
orientated towards aliphatic residues are highlighted in blue and protons orientated towards 
aromatic residues are highlighted in magenta. C) Docked structure of the GPIP4 in the binding 
site of Mtb UgpB. GPI4P is in stick representation with the carbon atoms in yellow. D) Close-up 
overlay of the binding orientations of GPC (magenta carbon atoms) with GPI(4)P (yellow carbon 
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DEEP-STD NMR was also carried out to probe for additional information about how the 
GPI(4)P ligand is orientated in the binding site (Figure 5.20B) and it revealed that 
protons at positions 1 and 2 of the glycerol group (H1G), (H2G) and protons at position 
4 of the inositol ring (H4I) are orientated towards the aliphatic residue Leu205 whereas 
protons at position 3 of the glycerol group (H3G) and positions 1, 3, 5 and 6 of the 
inositol ring (HI1), (H3I), (H5I) and (H6I) are orientated toward the aromatic Tyr78 and 
Tyr345 residues.  
 
To investigate the 3D structural determinants of this interaction docking calculations 
were carried out using Autodock Vina to dock the experimentally obtained DEEP-STD 
factor values of GPI(4)P to the Mtb UgpB X-ray structure (Trott et al., 2010). By 
comparing the CORCEMA-ST calculated STD signals from the best scored docked 
structure of GPI(4)P bound Mtb UgpB and the experimental STD signals, a NOE R-
factor of 0.31 was obtained and demonstrates very good data agreement of the docked 
structure to the experimental STD-NMR data as a NOE R-factor of 0.31-0.39 is typical 
for accurate structures (Edmondson, 1992) (Figure 5.20C). Interestingly alignment of 
the GPC ligand revealed that the glycerol tail of GPI(4)P had orientated differently 
possibly to accommodate the larger inositol-phosphate head-group (Figure 5.20D). 
Combined these data further suggest that the glyceorphosphodiester head-group size 
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5.4 Discussion 
The structure of GPC bound Mtb UgpB was successfully solved by X-ray 
crystallography to 2.3 Å resolution. Initial attempts to co-crystallise GPC bound Mtb 
UgpB without chemical modification of the Mtb UgpB protein were unsuccessful. 
However determining the structures of dynamic and flexible proteins by X-ray 
crystallography is challenging as many molecules have to be aligned in the exact same 
orientation within the crystal lattice (Palamini et al., 2016). As SBP’s undergo large 
conformational changes between the two-α/β domains, obtaining a ligand bound 
structure is difficult because the particular conformation needs to be stabilised, and this 
could explain the difficulty in obtaining a structure of D-glucosamine-6-phosphate 
bound Mtb UspC (Fullam et al., 2016). Large-scale motions may be necessary for 
ligand binding however previous methods to reduce flexibility and promote crystal 
formation include using a crystallisation chaperone for example an antibody (Iwata et 
al., 1995) or by controlled dehydration (Heras et al., 2003). Alternatively the surface of 
the protein can be targeted by mutating large, charged and surface exposed flexible 
amino acids e.g. lysine and glutamate to smaller hydrophobic residues (Lawson et al., 
1991). 
 
Instead of using those methods we chose to chemically modify the Mtb UgpB surface 
by reductive methylation of free amines e.g. lysine and the N-terminus amine. 
Reductive methylation of the surface exposed lysine residues of which there are 
potentially 13 modifiable residues likely improved the ability for GPC bound Mtb UgpB 
to crystallise as methylated lysines favour protein-protein interactions. In the GPC 
bound X-ray crystal structure only a single methylated lysine residue (MLZ 161) was 
identified. Structural alignment of GPC bound Mtb UgpB to the ligand unbound 
structure (PDB ID 4MFI) revealed as expected for SBP’s that Mtb UgpB had 
undergone a large conformational change upon ligand binding associated with closure 
of the two-α/β domains around the GPC ligand. The conformational change was 
quantified by DynDom and CAVER analyses and indicated a rotation of 21.8° between 
domain I relative to domain II about the interdomain screw-axis which is comparable to 
other SBP’s including MetQ that undergoes a 24° twist as a complex with MetNI 
(Nguyen et al., 2018). Compared to others SBP’s this is moderate because the degree 
of rotation can be only a few degrees in the case of BtuF (Karpowich et al., 2003) and 
TroA (Y. H. Lee et al., 2002) or as large as 60° in the case of LivJ (Trakhanov et al., 
2005). 
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In all of the Mtb UgpB molecules in the asymmetric unit, the GPC electron density was 
clearly defined and enabled the ligand and interacting amino acid residues to be 
accurately fitted. The residues involved in binding interacted primarily via the glycerol 
and phosphate moieties of GPC where Ser272, Ser153, Tyr78 and Tyr345 contacted 
the phosphate moiety via hydrogen bonding. Asp102 and Arg385 contacted the 
glycerol moiety also via hydrogen bonding. Trp208 contacted the glycerol backbone via 
a π-stacking interaction and Leu205 contacted the glycerol via Van Der Waals forces. 
Mutational analyses (Chapter 4, 4.3.13) supported that all of these residues were 
important for binding as replacement to alanine either completely abolished or reduced 
the GPC binding affinity as measured by microscale thermophoresis (MST). 
Interestingly no interactions occurred via the positively charged choline group despite 
the presence of this head-group being a key requirement for ligand binding by MST 
(Chapter 4, 4.3.12). 
 
Compared to the G3P bound E. coli UgpB structure the binding pocket had similarly 
conserved residues however Mtb UgpB Leu205 and Asp102 specific residues were 
replaced by the larger aromatic Trp169 and the negatively charged Glu66 in E. coli 
UgpB (Wuttge et al., 2012). However when Mtb UgpB Leu205 was mutated to Trp169 
(Jiang et al., 2014) no binding to GPC was observed by ITC. In E. coli UgpB Trp172, 
Tyr42 and Tyr323 also stabilise G3P and were conserved in Mtb UgpB. Similarly in E. 
coli UgpB Arg374 that binds to the C1 hydroxyl of G3P is conserved. As expected the 
ligand-binding pocket was more closed in G3P bound E. coli UgpB. Mutating Mtb UgpB 
Leu205 to alanine in a previous study (Jiang et al., 2014) also led to loss of binding to 
GPC supporting how Leu205 was essential for binding to GPC. These key differences 
in the structure of G3P bound E. coli UgpB compared to GPC bound Mtb UgpB likely 
reflect differences in the evolutionary origins of these organisms as Mtb is a well 
adapted as a human pathogen and may have evolved Mtb UgpB to scavenge 
glycerophosphodiesters as a nutrient source in macrophages. 
 
In-solution methods were also used to investigate and support Mtb UgpB binding to 
GPC. STD-NMR experiments of the GPC Mtb UgpB interaction showed good 
agreement compared to the X-ray crystal structure. The ligand binding moieties were 
identified and indicated that H3G, H2G and H1G of the glycerol backbone showed the 
highest STD signals compared to weaker signals for H1C and H2C and the weakest 
signal for Me3C of the choline group. Furthermore DEEP STD-NMR analysis revealed 
that H3G of the glycerol group interacted with aliphatic residues modelled as Leu205 
as it is the closest aliphatic residue in the ligand bound X-ray structure. H1C interacted 
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with aromatic residues and the closest residues identified in the crystal structure were 
Tyr78 and Tyr345 although these residues were actually identified to be interacting 
with the phosphate group. Saturation transfer difference NMR experiments also 
revealed that the alternative glycerophosphodiester GPI(4)P also binds to Mtb UgpB. 
The results indicated strong STD signals in regions of the inositol ring, part of the head-
group whereas head-group interactions had not been previously observed for GPC 
suggesting that glycerophosphodiester size influences binding. Interestingly molecular 
docking based on STD-NMR measurements also found that the glycerol backbone of 
GPI(4)P re-orientated in order to accommodate the larger head-group supporting the 
idea that Mtb UgpB has the ability to accommodate and bind to alternative larger lipid 
head-groups. 
 
Mtb UgpB was also co-crystallised with GPS and the putative GPS bound structure 
was solved by X-ray crystallography to 1.76 Å resolution. However although the 
electron density of the glycerol and phosphate groups was well defined, the serine 
group was not as well defined. It’s possible that G3P is actually bound because the 
GPS ligand was produced to only 80 % purity. By NMR the impurity was glycerol 
however its possible that GPS is being hydrolysed leading to loss of the serine group 
during crystallisation conditions. However our microscale thermophoresis data 
(Chapter 4, 4.3.12) does not support binding to G3P. Interestingly the conformation of 
the putative GPS bound Mtb UgpB was almost identical to GPC bound Mtb UgpB. Also 
the orientation of the putative GPS ligand was identical to GPC, involving the glycerol 
and phosphate groups and no interactions with the head-group. Currently we cannot 
conclude that GPS is bound to Mtb UgpB based on this X-ray crystallography data 
therefore further studies are required. 
 
This combined structural data suggests that Mtb UgpB is capable of binding to a wide 
range of glycerophosphodiester substrates and is possibly an evolutionary 
consequence of residing inside a nutrient limited environment. Mtb UgpB may be 
adapted to uptake glycerophosphodiesters derived from the degradation of membrane 
phospholipids generated by either bacterial or host derived phospholipases. It is 
interesting to note that GPC is a major component of lung surfactant and is also found 
at high levels in Mtb infected guinea pig granuloma (Somashekar et al., 2011). It’s 
therefore possible that Mtb is in close proximity to large amounts of GPC that could be 
imported by the Mtb UgpABCE transporter enabling Mtb to survive in phosphate and 
carbon limited conditions.  
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Importantly our structural analysis of Mtb UgpB bound to GPC has facilitated the 
possibility of future medical chemistry research. Bacterial ABC importers provide 
access for essential nutrients therefore targeting importers is emerging as a new 
method to tackle antibiotic resistance (Tanaka et al., 2018). For example bacteriocins 
are natural antibiotics that mimic the natural substrates of several ABC transporters. 
Microcin C is a peptide-nucleotide antibiotic transported by the E. coli yejABEF ABC 
transporter and blocks tRNAasp (Novikova et al., 2007). Another example is albomycin 
that is an iron siderophore-antibiotic conjugate and is transported via the substrate 
binding protein of E. coli FhuD and inhibits seryl-tRNA synthetase (Clarke et al., 2002) 
(Rebuffat, 2012).  
 
Synthetic antibiotics have also been designed to target and be imported by ABC 
transporters using a “Trojan horse like” method. For example the orthine 
carbamoyltransferase inhibitor, phaseolotoxin is imported by a dipeptide transporter 
dppABCDF (Pletzer et al., 2014) and kasugamcyin and blasticidin the translation 
initiation and termination inhibitors are transported by E. coli oppABCDF (Shiver et al., 
2016). There are also reports of the SBP’s of ABC transporters being directly targeted 
by drug candidates. For example RDS50 and RDS51 inhibited S. typhimurium growth 
and decreased invasion of intestinal epithelial cells (Ilari et al., 2016). Also X-ray 
crystallography revealed that the SBP interaction involved RDS51 co-ordinating a Zn2+ 
ion in the ZnuA SBP binding site, bridging the two-α/β domains of ZnuA by forming 
hydrophobic contacts and thereby either preventing ZnuABC transporter complex 
formation or the release of zinc (Ilari et al., 2016), resulting in starvation of essential 
Zn2+.  
 
Overall our structural analysis of Mtb UgpB provides a firm basis to design and develop 
inhibitors or substrate mimics. For example inhibitors could be designed based on the 
GPC bound Mtb UgpB structure, to contain a glycerol tail and phosphate group and a 
potentially toxic head-group moiety that could be used to target the Mtb UgpABCE 
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Chapter 6: Cloning, expression and purification of 
Mycobacterium tuberculosis UgpC and UgpAE 
 
Now that we have biochemically characterised Mtb UgpB we wanted to understand the 
functions of the other components of the Mtb UgpABCE transporter therefore we 
decided to attempt to express and purify the nucleotide-binding protein Mtb UgpC (6A) 




6.1.1 What do we know about Mtb UgpC 
The Mtb ugpC gene (Rv2832c) encodes the predicted nucleotide-binding protein (NBP) 
of the Mtb UgpABCE transporter (Figure 6.1) and is annotated to be involved in energy 
coupling and active transport of sn-glycerol-3-phosphate across the plasma membrane 




Figure 6.1: Predicted architecture of the Mtb UgpABCE ATP-binding cassette (ABC) 
transporter. UgpB is the substrate binding protein, UgpA and UgpE are the membrane 
spanning proteins and UgpC is the nucleotide binding protein. 
 
The Mtb ugpC gene is located in the Mtb ugpABCE ATP-binding cassette (ABC) 
transporter operon (Chapter 3, 3.3.2) and is predicted to be the ATPase involved in 





ATP 	   ADP + Pi 
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sequence by bioinformatics (Figure 6.2A) revealed that Mtb UgpC has the 
characteristic features of nucleotide-binding proteins (Locher, 2016) (Figure 6.2B). Mtb 
UgpC has a Walker-A motif shown in yellow (Figure 6.2A), predicted to bind to the α 
and β phosphates of ATP. A Walker-B motif shown in cyan (Figure 6.2A), that provides 
the catalytic glutamate residue, and a signature motif shown in green (Figure 6.2A), 
predicted to orientate ATP during hydrolysis. 
Figure 6.2: Amino acid sequence of Mtb UgpC and architecture of a single nucleotide-
binding protein. A) Amino acid sequence of Mtb UgpC. The Walker-A motif (yellow), Walker-B 
motif (cyan) and signature motif (green) are highlighted. B) Architecture of an ABC-transporter 
single nucleotide binding protein showing features important for ATP binding and hydrolysis 
(Locher, 2016). 
 
In order to biochemically investigate Mtb UgpC we wanted to clone, express, and purify 
Mtb UgpC and determine if it is a functional ATPase. Overall the aim is then to 
reconstitute the whole transporter and determine its structure, as this will help us to 
understand its function.  
 
6.1.2 Assays to measure ATPase activity 
ATPase activities can be characterised using several different methods. These include 
measuring phosphate release using colorimetric, fluorescent or radioactive substrates 
A 
B 
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(Lanzetta et al., 1979) (Brune et al., 1994) (Seals et al., 1978). A popular colorimetric 
assay for measuring phosphate release is the malachite green assay (Figure 6.3). The 
assay works by rapidly forming a coloured complex between malachite green, 
molybdate and phosphate in the presence of an acid. This coloured complex has an 
absorbance maximum at 600-660 nm and can be conveniently measured using a plate 
reader (Lanzetta et al., 1979). The advantages of the malachite green assay are that it 
is simple, very fast and highly sensitive, capable of measuring as little as 1.6 pmoles of 
phosphate. Therefore we decided to investigate this method. 
 
Figure 6.3: ATPase activity and the measurement of phosphate release by the malachite 
green assay. ATP is hydrolysed to ADP and Pi by ATPase activity. In the presence of acid, 
molybdate releases H2O and forms a complex with free Pi. The resulting phosphomolybdate 
complex associates with malachite green (MG) producing a colour change that is measured by 
absorbance in the range of 600-660 nm. 
 
Other methods to measure ATPase activity include using radioactive [γ-32P] ATP 
substrates and measuring the release of radioactive 32Pi (Seals et al., 1978). 
Fluorescent methods, for example the fluorescent reporter, E. coli phosphate binding 
protein (PBP) was conjugated to a fluorophore: N-[2-(1-maleimidyl)ethyl]-7-
(diethylamino)coumarin-3-carboxamide (MDCC) and in the presence of phosphate 
forms a complex resulting in increased fluorescence emission (Brune et al., 1994). 
Other available fluorescent methods use enzyme cascades that convert phosphate into 
different substrates resulting in the release of hydrogen peroxide, detected by a 
specific fluorescent probe (CellBiolabs). Alternatively ADP release can be measured, 
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for example in the ADP-GloTM assay, ATPase activity releases ATP that is converted to 
ATP by a kinase enzyme, the ATP produced is then converted by a luciferase enzyme 
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6.2 Hypotheses and Aims 
I hypothesised that the NBP Mtb UgpC could be expressed and purified in isolation 
without the membrane spanning subunits UgpA and UgpE. The protein could be 
purified to homogeneity using a combination of immobilised metal affinity and gel 
filtration chromatography, and its identity confirmed by mass spectrometry. In addition I 
hypothesised that the UgpC protein in the absence of the membrane spanning 
proteins, UgpA and UgpE would be a functional ATPase and I tested its activity using a 
malachite green ATPase assay. 
 
The specific aims of the work presented in this chapter were: 
• To clone, express and purify Mtb UgpC, the NBP of the UgpABCE ATP-binding 
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6.3 Results 
6.3.1 Cloning of ugpC-pET160Dest  
ugpC-pET160Dest had been cloned previously in the lab using the Gateway cloning 
method. The vector (Figure 6.4) encodes the T7 IPTG inducible promoter and the full 
length Mtb ugpC (Rv2832c) gene with an N-terminal hexa-His tag. The vector also 
encodes the ampicillin resistance gene for selection purposes. 
 
 
Figure 6.4: Mtb ugpC-pET160Dest plasmid map. Abbreviations: AmpR ampicillin resistance 
gene, ori origins of replication in E. coli. 
 
6.3.2 Expression of UgpC-pET160Dest  
The ugpC-pET160Dest construct was transformed into E. coli BL21 (DE3) competent 
cells, and incubated in 1 L of terrific broth containing ampicillin (100 µg/mL) with 
shaking at 180 rpm at 27 °C until optical density 0.6 was reached. Cells were induced 
by the addition of 1 mM IPTG and the culture temperature was lowered to 16 °C and 
expressed overnight. After expression the cells were suspended in UgpC buffer (300 
mM NaCl, 20 mM tris-HCl, 20 % glycerol, 5 mM ATP, pH 7.5) (Chapter 2, Table 2.1) 
lysed by sonication and the cell lysate was passed over a Ni2+ immobilised metal 
affinity (IMAC) column. The bound proteins were eluted with a step-wise imidazole 
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gradient (Figure 6.5) however expression was not observed. Mtb UgpC was not 
produced as soluble protein as no band at 39 kDa was observed. It may have not been 
expressed or was insoluble. Therefore in order to optimise soluble expression we tried 
















Figure 6.5: SDS-PAGE analysis of the expression of Mtb UgpC from E. coli BL21 (DE3). 
Elution of His6-tagged Mtb UgpB from a Ni2+ IMAC-column. M = molecular weight marker in 
kDa, S = soluble lysate, W = washes, FT = flow through, numbers 20 – 1000 refer to the 
imidazole concentration in the elution buffer (units of mM).  
 
 
6.3.3 Expression of UgpC-pET160Dest using different host strains 
To improve expression of Mtb UgpC-pET160Dest it was also transformed into BL21 
(DE3) pLysS cells, incubated in 100 mL of terrific broth culture media at 27 °C until 
optical density 0.6 was reached.  The cells were induced by the addition of either 0.1 or 
1 mM IPTG and expressed overnight at 16 °C. The cells after expression were 
suspended in UgpC buffer (300 mM NaCl, 20 mM tris-HCl, 20 % glycerol, 5 mM ATP, 
pH 7.5) (Chapter 2, Table 2.1) and lysed by sonication. The whole cell and soluble 
fractions were analysed by SDS-PAGE and Western blot (Chapter 2, 2.5.7) probed 
with a penta-His primary antibody and anti-mouse IgG alkaline phosphatase secondary 
antibody to investigate if the correct protein was expressed (Figure 6.6). Mtb UgpC 
expression could not be observed (Figure 6.6) at both IPTG concentrations or in E. coli 
BL21 (DE3) pLysS that control background protein expression through expression of 
T7 lysozyme. No expression was observed potentially because Mtb UgpC is 
membrane associated and previous studies have also found it is difficult to express 
NBP’s (Nikaido et al., 1997). 
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Figure 6.6: SDS-PAGE analysis and western blot of the expression of Mtb UgpC from E. 
coli. BL21 (DE3) and BL21 (DE3) pLysS A) SDS-PAGE analysis. M = molecular weight 
marker in kDa, UgpB = purified His6-tagged Mtb UgpB, WC = whole cell extract, S = soluble 
lysate, numbers 0.1 and 1.0 refer to the IPTG concentration (units of mM), expression strains 
are labeled. B) Western blot of A probed with a penta-His primary antibody, anti-mouse IgG 
alkaline phosphatase secondary antibody and detected with BCIP alkaline phosphatase 
substrate. 
 
6.3.4 Expression of UgpC-pET160Dest using different host strains and the 
addition of sorbitol: 
Osmolytes such as sorbitol have been used to improve soluble protein expression 
when added at high concentrations to the culture media (Prasad et al., 2011). In this 
experiment Mtb UgpC-pET160Dest was transformed into BL21 (DE3), BL21 (DE3) 
pLysS and T7 Shuffle competent cells. T7 Shuffle cells promote protein disulphide 
bond formation in the cytoplasm. As there are two cysteine residues in Mtb UgpC that 
potentially form a disulphide bridge these cells may promote soluble protein 
expression. The cells were incubated in 100 mL of terrific broth culture media 
containing 0.5 M sorbitol until they reached optical density 0.6. The cells were then 
induced by the addition of either 0.1 or 1 mM IPTG and incubated overnight at 16 °C. 
After expression, the cells were suspended in UgpC buffer (Chapter 2, Table 2.1) lysed 
by sonication and the whole cell and soluble fractions were analysed by SDS-PAGE 
however Mtb UgpC expression could still not be observed (Figure 6.7). Instead of 
optimising further we chose to investigate using a different construct (6.3.5). 
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Figure 6.7: SDS-PAGE analysis of the expression of Mtb UgpC from E. coli. M = molecular 
weight marker in kDa, UgpB = purified His6-tagged Mtb UgpB, WC = whole cell extract, S = 
soluble lysate, numbers 0.1 and 1.0 refer to the IPTG concentration (units of mM), expression 
strains are labeled, addition of sorbitol to the culture media is labeled.  
 
6.3.5 Cloning of ugpC-pWaldo 
Mtb ugpC-pWaldo was cloned previously in the lab. The plasmid (Figure 6.8) encodes 
the T7 IPTG inducible promoter and full length Mtb ugpC (Rv2832c) gene. The plasmid 
has a C-terminal TEV cleavable GFP tag for fluorescence detection. For purification 
purposes the plasmid has an octa-His tag. For selection purposes the plasmid has a 
kanamycin resistance gene. This was a potentially better expression vector because 
expression could be monitored by GFP fluorescence (Drew et al., 2001). Also by 
transforming the vector into E. coli Lemo21 cells the expression could be tuned using a 
L-rhamnose gradient to improve expression (Schlegel et al., 2012). 
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Figure 6.8: Mtb ugpC-pWaldo plasmid map. Abbreviations: KanR kanamycin resistance 
gene, f1 ori origin of replication in E. coli, GFP super folder green fluorescent protein. 
 
6.3.6 Green fluorescent protein standard curve 
To be able to calculate GFP expressed, a standard curve was produced (Figure 6.9) 
using purified GFP and measuring fluorescence in a plate reader at the following 
wavelengths, λex 485 nm λem 535 nm (Tecan Infinite F200, gain 35). Purified GFP was 
used because the concentration was known and therefore fluorescence emission could 
be used to estimate the concentration of the GFP protein expressed. From this curve, 1 
mg of GFP per L has 712 relative fluorescence units (RFU) at the measured gain of 35. 
For consistency a gain of 35 was used for all measurements. This standard curve was 
used to estimate the levels of Mtb UgpC-GFP protein expression in the L-rhamnose 
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Figure 6.9: GFP standard curve. λex 485 nm λem 535 nm (Tecan Infinite F200, gain 35). 
 
6.3.7 Expression of UgpC-pWaldo in E. coli Lemo21 (DE3) cells 
The UgpC-pWaldo construct was transformed into E. coli Lemo21 (DE3) cells and 
incubated in a small-scale trial in 5 mL of PASM-5052 media containing 
chloramphenicol (30 µg/mL) and kanamycin (50 µg/mL) (Chapter 2, Table 2.8) at 27 °C 
until optical density 0.6 was reached. At optical density 0.6, L-rhamnose was added to 
separate cultures to produce a L-rhamnose gradient from 0-1.0 mM (Table 6.1). The 
cultures were then either induced by addition of a single concentration of 0.4 mM IPTG 
or not induced, and incubated overnight at 16 °C. A single 0.4 mM IPTG concentration 
was used to evaluate the effect that different L-rhamnose concentrations had on 
protein expression. Following overnight expression GFP fluorescence of the whole 
cells was measured as described (Chapter 2, 2.5.3). The highest fluorescence reading 
of 39,294 RFU was observed for 0.1 mM L-rhamnose and 0.4 mM IPTG (Table 6.1). 
This fluorescence reading corresponded to approximately 9.5 mg of fluorescent protein 
per L of culture based on the GFP standard curve (Figure 6.9). As GFP fluorescence at 
the C-terminus normally indicates correct expressed protein folding this condition was 
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Table 6.1: L-rhamnose gradient expression of Mtb UgpC-GFP in E. coli. End-point optical 
density (OD600 nm) and fluorescence readings λex 485 nm λem 535 nm.  
 
IPTG (mM) L-rhamnose (mM) Optical density 
(OD600nm) 
Fluorescence  (RFU 
λex 485  λem 535 nm) 
0.4 0 0.177 19,129 
0.4 0.1 0.191 39,294 
0.4 0.25 0.207 32,739 
0.4 0.5 0.194 9,729 
0.4 0.75 0.194 4,816 
0.4 1.0 0.201 5,235 
0 0 0.201 12,327 
0 0.1 0.214 20,694 
0 0.25 0.194 25,097 
0 0.5 0.199 12,797 
0 0.75 0.190 6,402 
0 1.0 0.194 12,052 
Control Lemo Control Lemo 0.195 80 
Optical density readings are 1/20 dilution because 50 µL of cells were added to 950 µL PBS. 
Control Lemo refers to background fluorescence of E. coli Lemo21 cells that were not 
transformed with the construct. Red refers to the optimised expression condition. 
 
 
6.3.8 1 L expression and purification of UgpC-pWaldo in E. coli Lemo21 (DE3) 
cells 
Mtb UgpC-pWaldo E. coli Lemo21 was expressed in 1 L of PASM-5052 media 
containing chloramphenicol (30 µg/mL) and kanamycin (50 µg/mL) (Chapter 2, Table 
2.8) using the optimised condition (6.3.7) (Table 6.1) and induced with 0.4 mM IPTG 
and 0.1 mM L-rhamnose. Following expression the cells were suspended in UgpC 
buffer (Chapter 2, Table 2.1) and lysed by sonication and purified by affinity of the C-
terminal octa-His tag to a Ni2+ IMAC resin. Bound proteins were washed and eluted 
with a step-wise imidazole gradient and the fractions were analysed by SDS-PAGE 
(Figure 6.10). The expected Mtb UgpC-GFP fusion protein size was approximately 66 
kDa. After SDS-PAGE, in-gel fluorescence showed a low fluorescence signal at 66 kDa 
and 26 kDa (Figure 6.10B). However staining with Instant Blue indicated no expressed 
band visible at 66 kDa (Figure 6.10A). This result was unchanged following TEV 
cleavage of the GFP tag (Figure 6.10C and 6.10D). Despite the high level of GFP 
fluorescence most of this signal was due to free GFP being expressed. This is known 
to be a problem if the protein is incorrectly folded (Bird et al., 2015).  
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Figure 6.10: SDS-PAGE analysis and in-gel GFP fluorescence of the expression of Mtb 
UgpC-GFP from E. coli Lemo21 (DE3) cells. A) Elution of His6-tagged Mtb UgpC-GFP from a 
Ni2+ IMAC-column. M = molecular weight marker in kDa, numbers 5 – 1000 refer to the 
imidazole concentration in the elution buffer (units of mM). B) In-gel GFP fluorescence of A, λex 
473 nm λem 502 nm. C) Elution of His6-tagged TEV cleaved Mtb UgpC-GFP from a Ni2+ IMAC-
column. M = molecular weight marker in kDa, L = protein before TEV cleavage, TEV = protein 
after TEV cleavage, FT = flow through,  numbers 250 – 1000 refer to the imidazole 
concentration in the elution buffer (units of mM). D) In-gel GFP fluorescence  of C, λex 473 nm 
λem 502 nm.  
 
6.3.9 Cloning of ugpC-pYUB1062 and ugpC-pYUB1062-GFP 
A detailed procedure is described (Chapter 2, 2.3.3.2). Mtb ugpC was cloned into 
pYUB1062 and pYUB1062-GFP for expression in M. smegmatis. The difference 
between these constructs is that pYUB1062-GFP encodes a C-terminal GFP tag for 
monitoring protein expression. 
 
Mtb ugpC was amplified from Mtb H37Rv genomic DNA using gene specific primers 
(Chapter 2, Table 2.2). Following amplification by PCR (Figure 6.11A and 6.12A), the 
restriction enzymes NdeI and HindIII were used to digest the PCR product and vectors 
at 37 °C for 3 hours. The digested products were then ligated with a 3:1 ratio of vector: 
insert DNA at 22 °C for 1 hour. The ligation products were transformed into E. coli 
Top10 and plated onto LB agar containing hygromycin (150 µg/mL) and incubated at 
37 °C for 16 hours. Colonies that had formed after 16 hours were picked. PCR of each 
colony using vector specific primers (Chapter 2, Table 2.2) was used to determine if 
ligation had been successful. Six out of six colonies of Mtb ugpC-pYUB1062 E. coli 
Top10 screened were found to contain the Mtb ugpC insert (Figure 6.11B) and five out 
of five colonies of Mtb ugpC-pYUB1062-GFP E. coli Top10 screened were found to 
contain the Mtb ugpC insert (Figure 6.12B). The colonies were incubated in LB media 
containing hygromycin (150 µg/mL) and the plasmids were isolated (Chapter 2, 2.3.4). 
The plasmid from colony 3 (Figure 6.11B) and colony 4 (Figure 6.12B) were 
sequenced using vector specific primers (Chapter 2, Table 2.3) and found to have the 
correct ugpC insert sequences (Figure 6.13) (Figure 6.14). 
 Chapter 6: Cloning, expression and purification of Mycobacterium tuberculosis UgpC 
and UgpAE	  
 




Figure 6.11: PCR amplification of ugpC and colony PCR of ugpC-pYUB1062. A) The ugpC 
gene was amplified from Mtb H37Rv genomic DNA using the primers 5’-
aaaacatatggctaacgttcagt-3’ and 5’- aaaaaagcttgcgaagccgggtc-3’. The restriction enzyme sites 
are shown in italics. The PCR mixture contained: Q5 DNA polymerase (NEB), Q5 DNA 
polymerase buffer, 0.2 mM dNTP’s, 6 % (v/v) DMSO and 0.5 µM forward and reverse primers. 
The PCR cycle consisted of: denaturation (98 °C, 30 s) followed by 30 cycles of annealing 
gradient (64-80 °C, 30 s), extension (72 °C, 90 s), followed by a final extension step (72 °C, 5 
min). 20 µL of 50 µL PCR mixtures were loaded per lane onto a 1 % (v/v) agarose gel. M refers 
to 1 Kbp DNA ladder (Invitrogen). B) PCR of each colony using the specific primers (Chapter 2, 







Figure 6.12: PCR amplification of ugpC and colony PCR of ugpC-pYUB1062-GFP. A) The 
ugpC gene was amplified from Mtb H37Rv genomic DNA using the primers 5’- 
aaaacatatggctaacgttcagt-3’ and 5’-aaaaaagctttgcgaagccgggt-3’. The restriction enzyme sites 
are shown in italics. The PCR mixture contained: Q5 DNA polymerase (NEB), Q5 DNA 
polymerase buffer, 0.2 mM dNTP’s, 6 % (v/v) DMSO and 0.5 µM forward and reverse primers. 
The PCR cycle consisted of: denaturation (98 °C, 30 s) followed by 30 cycles of annealing 
gradient (64-80 °C, 30 s), extension (72 °C, 90 s), followed by a final extension step (72 °C, 5 
min). 20 µL of 50 µL PCR mixtures were loaded per lane onto a 1 % (v/v) agarose gel. M refers 
to 1 Kbp DNA ladder (Invitrogen). B) PCR of each colony using the specific primers (Chapter 2, 
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Figure 6.13: Mtb UgpC-pYUB1062 plasmid map. Abbreviations: HygR hygromycin resistance 
gene, f1 ori and f1 ori origins of replication in E. coli and Mycobacteria. 
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Figure 6.14: Mtb UgpC-pYUB1062-GFP plasmid map. Abbreviations: HygR hygromycin 
resistance gene, ori and f1 ori origins of replication in E. coli and Mycobacteria, GFP superfolder 
green fluorescent protein. 
 
6.3.10 Expression and purification of UgpC-pYUB1062 
The ugpC-pYUB1062 construct was electroporated into M. smegmatis MC24517 
electro-competent cells (Chapter 2, 2.3.11) and incubated in 1 L of LBGT media 
(Chapter 2, Table 2.8) at 37 °C until optical density 0.6 was reached. The cells were 
induced by the addition of 0.2 % acetamide and further incubated overnight at 37 °C. 
 
Following expression the cells were suspended in UgpC buffer (Chapter 2, Table 2.1), 
lysed by sonication and the expressed proteins were purified by affinity of the C-
terminal hexa-histidine tag to a Ni2+ IMAC resin. Proteins that were bound to the IMAC 
column were washed and eluted with a step-wise imidazole gradient and fractions were 
analysed by SDS-PAGE (Figure 6.15). The expected Mtb UgpC protein size was 
approximately 39 kDa. After SDS-PAGE analysis there was no expressed band visible 
at 39 kDa (Figure 6.15). This result suggested that expressing Mtb UgpC in the more 
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closely related M. smegmatis host did not improve expression unlike the result 











Figure 6.15: SDS-PAGE analysis of the expression of Mtb UgpC from M. smegmatis. 
Elution of His6-tagged Mtb UgpC from a Ni2+ IMAC-column. M = molecular weight marker in 
kDa, I = insoluble fraction, S = soluble lysate, FT = flow through, W = wash, numbers 5 – 1000 
refer to the imidazole concentration in the elution buffer (units of mM).  
 
6.3.11 Expression and purification of UgpC-pYUB1062-GFP 
The ugpC-pYUB1062-GFP construct was electroporated into M. smegmatis MC24517 
cells (Chapter 2, 2.3.11), incubated in 1 L of LBGT media (Chapter 2, Table 2.8) at 37 
°C until optical density 0.6 was reached. The cells were induced by the addition of 0.2 
% acetamide and further incubated overnight at 37 °C. The GFP fluorescence of the 
whole cells (Chapter 2, 2.5.3) after expression was 21,194 RFU and corresponded to 
approximately 5.1 mg of protein per L of culture based on the GFP standard curve 
(Figure 6.9). 
 
Following expression the cells were suspended in UgpC buffer (Chapter 2, Table 2.1), 
lysed by sonication and the expressed proteins were purified by affinity of the C-
terminal hexa-histidine tag to a Ni2+ IMAC resin. Proteins that were bound to the IMAC 
column were washed and eluted with a step-wise imidazole gradient and fractions were 
analysed by SDS-PAGE (Figure 6.16). The expected Mtb UgpC-GFP fusion protein 
size was approximately 66 kDa. In-gel fluorescence (Figure 6.16B) revealed a low 
fluorescence signal at 66 kDa however a larger band was found at approximately 26 
kDa that was likely to be free-GFP. This result was similar to UgpC-pWaldo expressed 
in E. coli Lemo21 cells. SDS-PAGE analysis revealed a band at approximately 66 kDa 
(Figure 6.16A). The 50-250 mM imidazole fractions containing the 66 kDa band were 
combined and passed over a Superdex 200 gel filtration chromatography column. 
However several contaminants co-eluted (Figure 6.16C) with the 66 kDa protein and it 
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was found to be low abundant (Figure 6.16D). This result confirmed that using an 
alternative more closely related M. smegmatis host to express Mtb UgpC was not 
successful under these conditions.  
 
 
Figure 6.16: SDS-PAGE analysis and in-gel GFP fluorescence of the expression of Mtb 
UgpC-GFP from M. smegmatis. A) Elution of His6-tagged Mtb UgpC-GFP from a Ni2+ IMAC-
column. M = molecular weight marker in kDa, I = insoluble fraction, S = soluble lysate, FT = flow 
through, W = wash, numbers 5 – 1000 refer to the imidazole concentration in the elution buffer 
(units of mM). B). In-gel GFP fluorescence of A, λex 473 nm λem 502 nm. C) Size exclusion 
chromatography of Mtb UgpC-GFP following a Ni2+ IMAC-column with the volumes shown as 
corresponding to D. L = protein before loading. D) Size exclusion trace of Mtb UgpC-GFP. 
 
6.3.12 Cloning of ugpC-pETSUMO  
Therefore the SUMO solubility tag was investigated, which has been successful for 
enhancing prokaryote protein expression (Peroutka Iii et al., 2011). A construct of 
ugpC-pETSUMO was not readily available therefore it was cloned. A detailed 
procedure is described (Chapter 2, 2.3.3.3). 
 
Mtb ugpC was amplified from Mtb H37Rv genomic DNA using specific primers 
(Chapter 2, Table 2.2). Following amplification by PCR (Figure 6.17A), the restriction 
enzymes BamHI and HindIII were used to digest the PCR product and vector at 37 °C 
for 3 hours. The digested products were then ligated with a 3:1 ratio of vector: insert 
DNA at 22 °C for 1 hour. The ligation products were transformed into E. coli Top10 and 
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plated onto LB agar containing kanamycin (50 µg/mL) and incubated at 37 °C for 16 
hours. Colonies that had formed after 16 hours were picked. PCR of each colony using 
specific primers (Chapter 2, Table 2.2) was used to determine if ligation had been 
successful. Six out of six colonies of Mtb ugpC-SUMO E. coli Top10 screened were 
found to contain the Mtb ugpC-SUMO insert (Figure 6.17B). The colonies were 
incubated in LB media containing kanamycin (50 µg/mL) and the plasmids were 
isolated (Chapter 2, 2.3.4). Sequenced of the plasmid from colony 2 confirmed it was 





Figure 6.17: PCR amplification of ugpC and colony PCR of ugpC-pETSUMO. A) The ugpC 
gene was amplified from Mtb H37Rv genomic DNA using the primers 5’-
aaaaggatccatggctaacgttc-3’ and 5’-aaaaaagctttcagcgaagccgg-3’. The restriction enzyme sites 
are shown in italics. The PCR mixture contained: Q5 DNA polymerase (NEB), Q5 DNA 
polymerase buffer, 0.2 mM dNTP’s, 6 % (v/v) DMSO and 0.5 µM forward and reverse primers. 
The PCR cycle consisted of: denaturation (98 °C, 30 s) followed by 30 cycles of annealing 
gradient (68-80 °C, 30 s), extension (72 °C, 90 s), followed by a final extension step (72 °C, 5 
min). 20 µL of 50 µL PCR mixtures was loaded per lane onto a 1 % (v/v) agarose gel. M refers 
to 1 Kbp DNA ladder (Invitrogen). B) PCR of each colony using the specific primers (Chapter 2, 
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Figure 6.18: Mtb ugpC-pETSUMO plasmid map. Abbreviations: KanR kanamycin resistance 
gene, f1 ori origin of replication in E. coli, SUMO small ubiquitin-like modifier tag. 
 
6.3.13 Expression and purification of UgpC-pETSUMO 
The construct was transformed in E. coli BL21 (DE3) competent cells, incubated in 1 L 
of terrific broth at 27 °C until optical density 0.6 was reached. The cells were induced 
with 1 mM IPTG and further incubated overnight at 16 °C. 
 
Following expression the cells were suspended in UgpC buffer (Chapter 2, Table 2.1) 
and lysed by sonication and the expressed proteins were purified by affinity of the N-
terminal hexa-histidine tag to a Ni2+ IMAC resin. Bound proteins were washed and 
eluted with a step-wise imidazole gradient and fractions were analysed by SDS-PAGE 
(Figure 6.19). The expected Mtb UgpC-SUMO fusion protein size was approximately 
50 kDa however only a small amount of the correct expressed protein was found in the 
gel (Figure 6.19A). The imidazole elution fractions (50-1000 mM) were combined and 
dialysed to remove the imidazole because imidazole can interfere with protease 
cleavage of the SUMO-tag. The dialysed fractions were then cleaved with a SUMO 
protease (2 mg/mL, 30 °C, 1 hour) and the digested protein was passed over a second 
Ni2+ IMAC column to remove the hexa-his SUMO tag (6.20B). A small amount of the 
Mtb UgpC protein was identified by the gel at approximately 39 kDa in the flow through 
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and wash step however a 60 kDa contaminant protein remained (Figure 6.19B). To 
increase the purity of the protein it was concentrated by ultrafiltration to 2 mL and 
passed over a Superdex 200 gel filtration chromatography column. However after gel 
filtration chromatography only a small amount of the 39 kDa protein was observed 
(Figure 6.19C). The protein was concentrated to 0.24 mg/ mL and stored at -80 °C 
prior to analyses. 
 
Figure 6.19: SDS-PAGE analysis of the purification of Mtb UgpC from E. coli. A) Elution of 
His6-tagged Mtb UgpC from a Ni2+ IMAC-column. M = molecular weight marker in kDa, I = 
insoluble fraction, S = soluble lysate, FT = flow through, numbers 5 – 1000 refer to the 
imidazole concentration in the elution buffer (units of mM). B). Elution of His6-tagged SUMO 
protease cleaved Mtb UgpC from a Ni2+ IMAC-column. M = molecular weight marker in kDa, L1 
= protein after dialysis, L2 = protein after SUMO protease cleavage, FT = flow through, W = 
washes, numbers 250 – 1000 refer to the imidazole concentration in the elution buffer (units of 
mM). C) Size exclusion chromatography of Mtb UgpC following a Ni2+ IMAC-column with the 
volumes shown. 
 
6.3.14 Mass spectrometry of UgpC-pETSUMO 
The identity of the 39 kDa protein was successfully confirmed to be Mtb UgpC by in-gel 
trypsin digest mass spectrometry (Figure 6.20). 33 exclusive unique peptides, 61 
exclusive unique spectra, 225 total spectra, 241/360 amino acids (67 % coverage). 
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Figure 6.20: In-gel trypsin digest mass spectrometry of Mtb UgpC. Band extracted from 
figure 6.20C). Sequences highlighted in yellow indicate coverage of the peptides identified. 
 
 
6.3.15 Large-scale expression of UgpC-pETSUMO 
In order to increase the yield and purity of Mtb UgpC a larger 10 L culture was 
expressed using the same method (6.3.13). 
 
6.3.16 Large-scale purification of UgpC-pETSUMO 
The expressed proteins were purified as before (6.3.13). To increase the purity of the 
protein it was concentrated and passed over a Superdex 200 gel filtration 
chromatography column however several contaminant bands were still found (Figure 
6.21C) therefore we decided to investigate the identity of these contaminants by mass 
spectrometry (6.3.17). The protein was concentrated to 1.05 mg/mL and stored at -80 
°C prior to analyses. 
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Figure 6.21: SDS-PAGE analysis of the purification of Mtb UgpC from E. coli. A) Elution of 
His6-tagged Mtb UgpC from a Ni2+ IMAC-column. M = molecular weight marker in kDa, I = 
insoluble fraction, S = soluble lysate, FT = flow through, W = washes, numbers 5 – 1000 refer to 
the imidazole concentration in the elution buffer (units of mM). B). Elution of His6-tagged SUMO 
protease cleaved Mtb UgpC from a Ni2+ IMAC-column. M = molecular weight marker in kDa, L1 
= protein after dialysis, L2 = protein after SUMO protease cleavage, FT = flow through, W = 
washes, numbers 250 – 1000 refer to the imidazole concentration in the elution buffer (units of 
mM). C) Size exclusion chromatography of Mtb UgpC following a Ni2+ IMAC-column with the 
volumes shown as corresponding to D. D) Size exclusion trace of Mtb UgpC. 
 
6.3.17 Mass spectrometry of UgpC-pETSUMO and contaminant proteins 
In total 5 of the most abundant protein bands (Figure 6.21C) were analysed by in-gel 
trypsin digest mass spectrometry (Figure 6.22). The 69 kDa protein was identified to be 
a chaperone DnaK: 73 exclusive unique peptides, 143 exclusive unique spectra, 791 
total spectra, 552/638 amino acids (87 % coverage). The 43 kDa protein was identified 
to be elongation factor tu tufA: 49 exclusive unique peptides, 109 exclusive unique 
spectra, 621 total spectra, 379/394 amino acids (96 % coverage). The 39 kDa protein 
was identified to be Mtb UgpC: 35 exclusive unique peptides, 108 exclusive unique 
spectra, 805 total spectra, 285/360 amino acids (79 % coverage). The 25 kDa protein 
was identified to be 30S ribosomal protein rpsC: 24 exclusive unique peptides, 37 
exclusive unique spectra, 74 total spectra, 208/233 amino acids (89 % coverage). The 
16 kDa protein was identified to be ferric uptake regulator protein fur: 23 exclusive 
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unique peptides, 51 exclusive unique spectra, 338 total spectra, 148/148 amino acids 
(100 % coverage). The identities of these proteins did not suggest they interacted with 
Mtb UgpC however they may have co-eluted due to the high concentration of glycerol 
and ATP present in the UgpC buffer. 
 
 
Figure 6.22: In-gel trypsin digest mass spectrometry of Mtb UgpC and contaminants. 
Bands extracted from Figure 6.21. Sequences highlighted in yellow indicate coverage of the 
peptides identified. 
 
In conclusion the Mtb UgpC nucleotide binding protein of the UgpABCE transporter 
was successfully expressed and its identity was confirmed by mass spectrometry. 
Despite its purity being low it was used to investigate enzymatic activity (6.3.18) 
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6.3.18 UgpC malachite green phosphate assay 
ATPase activity was investigated using a malachite green phosphate assay (Sigma 
Aldrich). In the assay, phosphate release from ATP hydrolysis results in the formation 
of a green colour complex between malachite green, molybdate and orthophosphate 
that can be measured by spectrophotometry (Figure 6.3). Firstly a standard curve was 
produced by dissolving the orthophosphate standard at different concentrations in 
assay buffer: 300 mM NaCl, 20 mM tris-HCl, 1 mM MgCl2, 4 % glycerol (Figure 6.23). 
20 µL of the malachite green assay reagent was added to 80 µL of orthophosphate 
standard and incubated at room temperature for 30 minutes prior to measuring 
absorbance at 595 nm as described (Chapter 2, 2.5.13). 
 
 
Figure 6.23: Malachite green phosphate standard curve.  
 
The Mtb UgpC protein was dialysed into assay buffer (300 mM NaCl, 20 mM tris-HCl, 1 
mM MgCl2, 4 % glycerol) to remove the excess 5 mM ATP included throughout the 
purification steps and concentrated by ultrafiltration (10 kDa MWCO) to 0.6 mg/mL. In a 
96-well plate, 80 µL of Mtb UgpC (0.6 mg/mL) and 0.1 mM ATP were added. Protein 
only and buffer only controls were also included. All of the reactions were incubated at 
37 °C at 300 rpm for 3 hours. At selected time intervals, 20 µL of the malachite green 
assay reagent was added to stop the reactions and incubated at room temperature for 
30 minutes to allow the colour to develop before measuring absorbance at 595 nm 
(Figure 6.24).  The results indicated that Mtb UgpC + 0.1 mM ATP showed a greater 
absorbance compared to the protein only and buffer only controls, suggesting that ATP 
was being hydrolysed (Figure 6.24). However it’s not clear why there was an increase 
in absorbance for the protein only control, it’s possible that some ATP was still present 

















Y = 0.01206*X + 0.1083
 Chapter 6: Cloning, expression and purification of Mycobacterium tuberculosis UgpC 
and UgpAE	  
 
	   218 
in the protein despite dialysis therefore the assay needs to be further optimised. As the 
protein preparation also contained E. coli DnaK, a chaperone known to have ATPase 
activity (Liberek et al., 1991) the purification needs to be optimised in order to confirm 
that Mtb UgpC is responsible for the observed ATPase activity. This assay was only 
carried out once. The assay would need to be repeated at least 3 times to show 
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6B 
6.4 Introduction 
6.4.1 What do we know about Mtb UgpA and Mtb UgpE  
We also wanted to express and purify Mtb UgpA (Rv2835c) and Mtb UgpE (Rv2834c), 
the two membrane spanning proteins of the UgpABCE transporter (Figure 6.1). This 
would facilitate crystal trials in order to determine the structure of Mtb UgpAE and aid in 
efforts to reconstitute the entire transporter. As elucidating the structure of Mtb UgpAE 
may reveal important features about the substrate transport mechanism.  
 
Outside of the Mycobacteria genus the highest amino acid sequence similarity to Mtb 
UgpA and Mtb UgpE is the carbohydrate ABC transporter, membrane protein 1 of the 
CUT1 family from Clotridioides difficile (72.5 %), and the binding-protein-dependent 
transport system, inner membrane protein of Clotridioides difficile (69 %) respectively. 
This initially suggested that the Mtb UgpABCE transporter imports carbohydrates, 
however this is likely not the case because we found that the substrate binding protein, 
Mtb UgpB binds preferentially to glycerophosphodiesters (Chapter 4 and 5). 
 
Topology mapping using Protter v1.0 (Omasits et al., 2014) predicted that Mtb UgpA 
and Mtb UgpE are both integral membrane proteins. Each is made up of 6 
transmembrane helices and both the N- and C- termini are found intracellularly (Figure 
6.25). As integral membrane proteins, Mtb UgpA and Mtb UgpE are anticipated to be 
difficult to express and purify (Schlegel et al., 2014). Therefore we chose to clone Mtb 
ugpAE in the pWaldo vector and express in E. coli Lemo21 (DE3) cells as this system 
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Figure 6.25: Predicted topology of Mtb UgpAE mapped using Protter v1.0 (Omasits et al., 
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6.5 Hypotheses and Aims 
I hypothesised that the membrane spanning proteins, UgpA and UgpE could be 
expressed using the same origin of replication in the pWaldo vector using an L-
rhamnose tuneable E. coli cell expression system. I tested this hypothesis by 
measuring GFP fluorescence to report protein expression. 
 
The specific aims of the work presented in this chapter were: 
• To clone, express and purify Mtb UgpAE, the membrane-spanning proteins of 
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6.6 Results 
6.6.1 Cloning of ugpAE-pWaldo 
A detailed cloning procedure is described (Chapter 2, 2.3.3.4). Mtb ugpAE was 
amplified from Mtb H37Rv genomic DNA using specific primers (Chapter 2, Table 2.2). 
Following amplification by PCR (Figure 6.26A), the restriction enzymes NdeI and 
BamHI were used to digest the PCR product and vector at 37 °C for 3 hours. The 
digested products were then ligated with a 3:1 ratio of vector: insert DNA at 22 °C for 1 
hour. The ligation products were transformed into E. coli Top10 and plated onto LB 
agar containing kanamycin (50 µg/mL) and incubated at 37 °C for 16 hours. Colonies 
that had formed after 16 hours were picked. PCR of each colony using specific primers 
(Chapter 2, Table 2.2) was used to determine if ligation had been successful. Six out of 
six colonies of Mtb UgpAE-pWaldo E. coli Top10 screened were found to contain the 
Mtb UgpAE insert. The colonies were grown in LB media containing kanamycin (50 
µg/mL) and the plasmids were isolated (Chapter 2, 2.3.4). The plasmid from colony 5 





Figure 6.26: PCR amplification of ugpAE and colony PCR of ugpAE-pWaldo. A) The 
ugpAE gene was amplified from Mtb H37Rv genomic DNA using the primers 5’-
aaaaaacatatggcggcgccgca-3’ and 5’-ttttttggatcctcccttgaccg-3’. The restriction enzyme sites are 
shown in italics. The PCR mixture contained: Q5 DNA polymerase (NEB), Q5 DNA polymerase 
buffer, 0.2 mM dNTP’s, 6 % (v/v) DMSO and 0.5 µM forward and reverse primers. The PCR 
cycle consisted of: denaturation (98 °C, 30 s) followed by 30 cycles of annealing gradient (72-82 
°C, 30 s), extension (72 °C, 90 s), followed by a final extension step (72 °C, 5 min). 20 µL of 50 
µL PCR mixtures was loaded per lane onto a 1 % (v/v) agarose gel. M refers to 1 Kbp DNA 
ladder (Invitrogen). B) PCR of each colony using the specific primers (Chapter 2, 2.3.3.4) were 
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Figure 6.27: Mtb UgpAE-pWaldo plasmid map. Abbreviations: KanR kanamycin resistance 
gene, f1 ori origin of replication in E. coli, GFP super folder green fluorescent protein. 
 
6.6.2 Expression and purification of UgpAE-pWaldo 
The ugpAE-pWaldo construct was transformed into E. coli Lemo21 (DE3) cells. The C-
terminal GFP tag was used to monitor expression. The cells were incubated in a small-
scale 5 mL PASM-5052 media containing chloramphenicol (30 µg/mL) and kanamycin 
(50 µg/mL)  (Chapter 2, Table 2.8) at 27 °C until optical density 0.6 was reached. At 
optical density 0.6, L-rhamnose was added to separate cultures to produce a L-
rhamnose gradient from 0-1.0 mM (Table 6.2). The cultures were then either induced 
by addition of a single concentration of 0.4 mM IPTG or not induced, and incubated 
overnight at 16 °C. A single 0.4 mM IPTG concentration was used to evaluate the 
effect that different L-rhamnose concentrations had on protein expression. Following 
overnight expression GFP fluorescence of the whole cells was measured as described 
(Chapter 2, 2.5.3). The fluorescence was found to be low in all the conditions tested 
(Table 6.2). To investigate protein expression the cells from conditions highlighted in 
red (Table 6.2) were suspended in UgpAE purification buffer (Chapter 2, Table 2.1), 
lysed by sonication and the whole cell and soluble fractions were analysed by in-gel 
fluorescence and SDS-PAGE (Figure 6.28). The approximate 90 kDa UgpAE-GFP 
protein could not be identified indicating that expression was not successful. This could 
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be due to the toxic effects of expressing an integral membrane protein in E. coli. Due to 
time, further optimisation was not possible.  
 
Table 6.2: L-rhamnose gradient expression of Mtb UgpAE-GFP in E. coli. End-point optical 
density (OD600 nm) and fluorescence readings λex 485 nm λem 535 nm.  
 
IPTG (mM) L-rhamnose (mM) Optical density 
(OD600nm) 
Fluorescence  (RFU 
λex 485  λem 535 nm) 
0.4 0 0.182 251 
0.4 0.1 0.196 103 
0.4 0.25 0.205 94 
0.4 0.5 0.189 90 
0.4 0.75 0.192 79 
0.4 1.0 0.182 70 
0 0 0.193 223 
0 0.1 0.18 168 
0 0.25 0.181 149 
0 0.5 0.187 124 
0 0.75 0.195 103 
0 1.0 0.182 95 
Control Lemo Control Lemo 0.187 80 
Optical density readings are 1/20 dilution because 50 µL of cells were added to 950 µL PBS. 
Control Lemo refers to background fluorescence of E. coli Lemo21 cells that were not 




Figure 6.28: SDS-PAGE analysis and in-gel GFP fluorescence of the expression of Mtb 
UgpC and Mtb UgpAE from E. coli. A) SDS-PAGE analysis of whole cell extracts. M = 
molecular weight marker in kDa, + = 0.4 mM IPTG, Rh = L-rhamnose concentration (mM). B) In-
gel GFP fluorescence of A , λex 473 nm λem 502 nm. 
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6.7 Discussion 
The aim of this chapter was to express and purify the NBP Mtb UgpC, and to 
investigate if it is a functional ATPase. An additional aim was to express and purify the 
membrane spanning proteins Mtb UgpAE. To attempt to express Mtb UgpC a range of 
different conditions were tested, these included: using different host strains including E. 
coli BL21 (DE3), pLysS, T7 Shuffle and the more closely related M. smegmatis host. 
Different IPTG concentrations were used and the osmolyte, sorbitol was added to the 
media. Different expression systems including a L-rhamnose tuneable expression 
system was used. GFP tags were used to monitor protein expression and the SUMO 
solubility enhancement tag was also used. 
 
From these studies we found we were able to successfully express Mtb UgpC with an 
N-terminal SUMO tag in E. coli (6.3.16), which was confirmed by mass spectrometry 
(6.3.17). However disappointingly, purification of Mtb UgpC proved to be difficult as 
several contaminants co-eluted following gel filtration chromatography. Previous 
studies have also had difficulties expressing NBP’s. For example HisP, the histidine 
permease NBP from Salmonella typhimurium (Nikaido et al., 1997), FbpC the NBP 
putative iron transporter from Neisseria gonorrhoaea (Lau et al., 2004) and MalK the 
NBP of the maltose transporter from Salmonella typhimurium (Schneider et al., 1995). 
In these studies it was found that including at least 2 mM of ATP and up to 50 % 
glycerol throughout the purification procedures greatly improved protein stability and 
prevented protein aggregation. This is possibly due to the requirement of NBP’s to be 
stable with ATP bound and the effect of glycerol disrupting hydrophobic interactions. 
Therefore we decided to include 5 mM ATP and 20 % glycerol in the buffer during cell 
lysis and protein purification. However, in hindsight the high concentration of ATP and 
glycerol may have contributed towards contaminant co-elution and further work will 
require optimising the buffer.  
 
Despite the low purity of Mtb UgpC we decided to investigate ATPase activity using the 
malachite green phosphate assay. Only a small number of studies have measured 
ATPase activity of prokaryote NBP’s from ABC transporters (Nikaido et al., 1997) (Lau 
et al., 2004) (E. Schneider et al., 1995). However the studies found that addition of 
Mg2+ or alternative divalent metals including Co2+ and Mn2+ were required for optimal 
ATPase activity. Therefore we decided to include 1 mM MgCl2 in the assay buffer. 
From the malachite green phosphate assay we found that phosphate release was 
higher in the presence Mtb UgpC and ATP compared to ATP without Mtb UgpC 
present, suggesting that Mtb UgpC did have some ATPase activity (6.3.18). As the 
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assay was only carried out once it would need to be repeated at least 3 times to 
confirm ATPase activity.  However, as the Mtb UgpC protein preparation was impure 
and also contained a chaperone, E. coli DnaK that is known to hydrolyse ATP (Liberek 
et al., 1991) further purification is required to remove this contaminant. The assay also 
requires further optimisation because it was unclear why Mtb UgpC alone produced an 
increased absorbance signal despite extensive dialysis to remove the 5 mM ATP 
present in the purification buffer. Another problem may be due to high acidity of the 
assay liberating free phosphate from ATP in the absence of ATPase enzymatic activity. 
Instead it may be advantageous to use alternative methods to measure ATPase 
activity for example fluorescent methods have been reported (Brune et al., 1994) that 
may be more stable and sensitive compared to this colorimetric assay. Alternatively 
ADP release instead of phosphate release could be measured to report ATPase 
activity, using enzyme coupled systems and luminescent reagents (Zegzouti et al., 
2009). 
 
We also attempted to express and purify the predicted membrane spanning proteins 
Mtb UgpA and Mtb UgpE of the Mtb UgpABCE transporter. Being integral membrane 
proteins they are potentially more challenging to express because they may be toxic 
and more challenging to purify because detergents need to be added to stabilise and 
mimic the lipid environment (Schlegel et al., 2014). Expressing integral membrane 
proteins in the pWaldo vector in E. coli Lemo21 (DE3) cells and using a tuneable L-
rhamnose gradient has previously found to be effective (Drew et al., 2001). Therefore 
we cloned the combined Mtb ugpAE genes into pWaldo and expressed it in this 
system, however, no expression was observed and only low GFP fluorescence was 
observed in all conditions tested. Instead a better system may have been to use the 
pDuet vector (Novagen) that has two multiple cloning sites containing different origins 
of replication to independently co-express Mtb UgpA and Mtb UgpE in the same 
plasmid. A previous study successfully expressed 70 Mtb integral membrane proteins 
in pET vectors (Korepanova et al., 2005). One of the strategies to express Mtb integral 
membrane proteins was to use the E. coli BL21 (DE3) Codon Plus-RP (Stratagene) 
strain that is designed to compensate for the codon usage differences of Mtb and E. 
coli (Korepanova et al., 2005). The difficulty of solving Mtb integral membrane protein 
structures is partly due to the difficulty in purifying sufficient quantities of protein. This is 
reflected by the observation of only a single X-ray structure of an integral membrane 
Mtb protein is available (PDB ID 2OAD), the Mtb mechanosensitive channels of large 
(MscL), reported at 3.5 Å resolution (G. Chang et al., 1998). 
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Previous studies have demonstrated it is possible to express and purify the membrane 
spanning proteins of ABC transporters (Wuttge et al., 2012). For example the E. coli 
UgpAEC2 complex consisting of the two membrane spanning proteins and UgpC, the 
NBP were co-expressed in pET vectors under the control of the T7 promoter in E coli. 
The membrane protein complex was isolated from membranes and extracted with the 
detergent n-dodecyl-B-D-maltoside and purified by Ni2+ IMAC and gel filtration 
chromatography. The purified complex was re-constituted into proteoliposomes and 
was found to have ATPase activity (Wuttge et al., 2012). Therefore another more 
effective strategy may be to express the Mtb UgpA and Mtb UgpE the membrane 
spanning proteins together with the Mtb UgpC NBP as a complex. Also instead of 
using detergents for membrane protein purification, styrene maleic acid co-polymers 
(SMALPS) could be used to stabilise the complex because it would remain in the 
natural membrane environment (Gulati et al., 2014). 
 
Previous studies of the E. coli maltose ABC transporter have been used to model the 
alternating access transport mechanism of type I ABC transporters (Locher, 2016). 
UgpABCE is also a predicted type I ABC transporter and therefore may undergo a 
similar transport mechanism to the maltose ABC transporter. This mechanism utilises 
ATP hydrolysis activity of the NBP dimer and substrate binding to the SBP in order to 
transport the substrate across the membrane. However, to prevent depleting the cell of 
ATP, the transport mechanism is closely coupled to substrate binding by the SBP so 
that ATP is not used in the absence of substrate.  
 
Initially, the transporter exists in the inward facing conformation (Figure 6.29 (1)). The 
SBP present in the periplasm binds to its cognate substrate and adopts a closed 
conformation. The closed substrate bound SBP then engages with the external side of 
the transporter. Engagement of the SBP to the transporter triggers a conformational 
change that results in the NBP dimer closing (Figure 6.29 (2)). Because the NBP dimer 
is attached to the transmembrane domains, closure also converts the transporter to the 
outward facing conformation. A tunnel forms between the SBP and the transmembrane 
domains with the substrate bound in a temporary low affinity-binding site, half way 
across the membrane. In the final step, the closed NBP dimer hydrolyses ATP to ADP 
and inorganic phosphate resulting in a conformational change in the NBP to the inward 
facing conformation. This opens the transporter and enables the substrate to dissociate 
into the cytoplasm (Figure 6.29 (3)). In order for the cycle to reset, ADP is exchanged 
for ATP, priming the transporter to bind to the substrate bound SBP and the transport 
cycle is then repeated. 
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Figure 6.29: The predicted transport mechanism of the type I UgpABCE transporter 
(Locher, 2016). Green and yellow represent the transmembrane domains (TMD). Pink and 
purple represent the nucleotide binding proteins (NBP). Orange represents the substrate 
binding protein (SBP). Dark blue represents the substrates. 
 
Therefore in the absence of the transmembrane domains, the UgpC NBP dimer in 
isolation is likely to be separated and not possess ATPase activity. A better 
experimental approach to investigate ATPase activity would be to express and purify 
the transmembrane domains together with the NBP and purify the membrane complex 
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Conclusions 
Overall the aim of this PhD was to carry out an extensive structural and functional 
analysis of the substrate-binding protein Mtb UgpB. The specific aims are described 
(Chapter 1, 1.3). Summaries of the key achievements from each chapter are described 
here. 
 
Chapter 3: Cloning, expression and purification of Mycobacterium tuberculosis 
UgpB. 
The substrate-binding protein, Mtb ugpB (Rv2833c) of the Mtb ugpABCE transporter 
was successfully expressed and purified to homogeneity. To do this, N-terminally 
truncated Mtb UgpB (residues 1-34) was expressed in pYUB1062 under the control of 
the acetamidase promoter in the more closely related host, Mycobacterium smegmatis 
mc24517. The expression yielded approximately 1.1 mg of protein per L culture and 
was sufficient to carry out further biochemical analyses. However, the purification 
strategy had to first be optimised due to the co-elution of several low molecular 
contaminants. By using a combination of IMAC, using Co2+ instead of Ni2+, followed by 
QHP anion exchange chromatography and gel filtration chromatography using 
Superdex 75 instead of Superdex 200, we successfully purified Mtb UgpB. This was 
crucial to carry out a more extensive biochemical characterisation of ligand binding and 
for structural studies. Following successfully solving the X-ray structure of glycerol-3-
phosphocholine (GPC) bound Mtb UgpB (Chapter 5, 5.3.7) we then generated site 
directed mutants based on the binding site and produced these genetic variants using 
the same strategy. The genetic variants were expressed and purified with yields 
between 0.2-2.6 mg of protein per L culture. All of the genetic variants were found to be 
soluble and stable and had similar secondary structure profiles as measured by circular 
dichroism analyses. 
 
Chapter 4: Characterisation of Mycobacterium tuberculosis UgpB. 
By bioinformatics, Mtb UgpB is predicted to be a carbohydrate binding protein therefore 
to carry out a more extensive biochemical characterisation we investigated binding of 
Mtb UgpB to a wide range of potential substrates. We measured binding to a panel 
carbohydrates, amino acids, glycerophosphodiester variations and anti-mycobacterial 
antibiotics by thermal shift assay and found GPC produced the highest thermal shift of 
+7.3 °C. This result was comparable to a previous study by isothermal calorimetry 
(Jiang et al., 2014). Our lipid strip analyses also found that Mtb UgpB binds to 
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phosphoinositides, phosphatidylserine and sulfatide, suggesting it may also have 
adapted to bind to alternative glycerophosphodiesers. Microscale thermophoresis 
(MST) was used to investigate the specificity of binding by testing GPC, the structurally 
related glycerol-3-phosphate (G3P) and phosphocholine. The MST results revealed 
that Mtb UgpB binds to GPC, with a Kd of 3.6 µM, suggesting that the combined 
glycerol, phosphate and choline moieties are required for binding recognition. By MST 
analysis all of the genetic variants of Mtb UgB had a lower binding affinity and some 
variants showed no binding for GPC compared to apo-Mtb UgpB. This confirmed that 
these residues, identified from the GPC bound Mtb UgpB X-ray structure are important 
for GPC binding recognition.  
 
Based on the GPC bound structure (Chapter 5, 5.3.7) no interactions were found to 
occur through the choline head-group therefore we hypothesised that alternative 
glyerophosphodiesters containing different head-groups could also bind to Mtb UgpB. 
We attempted to produce glycerophosphodiesters using a synthetic route to produce 
glycerophosphoethanolamine (GPE) and glycerophosphoserine (GPS). We reacted 
protected building block reagents to synthesise these glycerophosphodiesters, 
however in all cases a mixture of the correct product, and by-products were produced, 
that could not be effectively separated. Therefore we decided to use a different route 
starting with the intact phospholipids containing the glycerophosphodiester, and 
removing the fatty acid tails using a chemical or enzymatic method. The chemical 
method resulted in several by-products however the enzymatic method produced the 
correct GPE and GPS products, and were characterised. We also produced a GPC 
enantiomer using the same enzymatic method to investigate if the stereo-configuration 
of the 2-hydroxyl of the glycerol group affected GPC binding recognition.  Binding of 
the alternative glycerophosphodiesters was investigated by MST and revealed the 
order of binding preference to be: GPC>GPS>GPE>GPI(4)P>GPI>GPC enantiomer. 
Combined, this extensive biochemical characterisation suggested that Mtb UgpB is 
promiscuous for binding to a wide range of glycerophosphodiester substrates that Mtb 
may acquire during infection. 
 
Chapter 5: Structural studies of Mycobacterium tuberculosis UgpB. 
In order to co-crystallise Mtb UgpB and GPC we had to first reductively methylate the 
protein. We obtained crystals of Mtb UgpB and solved the structure of GPC bound Mtb 
UgpB by X-ray crystallography. The GPC bound structure revealed that Mtb UgpB had 
the typical structure of substrate-binding proteins (type II, cluster D) of the ATP-binding 
cassette (ABC) family. Upon GPC binding, Mtb UgpB had undergone closure between 
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the two α/β lobes. We also identified the precise molecular interactions in the GPC 
binding pocket, revealing that the glycerol and phosphate groups of GPC were the 
primary binding recognition elements. Residues Arg385 and Asp102 hydrogen bonded 
with the glycerol group. The glycerol backbone was also stabilised by π-stacking 
interactions from Trp208 and Van Der Waal’s forces between Leu205. Tyr78, Tyr345, 
Ser153 and Ser272 hydrogen bonded with the phosphate moiety. Surprisingly from the 
structure no interactions were identified for the choline head-group despite the clear 
preference for binding to GPC. Our GPC bound X-ray structure observations were also 
supported by in-solution STD-NMR experiments in collaboration with Dr Ridvan 
Nepravishta and Dr Jesus Angulo, that revealed that the highest STD intensity signals 
involved the glycerol group. STD-NMR also revealed binding of the alternative 
glycerophisphodiester: glycerophosphoinositol-4-phosphate (GPI(4)P) and revealed 
that the glycerol backbone had re-orientated in order to accommodate the larger 
inositol-4-phosphate head-group. We also wanted to determine the binding mode of 
glycerophosphoserine (GPS) and we were able to solve a putative GPS bound Mtb 
UgpB structure by X-ray crystallography. The putative GPS bound structure revealed 
clear density for the glycerol and phosphate moieties, which aligned identically to the 
glycerol and phosphate moieties of GPC. However the serine head-group density was 
not as well defined. 
 
Chapter 6: Cloning, expression and purification of Mycobacterium tuberculosis 
UgpC and UgpAE. 
We also wanted to determine the structure and function of the other components of the 
Mtb UgpABCE transporter. We successfully expressed the nucleotide-binding protein 
Mtb ugpC (Rv2832c). To do this a range of different conditions were tested including: 
using different expression systems, host strains, IPTG concentrations, media additives 
and tags. We successfully expressed Mtb UgpC using the SUMO, solubility 
enhancement tag, which was confirmed by mass-spectrometry. ATPase activity was 
initially investigated using a malachite green phosphate assay however due to the low 
protein purity, ATPase activity could not be confirmed. We also investigated ugpAE the 
membrane spanning proteins and cloned these genes into the vector pWaldo. 
However, we could not successfully express these proteins using the E. coli Lemo21 
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Future work 
The work carried out during this PhD has raised several further questions that need to 
be addressed. 
  
We have successfully revealed the molecular basis of Mtb UgpB binding to GPC and 
also found that Mtb UgpB is promiscuous for binding to alternative 
glycerophosphodiesters, potentially derived from macrophage membranes. Future 
work will therefore require further biochemical and structural characterisation of these 
substrates. We would especially like to establish how the binding recognition mode of 
GPS compares to GPC given that these substrates have very similar binding affinities. 
This will require further optimisation of the GPS co-crystallisation conditions. GPC was 
found to bind primarily through the glycerol and phosphate groups however it’s still not 
clear why glycerol-3-phosphate cannot be recognised. Potentially differences in 
substrate head-group charge play a role therefore this could be investigated further by 
setting crystal trials and measuring binding at different pH values. Intriguingly, we also 
found ethambutol, the anti-TB drug, to have low binding to Mtb UgpB by thermal shift 
assay. Ethambutol is structurally similar to GPC as it also contains several hydroxyl 
groups therefore this potential binding requires further investigation. 
 
Overall we want to determine the structure and function of the whole Mtb UgpABCE 
transporter, as this is the physiological unit, and may reveal important biochemical 
insights. We’ve had some success expressing the nucleotide-binding protein Mtb UgpC 
together with a SUMO tag. However we need to further optimise the expression and 
purification conditions in order to produce pure protein. This will enable us to 
investigate if Mtb UgpC is a functional ATPase. We also attempted to express the 
membrane spanning proteins, UgpA and UgpE. In the future, we could also try 
expressing the whole transporter complex together and extract the complex using 
SMALP’s. Other strategies include independently co-expressing the membrane 
spanning proteins, Mtb ugpA and Mtb ugpE in the pDuet vector (Novagen). Different 
strains could also be used such as E. coli BL21 (DE3) Codon-PlusRP, optimised for 
efficient codon usage, or E. coli (DE3) ArcticExpress cells, designed to have improved 
protein expression at lower temperatures. 
 
We now have an excellent understanding of the substrates of Mtb UgpB and how they 
are recognised therefore this provides an excellent basis to investigate the role of Mtb 
UgpB in vivo. In the lab, Magdalena Karlikowska has successfully produced an Mtb 
knockout of the whole UgpABCE transporter that is currently being evaluated in mice. 
Conclusions and future work	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The Mtb UgpABCE knockout strain will also facilitate investigations of substrate uptake 
in whole cells and serve as a useful tool for comparisons to wild type. Alternatively, 
Mycobacterium bovis BCG could be used to investigate substrate uptake in whole 
cells. M. bovis BCG has a frame-shifted, non-functional ugpB gene (Brosch et al., 
2007) therefore by cloning the functional Mtb ugpB  gene into a vector such as 
pMV261 (Stover et al., 1991) for constitutive expression in M. bovis BCG, we could 
investigate substrate uptake and assess if the UgpABCE transporter function is 
restored. Several potential methods are available to investigate substrate uptake in 
whole cells. For example ion chromatography (Dionex) could be used to quantitatively 
measure substrate depletion from the culture media (Hanko et al., 2000) or radioactive 
or fluorescent reporter substrates could be generated and used to evaluate if 
glycerophosphodiesters are recycled and incorporated into the Mtb cell membrane. 
 
Identification of new targets for drug development is essential to combat the 
emergence of drug resistant tuberculosis. Importantly, our structural analysis of 
glycerophosphodiester recognition by Mtb UgpB has facilitated the possibility of future 
medicinal chemistry research. Competitive inhibitors of Mtb UgpB could now be 
strategically designed to have tighter binding compared to GPC, leaving the transporter 
unable to function. Furthermore, given that it is really difficult to transport antibiotics 
across the Mtb cell wall, if we know what particular molecules are transported, then this 
could be used as a route to potentially smuggle toxic molecules into the cell. For 
example the GPC ligand could be modified to include a toxic head-group that when 
imported causes Mtb cell death. This could follow a similar “Trojan horse-like” strategy 
to previous ABC-transporter studies (Pletzer et al., 2014).  
 
In conclusion, this PhD has opened up several new exciting avenues for research. Our 
biochemical and structural characterisation of Mtb UgpB has revealed the molecular 
basis of binding to GPC and alternative glycerophosphodiesters that requires further 
investigation. Recently, a potential Mtb phospholipid recycling pathway has been 
discovered (Larrouy-Maumus et al., 2013) therefore its tantalising to postulate that the 
Mtb UgpABCE transporter may play a crucial role in the uptake of 
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